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Introduction
Hemolytic disease of the fetus and newborn (HDFN) due to red cell alloimmunization has 
been a fascinating clinical picture for many centuries. The first report of a condition called 
hydrops fetalis dates back to 1609,1,2 when a French midwife described the delivery of twins. 
The first twin was hydropic and stillborn and the second suffered from jaundice and subse-
quently died of kernicterus. These two conditions were not linked until 1932, when Diamond 
et al. described that hydrops and kernicterus were manifestations of the same disease, 
which they called erythroblastosis fetalis.3 However, the exact cause was still unknown. 
Since 1940, the analyses of Landsteiner and Wiener contributed largely to a better under-
standing of the pathogenesis of HDFN.4-7 In their studies with rhesus monkeys Landsteiner 
and Wiener observed that agglutination of human red blood cells occurred in the presence 
of rhesus monkey red cell antiserum, whereas subjects who lacked the antigen on their red 
cells did not show agglutination.4,7 The authors called this antigen ‘Rhesus’ (Rh) and conse-
quently the Rh-blood group system was born. Since then it has become clear that the most 
common cause of severe HDFN is ‘Rhesus disease’, resulting from maternal immunization to 
the Rhesus D (Rh D) antigen.8 However, more than 50 other red cell antigens associated with 
hemolytic disease have been described. Not only anti-Rh D, but also anti-Rh c and anti-Kell 
antibodies are associated with severe fetal and neonatal disease.9 
Untreated HDFN is a major cause of perinatal mortality. In HDFN due to red cell alloim-
munization, maternal immunoglobulin (IgG) antibodies directed against fetal red blood 
cells, pass the placenta into the fetal circulation and cause destruction of fetal red cells. The 
resulting progressive fetal anemia will then lead to fetal hydrops and perinatal death.10
During the last few decades prenatal care for patients with red cell alloimmunization has 
improved significantly. The introduction of Rh D prophylaxis in the late 1960s,11,12 the use of 
Doppler ultrasound to detect fetal anemia since the early 1970s13 and treatment with intra-
uterine intravascular red cell transfusions (IUT) since the 1980s14-16 have led to a remarkable 
reduction in perinatal mortality. Before the introduction of Rh D prophylaxis and IUTs, peri-
natal mortality was approximately 50% and the rate of perinatal morbidity was extremely 
high.1,17 The current most successful treatment, the use of IUTs, contributed largely to peri-
natal survival rates exceeding 95% in experienced centers.10,18 As a result of improving pre-
natal care strategies and consequently increased perinatal survival, attention is now shifting 
towards postnatal short-term and long-term management and morbidity. 
Neonatal red cell alloimmunization may lead to excessive hyperbilirubinemia and per-
manent brain damage due to kernicterus. Postnatal management is based mainly on the 
treatment of hyperbilirubinemia and consists of intensive phototherapy and exchange 
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transfusion (ET).18 Despite improvement in neonatal intensive care, ET remains a high risk 
invasive procedure requiring the use of central lines and is associated with a significant 
rate of adverse reactions.19-26 Neonatal treatment with intravenous immunoglobulins (IVIg) 
has been suggested and used as an alternative therapy for ET.27 In a few small random-
ized controlled trials IVIg reduced the need for ET and duration of phototherapy. However, 
these studies were restricted by several important methodological limitations.28-31 In 2002 a 
Cochrane review suggested that more well-designed trials were needed before routine use 
of IVIg could be recommended for treatment of HDN due to red cell alloimmunization.32 
Postnatal management also consists of treatment of early and late anemia using top-up 
red blood cell transfusions.33 Several risk factors for neonatal anemia secondary to red cell 
alloimmunization have been reported, including IUT34, severity of HDN35,36, type of alloim-
munization (including Kell versus Rh D)37 and the use of ET.18,38 However, only a limited 
number of studies (mostly case reports) have been published on differences in type of 
alloimmunization related to severity of neonatal anemia.37,39-41 In addition, the protective 
role of ET for neonatal anemia has only been demonstrated in one small study.38 Therefore, 
further research on anemia secondary to red cell alloimmunization is needed. 
In the past, various other postnatal complications in neonatal red cell alloimmunization 
have been reported, including cholestatic liver disease and thrombocytopenia. The etiology 
of cholestasis in neonates with HDN due to red cell alloimmunization has been attributed 
to iron overload due to IUT.42-45 However, data on incidence, potential risk factors, neonatal 
management and outcome of cholestasis in red cell alloimmunization is scarce. Simultane-
ously, only a few small studies have been published on incidence and severity of throm-
bocytopenia in neonates with red cell alloimmunization.36,46-48 Therefore, more studies are 
needed to investigate these and other associated complications of neonatal red cell alloim-
munization. 
As perinatal survival improves, attention is shifting towards long-term outcome in survivors. 
One of the concerns of the successful use of IUTs is that a decrease in perinatal mortality 
may lead to an increase in children with long-term handicaps. Moreover, not much is known 
about the relation between the severity of fetal anemia and long-term neurodevelopmen-
tal outcome.18 To date, only a few studies with small patient numbers have reported long-
term neurodevelopmental outcome after IUT.49-56 Further research on this topic is needed to 
determine incidence of and risk factors for adverse neurodevelopmental outcome after IUT. 
The aim of this thesis was to investigate various management options and to describe com-
plications and outcome of neonatal red cell alloimmune hemolytic disease.
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Outline of the thesis
During this study period several study projects on management, complications and 
outcome in hemolytic disease of the newborn (HDN) due to red cell alloimmunization were 
performed, including the Leiden’s IVIg trial in Rhesus disease of the Neonate (LIVIN study) 
and the LOng-Term follow-up after intraUterine transfusionS (LOTUS) study. The LIVIN study 
is a randomized controlled trial (RCT) designed in collaboration with Sanquin Blood Bank 
(Southwest Region, Amsterdam) to determine whether the prophylactic use of IVIg reduces 
the need for ET in neonates with Rh D or c hemolytic disease. The LOTUS study is a large 
national cohort study designed in close collaboration with the Department of Obstetrics 
and the Department of ImmunoHematology and Blood Transfusion of the Leiden University 
Medical Center (LUMC). One of the aims of the LOTUS study was to evaluate the long-term 
neurodevelopmental outcome of children treated with IUT. The aims and outcomes of these 
and other studies are described in the following chapters:
Chapter 2
Review of the literature on HDN due to red cell alloimmunization. This review focuses on 
postnatal management, associated morbidity and long-term outcome.
Chapter 3
Randomized controlled trial on the use of IVIg in neonates with Rhesus HDN (LIVIN study), 
investigating the effect of IVIg on number of ETs.
 
Chapter 4 
Case report describing a term neonate with Rhesus hemolytic disease treated with ET and 
developing a rare but severe cerebral infection after umbilical cord catheterization.
Chapter 5 
Study on morbidity associated with ETs in neonatal red cell alloimmune hemolytic disease.
Chapter 6 
Study on cholestasis in neonates with red cell alloimmune hemolytic disease, describing 
incidence, risk factors and outcome.
  
Chapter 7 
Study on thrombocytopenia at birth in neonates with red cell alloimmune hemolytic disease, 





Study on top-up red blood cell transfusions in neonates with Rhesus hemolytic disease in 
relation to ETs.
Chapter 9 
Study on neonates with Kell hemolytic disease, focusing on ETs and top-up red blood cell 
transfusions.
Chapter 10 
Study on long-term neurodevelopmental outcome after IUT for fetal alloimmune anemia 
(LOTUS study), to determine the incidence of and risk factors for neurodevelopmental 
impairment (NDI). 
Chapter 11 
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2 
Rhesus hemolytic disease of the newborn: 




Enrico Lopriore  




Rhesus hemolytic disease of the newborn can lead to complications such as hyperbiliru-
binemia, kernicterus and anemia. Postnatal management consists mainly of intensive pho-
totherapy, exchange transfusion and blood transfusion. During the last decades, significant 
progress in prenatal care strategies for patients with Rhesus hemolytic disease has occurred. 
New prenatal management options have led to a remarkable reduction in perinatal mor-
tality. As a result of the increase in perinatal survival, attention is now shifting towards 
short-term and long-term morbidity. This review focuses on the management of neonatal 
and pediatric complications associated with Rhesus hemolytic disease, discusses postna-
tal treatment options and summarizes the results of studies on short-term and long-term 
outcome.
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Introduction 
Rhesus hemolytic disease of the newborn (RHDN) results from maternal red-cell alloimmu-
nization. Production of maternal antibodies directed against the fetal red blood cells occurs 
when fetal red blood cells positive for a certain antigen, usually Rhesus D (Rh D), pass into 
the blood circulation of a mother negative for that particular antigen. Maternal immuno-
globulin (IgG) antibodies might then cross the placenta into the fetal circulation and cause 
a wide variety of symptoms in the fetus, ranging from mild to severe hemolytic anemia and 
fetal hydrops. During the last few decades, a significant evolution in prenatal care strategies 
for patients with RHDN has occurred, including the introduction of Rh D prophylaxis, use 
of Doppler ultrasound to detect fetal anemia and in particular treatment with intrauterine 
blood transfusions (IUTs). These new management options have led to a dramatic decrease 
in perinatal mortality. Before the introduction of Rh D prophylaxis and IUTs, perinatal mor-
tality was approximately 50% and the rate of perinatal morbidity was extremely high.1,2 With 
the use of IUTs, overall perinatal mortality in severe RHDN has decreased to less than 10%.3 
As a result of the increase in perinatal survival, attention is now shifting towards short-term 
and long-term morbidity. Postnatal management of RHDN is based mainly on the treat-
ment of hyperbilirubinemia and consists of intensive phototherapy (PT) and exchange 
transfusions (ETs) to prevent kernicterus. Various other postnatal complications in RHDN 
have been reported, including early and late anemia, thrombocytopenia, cholestasis and 
adverse long-term neurodevelopmental outcome. However, few studies have focused on 
postnatal management and outcome of RHDN.2,4-7
This chapter focuses on the management of neonatal and pediatric complications associ-
ated with RHDN, discusses the efficacy of various postnatal treatment options and summa-
rizes the results of studies on short-term and long-term outcome in RHDN.
Management of hyperbilirubinemia and the prevention 
of kernicterus
RHDN can lead to severe hyperbilirubinemia, acute bilirubin encephalopathy and even-
tually chronic bilirubin encephalopathy, also known as kernicterus. Prevention of kernict-
erus is considered to be the primary goal of postnatal treatment of RHDN.8
The acute stage of bilirubin encephalopathy is divided into three phases. In the early phase, 
affected infants become lethargic, hypotonic and suck poorly; the intermediate phase is 
characterized by stupor, irritability, fever, high-pitched cry and alternating hypertonia 
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and hypotonia; the advanced phase is characterized by irreversible damage to the central 
nervous system (CNS) resulting in pronounced retrocollis and opisthotonus, shrill cry, no 
feeding, apnea, fever, deep stupor to coma, sometimes seizures and death. 
The chronic stage of bilirubin encephalopathy, i.e. kernicterus, refers to the clinical CNS 
findings caused by bilirubin toxicity to the basal ganglia and various brain stem nuclei. In 
kernicterus, infants develop a severe form of athetoid cerebral palsy, hearing problems and 
psychomotor handicaps.8-10
Phototherapy 
Treatment of neonatal hyperbilirubinemia with phototherapy (PT) was introduced in the 
early 1970s.8,11 PT lowers serum bilirubin levels through photo-oxidation and converts bili-
rubin to a water-soluble substance. To deliver conventional PT, the infant is nursed under 
halogen or fluorescent lamps and the eyes are covered with a mask to prevent retinal 
damage. However, in the last 10 years new devices for delivering PT have been developed, 
these are the so-called fibreoptic PT devices. The infant is nursed on a blanket containing 
optical fibres that deliver light to the back. A recent Cochrane review suggests that even 
though fibreoptic PT has a place in the management of physiological neonatal hyperbili-
rubinemia, the use of fibreoptic PT in the treatment of pathological neonatal hyperbilirubi-
nemia due to hemolysis should be investigated in a randomized controlled clinical trial.11 
The efficacy of PT is dependent on a number of factors, including spectral qualities of the 
delivered light (optimal wavelength range 400-520 nm), irradiance (intensity of light), 
surface area receiving PT, distance from the light to the skin (the optimal distance is approx-
imately 30 cm), skin pigmentation, total serum bilirubin concentration at the start of PT 
and duration of exposure.4,12,13 PT is required when total serum bilirubin levels exceed the 
predefined bilirubin thresholds. Recently, new PT guidelines for bilirubin thresholds for chil-
dren with RHDN have been published by the American Academy of Pediatrics (AAP).8  
In RHDN, intensive PT should be started immediately after birth, as bilirubin levels may 
rise sharply after birth. Prompt and intensive PT treatment might prevent the need for ETs. 
Intensive PT implies the use of high levels of irradiance (430-490 nm, i.e. usually 30 µW/cm2 
per nm or higher) distributed to as much of the infant’s surface as possible. In intensive PT 
the nappy (diaper) should be removed to achieve optimal surface area exposure. Additional 
surface area exposure can be achieved by lining the sides of the bassinet with aluminium 
foil or a white cloth. Intensive PT consists of (at least) two PT lamps above and a fibreoptic 
pad under the infant.8
Antenatal treatment with IUTs can reduce the need for PT. In a recent study performed at 
our center, we compared postnatal outcomes in 89 term and near-term infants with RHDN 
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treated with and without IUTs.7 We found a significant reduction in duration of PT in the 
IUT group: the duration of PT in the IUT and no-IUT groups was 3.8 and 5.1 days, respec-
tively (p = 0.01). Replacement of fetal red blood cells by donor adult red blood cells via IUT 
reduces hemolysis and hence also the need for PT. We found no correlation between the 
number of IUTs and the duration of PT.
In some forms of RHDN, in particular Kell alloimmunization, anemia is more prominent than 
hyperbilirubinemia. Kell alloimmunization is the second most common alloimmunization 
after anti-D and accounts for 10% of the cases of severe hemolytic disease of the neonate. In 
Kell alloimmunization, a trilineage pancytopenia due to suppressed hematopoiesis is seen. 
Therefore, antibodies against antigens of the Kell blood group system should be consid-
ered as a potential cause of unexplained inhibition of myelopoiesis14. Kell alloimmuniza-
tion might therefore lead to severe fetal and neonatal anemia secondary to bone marrow 
depression rather than hemolysis. Consequently, only minimal PT might be necessary, 
despite severe anemia.4,15,16
Exchange transfusion 
Treatment of neonatal hyperbilirubinemia with exchange transfusion (ET) was introduced in 
the early 1950s.17 RHDN is one of the most common indications for ET. ET prevents kernict-
erus by removing bilirubin from the circulation. In infants with RHDN, ET has the additional 
benefits of removing maternal antibodies (thus limiting further hemolysis) and correcting 
the associated anemia.  ETs are performed with double volume transfusion (160 mL/kg) 
using irradiated, leukocyte-depleted erythrocytes (cross-matched against the mother and 
compatible with the infant) via an intravenous catheter, usually an umbilical vein. 
ET is required in RHDN when intensive PT management fails and serum bilirubin levels 
approach the threshold for ET. The percentage of children with RHDN requiring treatment 
with ET ranges from 20% to more than 70%.7 This wide range is partly due to the use of dif-
ferent serum bilirubin thresholds for ET. Comparison of the incidence of ET in children with 
RHDN between the various studies is therefore difficult to accomplish. Several studies man-
dated the use of early ET, resulting in a higher rate of ET. Until 2005, management guidelines 
for RHDN at our center also mandated the use of early ET. The incidence of ET in term infants 
with RHDN delivered at our center before 2005 was 69%.7 Most ETs (88%) were performed 
within the first 12 h of birth. In 2004, the AAP published new ET guidelines and serum bili-
rubin thresholds for children with RHDN.8 These new guidelines do not recommend the use 
of early ET. Our center adopted these new guidelines in 2005 and the incidence of infants 




Whether treatment with IUT also reduces the need for ET in infants with RHDN is not clear. 
Neonates treated with IUT have a high percentage of adult (donor) red blood cells and a 
lower percentage of fetal red blood cells,18 which should result in reduced hemolysis and 
less need for ET. In a recent retrospective study performed at our center, we compared the 
need for ET in infants with RHD treated with or without IUT.7 We found that the median 
number of ETs was similar in the IUT and no-IUT groups. However, this paradoxical result 
might be related to the specific early ET criteria used in this study.7,19,20
Despite improvement in neonatal intensive care, ET still remains a high-risk invasive pro-
cedure associated with a significant rate of adverse reactions. Although the mortality rate 
associated with ET is nowadays less then 0.3% in term infants, morbidity rates may reach 
24%.21-25 Morbidity associated with ET includes, in particular, catheter-related complications. 
Umbilical venous catheterization is often required to perform an ET. Although umbilical 
venous catheterization is a common procedure in the management of sick neonates, it can 
lead to serious complications, including dislodgement, thrombosis, hemorrhage, arrhyth-
mias, (pericardial) effusions, portal hypertension and infection.25-30 The incidence of sepsis 
related to umbilical venous catheterization is reported to range between 6% and 24%.31
Intravenous Immunoglobulin 
The new AAP guidelines recommend the use of 0.5–1.0 g/kg intravenous immunoglobu-
lin (IVIg) in RHDN in case of failure of PT to reduce the need for ET.8 The exact mechanism 
for IVIg in RHDN is yet incompletely unraveled and is the subject of ongoing research. 
IVIg might increase IgG catabolism, resulting in a shorter half-life of antibodies (including 
anti-Rh antibodies); IVIg might also block the IgG-receptor on macrophages, resulting in a 
decreased removal of anti-Rh-coated erythrocytes from the circulation. A third hypothesis 
is the presence of anti-idiotypic antibodies as a result of IVIg treatment neutralising anti-Rh 
antibodies.32 
A few small, randomized controlled trials have suggested that IVIg combined with PT reduces 
serum bilirubin levels and the need for ET in neonates with RHDN compared with PT alone. 
In these studies, treatment with IVIg also reduced the duration of PT and length of hospital-
ization, but increased the need for late red blood cell transfusions. However, the number of 
patients included in these randomized controlled trials was small and the study-design and 
inclusion criteria varied considerably. One study included infants with ABO incompatibility;33 
an unexpected and large number of these children with ABO incompatibility and hemo-
lytic disease required an ET. Finally, the criteria for ET were discordant between the various 
studies.33-36 A recent Cochrane review suggested that the results of further trials of higher 
quality should be awaited and stated that: “further well designed studies are needed before 
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routine use of IVIg can be recommended for the treatment of isoimmune hemolytic jaun-
dice”.37 In view of this dilemma, we recently started a prospective, randomized double-blind, 
placebo-controlled trial to assess the short- and long-term effects of the prophylactic use of 
IVIg in neonates with RHDN who were delivered at our center (the LIVIN study: http://www.
controlledtrials.com/ISRCTN14013064/). A total of 40 patients is required in both arms of the 
study to detect a reduction in ETs from 30% in the placebo group to 6% in the IVIg group. To 
date, 38 patients have been enrolled, and final results will be awaited by the end of 2009. 
Albumin
Bilirubin is transported in the plasma bound to albumin. The fraction of bilirubin that is 
not bound to albumin can more readily cross the blood-brain barrier and may cause bili-
rubin encephalopathy. The recent AAP guidelines suggest that serum albumin levels should 
be measured routinely, as an albumin level of less than 3 g/dL can be considered as a risk 
factor for lowering the threshold for PT.8 The AAP also recommends that if an ET is being 
considered, the bilirubin/albumin ratio should be used to determine the need for an ET. 
Administration of albumin before ET may increase the efficacy of the ET, because more bili-
rubin will be mobilised from the tissues into the blood and excreted. However, evidence 
that albumin infusion increases the long-term outcome in infants with severe hyperbiliru-
binemia is not available and thus routine use of albumin is not recommended.8
Phenobarbital
Phenobarbital increases bilirubin uptake, conjugation and excretion. A few studies in the 
1970s and 1980s suggested that administration of phenobarbital at birth  to a child with 
hyperbilirubinemia might decrease the need for ET.38-40 However, recent studies suggest 
that postnatal administration of phenobarbital does not offer additional advantage over 
routine use of intensive PT.5,41 
A recent retrospective study by Trevett et al. showed that antenatal maternal administration 
of phenobarbital significantly reduces the need for ET in neonates affected with RHDN.42 
The incidence of ET in neonates with and without antenatal phenobarbital administration 
was 9% versus 52%, respectively (p < 0.01). As suggested by the authors, further study in a 
randomized controlled trial is necessary to confirm these results.42 
Metalloporphyrins
In recent years, various metalloporphyrins (also known as heme oxygenase inhibitors) have 
been used to prevent and treat unconjugated hyperbilirubinemia. Metalloporphyrins act 
by inhibiting the enzyme heme oxygenase, the rate-limiting step in the catabolism of heme 
to bilirubin. Metalloporphyrins are natural or synthetic heme analogues, which reduce the 
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production of bilirubin. By preventing the formation of bilirubin, metalloporphyrins have 
the potential to reduce the level of unconjugated bilirubin and thus decrease the need 
for PT and hospitalization. However, routine treatment is not recommended at present. A 
recent Cochrane review suggests that randomized controlled trials are required to compare 
metalloporphyrin treatment with placebo and to report on important outcomes such as 
severe hyperbilirubinemia, neonatal kernicterus, ET and long-term neurodevelopmental 
impairment.5,43,44
Hydration 
PT increases insensible water loss through the skin and raises the fluid requirements of 
infants undergoing PT.45-47 In addition, by-products of PT are eliminated in the urine. If oral 
hydration is inadequate, intravenous hydration may be necessary.48 However, there is no 
unequivocal evidence that increased fluid administration affects serum bilirubin concen-
tration. An exception should be made for infants who are dehydrated, as they might need 
supplemental fluid intake to correct their dehydration. For breastfed infants with evidence 
of dehydration, supplementation with a milk-based formula inhibits the enterohepatic cir-
culation of bilirubin and can improve the efficacy of PT.13 
Management of anemia 
Anemia may be present at birth (early anemia) or not until 1 - 3 weeks of age (late anemia). 
The degree of anemia varies in infants with RHDN. Late (hyporegenerative) anemia present-
ing 1 week - 3 months after birth is a common problem in neonates with RHDN. Late anemia 
in RHDN is characterised by a reduction in reticulocyte count and low serum erythropoietin 
(EPO) levels.49 Other causal factors include reduction of the half-life of the transfused eryth-
rocytes in infants who received IUTs and red blood cell transfusion or ET postnatally.7,49-52
The incidence of late anemia in neonates with RHDN ranges from 71 to 83%.7,49 Late anemia 
in RHDN usually resolves by the third month of life.5,7 In a recent study performed at our 
center we found that neonates with RHDN treated with IUTs required more top-up red cell 
transfusions during the first 6 months of life than neonates with RHDN not treated with IUTs 
(77% and 26.5% respectively; p < 0.01). Infants treated with IUTs had a significantly lower 
median reticulocyte count at birth than infants without IUT (7 ‰ versus 73 ‰, respectively; 
p < 0.01). The association between low reticulocyte count and increased need for top-up 
transfusions indicates that IUTs could result in suppression of erythropoiesis and in bone 
marrow hypo activity.
Infants with RHDN treated with IUT must receive irradiated blood transfusions to prevent 
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the risk of transfusion associated graft-versus-host disease. Infants must be checked for the 
rate of hemoglobin fall once or twice a week (depending on the level of the hemoglobin 
concentration) until 3 months of age. However, international guidelines for red blood cell 
transfusion in infants during the first months after birth are not available and consensus on 
appropriate transfusion triggers and the volume of blood to be transfused is not available. 
Most countries use a transfusion protocol based on clinical condition, mechanical ventila-
tion, gestational age, oxygen use and hematocrit or hemoglobin levels. In our center term 
neonates with RHDN are treated with transfusions of red blood cells when hemoglobin 
levels fall below 8.0 g/dL (5.0 mmol/L) or below 9.6 g/dL (6.0 mmol/L) when clinical symp-
toms of anemia are present (need of extra oxygen, poor feeding, tachycardia and/or tac-
hypnoea).
Erythropoietin
Erythropoietin (EPO) can be used to prevent late anemia and reduce the need for top-up 
transfusions of red blood cells. Recently, several studies and meta-analyses of EPO adminis-
tration showed insufficient evidence to comment on the possible advantages of EPO. Routine 
use of EPO in infants with late anemia due to RHDN is therefore not recommended.53-56 
Folic acid
The administration of folic acid until 3 months of age might - hypothetically - decrease the 
need for top-up transfusions of red blood cells by stimulating erythropoiesis. Suggested 
dosages vary from 25 to 1000 µg daily. However, there are no available data in the litera-
ture to support or refute this hypothesis. Current studies do not provide any evidence that 
administration of folic acid reduces the need for top-up transfusions of red blood cells. The 
available data are therefore insufficient to directly guide routine clinical practice.51 
Iron
As discussed above, neonates with RHDN often require IUTs and (multiple) transfusions of 
red blood cells. The risks and potential consequences of iron overload due to these multiple 
transfusions are poorly recognized. High levels of cord blood ferritine have been reported in 
infants with RHDN.57 As infants with RHDN already have high iron storage, supplementation 
of iron is not recommended and should not be used.57 
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Management of other associated morbidity
Hydrops fetalis
Severe fetal anemia in RHDN can lead to hydrops fetalis. The immediate postnatal manage-
ment of a newborn with hydrops fetalis constitutes one of the major challenges in neonatal 
medicine. Newborns with RHDN and hydrops fetalis have generalized subcutaneous edema 
and – often – fluid collections in pericardial, pleural or peritoneal spaces. Hydropic infants 
tolerate labour poorly and are usually depressed at birth. Intubation is often required and 
can be difficult because of edema. High pressures might be required during mechanical 
ventilation because of pulmonary edema and pulmonary hypoplasia (secondary to pleural 
effusions and ascites). Immediate drainage of ascites and pleural effusions in the delivery 
room might be life-saving procedures. If pulmonary hypertension induces severe hypox-
emia, other treatment options should be envisaged, such as mechanical ventilation with 
high-frequency ventilation, inhaled nitric oxide or extra corporal membrane oxygenation. 
Circulatory insufficiency is often present and requires adequate inotropic support. As new-
borns with fetal hydrops frequently show signs of cardiac decompensation, correction of 
chronic anemia should preferably be performed with a partial ET rather than with a simple 
transfusion accompanied by administration of diuretics.58
Thrombocytopenia
Recent literature suggests an association between low fetal platelet counts and fetal 
hydrops in severe Rh D alloimmunized pregnancies.59-61 Fetal thrombocytopenia may have 
grave consequences, such as intracranial hemorrhage and prolonged, possibly life-threat-
ening bleeding from the puncture site of the IUT. In a recent study performed at our center, 
fetal platelet counts were measured prior to 914 IUTs in Rh D alloimmunized pregnancies. 
Severe fetal thrombocytopenia (platelet count < 50x109/L) was found in 3% of all fetal blood 
samplings and in 23% of severely hydropic fetuses. Perinatal mortality in fetuses with severe 
thrombocytopenia was 36% (van den Akker, personal communication). The incidence and 
severity of thrombocytopenia during the neonatal period is not known.
Cholestasis 
Several case reports describe elevated levels of conjugated bilirubin in neonates with 
RHDN.8,62-65 The incidence and pathogenesis of cholestasis and bronze baby syndrome in 
newborns with RHDN is not known. Cholestatic liver disease in neonates with RHDN treated 
with multiple IUTs, red blood cell transfusions and/or ETs can result from hyperferritine-
mia and liver iron overload.8,62-65 Accumulation of copper porphyrines in serum and tissues, 
found in bronze baby syndrome, can be responsible for a lower plasma albumin concen-
tration and less binding of bilirubin, posing a greater risk for kernicterus in patients with 
bronze baby syndrome.64
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The current AAP guidelines state that thresholds for the treatment of hyperbilirubinemia 
should be based on the total serum bilirubin levels, without subtracting the conjugated bili-
rubin fraction. Nevertheless, when conjugated bilirubin is significantly elevated (i.e. > 50%) 
there is no bilirubin threshold at which intervention is recommended. Bilirubin encephal-
opathy is due to unbound, unconjugated bilirubin. Whether neonates with elevated conju-
gated bilirubin are at increased risk for kernicterus is not known and management remains 
controversial. Treatment should ideally be based on the measurement of unbound, uncon-
jugated bilirubin, but these measurements have not yet been adapted for clinical use.8,62-65 
Long-term neurodevelopmental outcome and morbidity 
Most study groups, including ours, nowadays report perinatal survival rates in red blood cell 
alloimmunization treated with IUTs above 90%.3 As perinatal survival improves, attention 
is shifting towards long-term outcome in survivors. To date, only a few small studies have 
reported on the long-term neurodevelopmental outcome in RHDN. The main limitation of 
these studies is the small number of patients included (range 16-69). Moreover, although 
hydrops fetalis is associated with increased mortality, not much is known about the associa-
tion between the severity of fetal anemia and long-term neurodevelopmental outcome.66-70 
Doyle et al. reported on the sensorineural outcome at 2 years of age in 38 survivors of fetal 
IUTs. The majority of these infants (92%) showed no sensorineural disability at 2 years of 
age.66 In a follow-up study performed at our center, Janssens et al. found that the neurode-
velopmental outcome for children with RHDN treated with IUTs compared favorably with 
a group of high-risk, very-low-birth- weight infants (10% versus 18%, respectively) and less 
favorably with a healthy control group (10% versus 6%, respectively).70 Hudon et al. studied 
the neurodevelopmental outcome in 40 infants with RHDN treated with IUT. All infants 
showed normal developmental outcome at the age of 62 months.69 Grab et al. described 35 
infants treated with IUTs for severe erythroblastosis. At 6 years of age no moderate or severe 
neurologic impairment was observed.68 Harper et al. evaluated long-term outcome in 18 
hydropic fetuses treated with IUT. Death or major neurological morbidity occurred in 22% 
of the fetuses and 12% of the survivors had major neurologic sequele.67
In 2008, we will perform a follow-up study of all the children (n=350) with RHDN treated 
with IUTs at our center between 1992 and 2007. Our primary objective is to assess long-
term neuromotor development, cognitive development and psychosocial well-being in 
the largest cohort reported so far. Our secondary objective is to investigate the association 
between adverse long-term outcome with risk factors, including gestational age at birth, 
cause and severity of fetal anemia, presence and severity of hydrops fetalis, and number of 




•	 New guidelines for PT and ET thresholds have been published recently by the AAP. 
•	 The new AAP guidelines do not recommend the use of early ET.
•	 Supplementation of iron in infants with RHDN is not recommended in consideration of 
the high iron storage.
Research agenda
•	 Well-designed randomized controlled trials are necessary to address the efficacy and 
safety of IVIg use in newborns with RHDN.
•	 Randomized controlled studies in RHDN are required to evaluate the efficacy of various 
interventions, such as EPO and folic acid administration, to reduce the need of top-up red 
blood cell transfusions. 
•	 Short-term outcome studies in infants with RHDN treated with IUTs are needed to inves-
tigate the incidence of associated morbidities, including cholestasis.
•	 Long-term follow-up studies in large cohorts of infants with RHDN treated with IUTs are 
required to determine their neurodevelopmental outcome and determine potential risk 
factors.
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Background: Despite limited data, international guidelines recommend the use of intravenous 
immunoglobulin (IVIg) in neonates with Rhesus hemolytic disease. 
Objective: To test whether prophylactic use of IVIg reduces the need for exchange transfusions 
in neonates with Rhesus hemolytic disease.
Design and setting: We performed a randomized double-blind placebo-controlled trial in 
neonates with Rhesus hemolytic disease. After stratification for treatment with intrauterine 
transfusion, neonates were randomized for IVIg (0.75 g/kg) or placebo (glucose 5%). Primary 
outcome was the rate of exchange transfusions. Secondary outcomes were duration of 
phototherapy, maximum bilirubin levels and the need of top-up red cell transfusions.
Results: Eighty infants were included, of whom 53 (66%) were treated with intrauterine trans-
fusion(s). There was no difference in the rate of exchange transfusions between the IVIg and 
placebo groups (17% (7/41) versus 15% (6/39), p=1.00) and in number of exchange transfusions 
per patient (median (range) 0 (0-2) versus 0 (0-2), p=0.90), nor in duration of phototherapy (4.7 
(1.8) versus 5.1 (2.1) days, p=0.34), maximum bilirubin levels (14.8 (4.7) versus 14.1 (4.9) mg/dL, 
p=0.52) and proportion of neonates requiring top-up red cell transfusions (83% (34/41) versus 
87% (34/39), p=0.76). 
Conclusion:  Prophylactic IVIg does not reduce the need for exchange transfusion nor the rates 
of other adverse neonatal outcomes. Our findings do not support the use of IVIg in neonates 
with Rhesus hemolytic disease.
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Introduction
Rhesus hemolytic disease of the neonate (HDN) may lead to excessive hyperbilirubinemia and 
permanent brain damage due to kernicterus. Traditional neonatal treatment of Rhesus HDN 
consists of intensive phototherapy and exchange transfusion (ET). Phototherapy lowers bili-
rubin through photo-oxidation, whereas ET removes bilirubin and hemolytic antibodies, and 
corrects anemia.1 However, ET is a high-risk invasive procedure associated with a significant 
rate of adverse effects. Although the mortality rate associated with ET is nowadays reported 
to be less than 0.3% in term infants, the morbidity rates can reach 24% and includes catheter-
related complications, sepsis, thrombocytopenia and hypocalcemia.1-7 
Neonatal treatment with intravenous immunoglobulin (IVIg) has been suggested as an alterna-
tive therapy for ET in Rhesus HDN.8 In many Western countries, including the Netherlands, IVIg 
is widely used.9 A few small randomized controlled trials (RCT) reported that IVIg combined 
with phototherapy reduces serum bilirubin levels and the need for ET in neonates with Rhesus 
HDN compared to phototherapy alone.10-13 In these studies, treatment with IVIg reduced the 
duration of phototherapy and length of hospitalization, but increased the need for top-up red 
cell transfusions. 
Recommendations for the routine use of IVIg are controversial due to various methodologi-
cal limitations of the studies. A Cochrane review suggested in 2002 that the results of further 
trials of higher quality should be awaited.14 The American Academy of Pediatrics (AAP) recom-
mended in 2004 the use of IVIg (0.5–1 g/kg) in Rhesus HDN in case of failure of phototherapy, 
based on the same limited data.8 Given these conflicting recommendations, a well-designed 
RCT for the use of IVIg in Rhesus HDN was urgently needed. We hypothesized that IVIg reduces 
the need for ET and we designed a RCT to address this question.  
Materials and Methods
We performed a prospective randomized single-center double-blind placebo-controlled 
trial (http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=832). The Leiden University 
Medical Center (LUMC) is the national referral center for the management and intrauterine 
treatment of red cell alloimmunization in the Netherlands. All neonates of 35 or more weeks 
of gestation with Rhesus HDN, born between 2006 and 2010 and admitted to the neonatal 
nursery of the LUMC were eligible. Rhesus HDN was defined as (1) Maternal Antibody Depen-
dent Cellular Cytotoxicity-test (ADCC) > 50%, a validated functional test predicting severe 
hemolysis and comparable with a titer of > 1:6415 and (2) positive direct antiglobulin test 
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caused by anti-Rhesus D (Rh D) or c antibodies in the  fetus/neonate of a Rh D or c negative 
mother. We excluded all neonates (1) with perinatal asphyxia (defined as an Apgar score at 5 
minutes less than 3 and/or umbilical cord arterial pH less than 7.0), (2) with hemolytic disease 
other than Rh D or c and (3) with Rhesus HDN presenting > 4 hours after birth.
Written informed parental consent was obtained before birth. After stratification into two 
groups (with and without IUT), infants were assigned at birth to the IVIg treatment group 
(IVIg-group) or placebo control group (placebo-group) through pharmacy-controlled random-
ization. Method of treatment allocation was computer-generated randomization sequence, 
with randomization code kept by the chief pharmacist. The block size for randomization was 
4 in the IUT-group and 2 in the group without IUT (because of the expected smaller propor-
tions of infants in the non-IUT-group). The hospital pharmacy provided identical coded drug 
boxes and infusion solutions were delivered in sequentially-numbered identical vials contain-
ing either IVIg or placebo. To prevent discrepancy between two children of the same family, 
in case of twins the same vial was used for both children. Clinicians, nurses and parents were 
blinded to the randomization and allocation.
In the IVIg-group, patients received conventional intensive phototherapy plus prophylactic 
IVIg as a single dose of 0.75 g/kg (administered in approximately 5-6 hours) starting within 
the first 4 hours after birth. In the placebo-group, patients received conventional intensive 
phototherapy plus an equal amount of glucose 5% intravenous infusion.
The IVIg product used in this trial (Nanogam®, Sanquin Amsterdam, The Netherlands) is treated 
with solvent-detergent to inactivate enveloped viruses and subjected to filtration through a 
15 nanometer filter to remove non-enveloped viruses, including Parvo B19. Nanogam® con-
tains more than 95% monomeric IgG and no aggregates.
All infants with Rhesus HDN admitted to our neonatal nursery receive intensive phototherapy 
directly after birth using white light with an intensity of 12-20 µW/cm/nm given by air shield 
and Ohmeda lamps, in combination with a bilirubin-blanket providing blue light 30 µW/cm/
nm. During phototherapy, extra fluids (10 ml/kg) are administered. Phototherapy and ET were 
performed according to the latest AAP guidelines.8 The criteria for ET were: (1) total serum bili-
rubin above (higher) ET thresholds and/or (2) rise of bilirubin > 0.5 mg/dL/hr despite intensive 
phototherapy, and/or (3) clinical symptoms of acute bilirubin encephalopathy regardless of 
bilirubin level. ET criteria were not based on fixed bilirubin thresholds, but were derived from 
the nomograms of AAP and varied according to postnatal age (hours/days) of the neonate. ET 
was performed with double-volume transfusion (160 mL/kg) using irradiated and leukocyte-
depleted compatible erythrocytes. 
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We recorded the following obstetric and neonatal data: fetal hemoglobin (Hb) concentration 
and gestational age at first IUT, number of IUTs, gestational age at birth, birth weight, Hb con-
centration, reticulocyte count and bilirubin level from cord blood at birth, maximum biliru-
bin level during admission, duration of phototherapy and admission (days), number of ETs 
required, number of top-up red blood cell transfusions received during the first 3 months of 
life and Hb levels prior to top-up transfusion. Hb levels were measured routinely every week 
up to three months of age. After discharge from our center, top-up transfusions were per-
formed in referring hospitals when Hb levels were < 8.0 g/dL, or < 9.6 g/dL in the presence of 
clinical symptoms of anemia (such as lethargy, feeding problems, need for oxygen or failure 
to thrive). Folic acid (50 mcg/day) was administered orally during the first three months of life 
to all neonates. Data on the number of top-up transfusions and Hb levels in infants managed 
(after discharge) outside our center were collected through correspondence with the local 
pediatrician or blood transfusion department.
Primary outcome was the rate of ET and the number of ETs per infant. Secondary outcomes 
were duration of phototherapy and hospital stay, maximum serum bilirubin levels and the 
need of top-up red cell transfusions in the first three months of life.
Statistical analysis
Based on the available literature, we calculated that a minimum of 40 infants in each study arm 
was required to demonstrate a 5-fold reduction in need of ET between the placebo-group and 
the IVIg-group (30% versus 6%) with a significance of 0.05 and a power of 80%, by two-tailed 
analysis. The expected rate (30%) of ET in the placebo-arm was derived from the recorded inci-
dence on ET at our department in 2005-2006. The expected rate (6%) of ET in the IVIg-group 
was calculated from the reported data in the literature (Gottstein and Cooke)11. According to 
the meta-analysis from Gottstein and Cooke, the use of IVIg in neonates with Rhesus HDN 
could lead to a 5-fold reduction in the incidence of ET (relative risk (RR) 0.21, 95% confidence 
intervals (CI) 0.10 to 0.45).
Data are reported as means and standard deviations (SD) or as median and ranges, as appro-
priate. Statistical analysis was performed using Student-t-test and Mann-Whitney test for con-
tinuous variables. Chi square and Fisher’s exact test were used for categorical variables, as 
appropriate. A p-value <0.05 was considered statistically significant. Statistical analysis was 




A total of 121 neonates with Rhesus hemolytic disease were born in the study period, of whom 
41 (34%) were excluded (Figure 1). We enrolled 80 patients in the study, 41 patients in the 
IVIg-group and 39 in the placebo-group. One pair of twins was included in the IVIg-group. 
Both children received IVIg from the same vial according to the protocol. During infusion of 
the study medication no potential side-effects such as hypotension, tachycardia or allergic 
reactions were reported. The baseline characteristics of the two treatment groups were similar 
(Table 1). 
Neonatal outcome: phototherapy and ET
All neonates were treated with intensive phototherapy directly after birth. The mean number 
(SD) of days of phototherapy in neonates in the IVIg-group and placebo group was 4.7 (1.8) 
and 5.1 (2.1), respectively (p=0.34). At least one ET was required in 17% (7/41) of the neonates 
in the IVIg-group compared to 15% (6/39) in the placebo-group (p=1.00). The median number 
of ETs in the IVIg-group and placebo-group was 0 (range 0-2) and 0 (range 0-2), respectively 
(p=0.90). Median time from birth to (first) ET was 44 hours (range 9-60) in the IVIg-group and 
31 hours (range 22-66) in the placebo-group. IVIg or placebo was administered within the first 
4 hours after birth.
Maximum mean bilirubin levels during admission were similar in both groups (14.8 ± 4.7 
versus 14.1 ± 4.9 mg/dL, respectively (p=0.52). Similar results for the primary and secondary 
outcomes were observed for the sub-groups of neonates after stratification for treatment 
with or without IUT. Detailed information on neonatal treatment and outcome in both groups, 
overall and after stratification for IUT, is presented in Table 2. 
One included patient developed a Bacillus cereus sepsis with brain abscesses a few days after 
an ET performed through an umbilical venous catheter. Because of this serious adverse event 
the randomization code for the patient was opened and showed that the infant had received 
IVIg. Sterility tests on the used IVIg batches were subsequently performed and found to be 
sterile. In addition, cultures of all donor blood products used for the IUTs and ET were exam-
ined and found to be sterile. Therefore the cause of infection remained unclear and may have 
been related to the umbilical venous catheterization and ET. Detailed information on this 
exceptional case can be found in a case report.16
 
Top-up transfusions
The percentage of neonates requiring a top-up transfusion in the IVIg-group and placebo-
group was 83% (34/41) and 87% (34/39), respectively (p=0.76). The median number of top-up 
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Gestational age at birth-weeks a 36.7 ± 1.0 36.5 ± 0.6 0.23
Birth weight-grams a 2994 ± 485 2953 ± 424 0.68
Male-n (%) 29 (71) 25 (64) 0.64
Neonates treated with IUT-n (%) 27 (66) 26 (67) 0.99
Number of IUTs per neonate b  1 (0-4)  1 (0-6) 0.47
Gestational age at first IUT-weeks a 29 ± 4 28 ± 6 0.44
Hemoglobin level at first IUT-g/dL a  6.9 ± 2.2  6.5 ± 2.3 0.44
Rhesus D immunization-n (%) 36 (88) 35 (90) 0.59
Hemoglobin level at birth-g/dL a 12.2 ± 2.9 11.9 ± 2.6 0.52
Reticulocyte count at birth-‰ a  64 ± 51  52 ± 57 0.31
Bilirubin level at birth-mg/dL a  7.0 ± 3.9  5.7 ± 2.3 0.07
a Value given as mean ± SD
b Value given as median (range)
121 neonates assessed for eligibility
80 randomly assigned
41 assigned to IVIg-group 39 assigned to placebo-group
41 included in analysis 39 included in analysis
41 excluded
• 6 gestational age < 35 weeks
• 16 hemolytic disease other than 
   Rhesus D or c
• 19 refused to participate































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































transfusions per neonate in the IVIg-group and placebo-group was 2 (range 0-6) and 2 (range 
0-6), respectively (p=0.93). Mean hemoglobin level at first top-up transfusion and median 
number of days until first top-up transfusion were similar in both groups. Detailed informa-
tion on the use of top-up transfusions in the IVIg-group and the placebo-group is presented 
in Table 3.
Comment
In this RCT we have shown that prophylactic treatment with IVIg in neonates with Rhesus 
hemolytic disease did not reduce the need for ET nor the rates of other adverse neonatal 
outcomes. Our results do not support the recommendation to give IVIg in Rhesus hemolytic 
disease, as stated in recent AAP guidelines8. Our study adds to the Cochrane analysis that 
there is no evidence to recommend routine use of IVIg.14
In the past, several studies have suggested a positive effect of IVIg in reducing the rate of 
hemolysis in Rhesus hemolytic disease.10,12,13,17-19 Although the exact mechanism of action of 
IVIg remains unclear, IVIg has been reported to block Fc-receptors on macrophages, result-
ing in a decreased removal of anti-Rh antibody coated erythrocytes from the circulation. IVIg 
might increase IgG catabolism, resulting in a shorter half-life of antibodies (including anti-Rh 
antibodies). A third hypothesis is the presence of anti-idiotypic antibodies in IVIg neutralizing 
anti-Rh antibodies.12,20-22
Our results are in contrast with the most recent recommendations of the AAP to use 0.5-1.0 
g/kg IVIg in Rhesus hemolytic disease in case of failure of phototherapy.8 These guidelines 
were published in 2004 and based on a limited number of small RCTs. Several important 
methodological limitations hampered the interpretation of these studies, including sub-opti-
mal study-designs and the wide range of inclusion criteria.18,19 The Cochrane Collaboration 
performed a review on three studies, in which a total of 189 infants were included.10,12-14 Rubo 
et al.10 included 32 infants with Rhesus hemolytic disease in a multicenter RCT. No details on 
IUT and gestational age were given. Several years later Dagoglu et al.13 included 29 preterm 
and 12 term infants in a RCT. Cut-off for prematurity and criteria for top-up red cell transfu-
sions were not defined. In 1999 Alpay et al.12 enrolled 116 infants, predominantly with ABO 
incompatibility (n=93), but also neonates with Rhesus hemolytic disease (n=16) and both Rh 
and ABO incompatibility (n=7) were included. However, results were not given for each group 
separately. None of the studies described detailed phototherapy guidelines and none of them 
used a placebo in the control-group or described any method of blinding the intervention 
after allocation concealment. According to the Cochrane review, none of the trials fulfilled 
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criteria for high quality study. Our study is the first well-designed randomized double-blind 
placebo-controlled trial on this topic.  
In 4 other studies, infants with ABO incompatibility were included.12,17,18,23 In general, com-
pared to Rhesus immunization, ABO incompatibility causes less severe hemolysis and there-
fore less neonatal morbidity.24 For that reason, we included only neonates with Rhesus disease. 
These important methodological differences between our study and the previous ones may 
explain the discordant results. 
Several other explanations can be envisaged to explain the lack of effect of IVIg in our study. 
A possible explanation could be the treatment with intensive and prophylactic phototherapy 
starting immediately after birth, thereby reducing the risk of severe hyperbilirubinemia. In 
addition, the majority of infants included in our study were treated with IUT. By IUT, Rhesus 
incompatible erythrocytes of the fetus are replaced by Rhesus compatible cells of the donor. 
Dependent on the interval between the last IUT and delivery, these donor cells are still present 
after birth, resulting in less or more delayed hemolysis.25, 26 However, several groups includ-
ing ours have shown that even after IUT, neonates with Rhesus hemolytic disease still often 
require ET.27,28 In our study, IVIg was neither effective in the IUT group nor in the group without 
IUT. However, the number of patients included in the subgroup without IUT (n=27) may be too 
small to draw firm conclusions. Recently, a research group from Brazil finalized a similar RCT on 
IVIg for neonates with Rhesus hemolytic disease and, in accordance with our results, found no 
difference between both groups on the rate of ET. Importantly, in their study the vast majority 
of patients (n=80) had no prior treatment with IUT (ClinicalTrials.gov NCT00288600).29 There-
fore, both our RCT and the RCT from the Brazilian research group failed to show any effect 
of IVIg in Rhesus hemolytic disease infants, irrespective of whether or not the infants were 
treated with IUT. Care should be taken when interpreting our results, particularly the sub-
group analyses, due to the relatively limited number of patients. In addition, caution should be 
used before applying the results of this study to all Rhesus isoimmunized infants. There may 
be a subset of Rhesus isoimmunized infants with (inappropriate) delayed start of intensive 
phototherapy, for whom IVIg might be effective. More studies are needed to study the effect 
of IVIg in this specific subset of infants.
Although IVIg is considered to be an extremely safe product, adverse events can not be totally 
eliminated. Rare but serious side effects such as transfusion transmitted diseases, anaphylaxis, 
hypersensitivity, thrombosis, pulmonary emboli and renal failure have been reported.21,22 
Recently, Figueras-Aloy et al30 reported a higher incidence of necrotizing enterocolitis (NEC) 
in near-term infants with Rhesus hemolytic disease treated with IVIg compared to a control 
group managed without IVIg. The authors correctly suggest that their results must be inter-
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preted with care given the retrospective nature of the study. Whether occurrence of NEC was 
related to the administration of IVIg or to the fact that infants receiving IVIg were more ill than 
the control group is not clear. Nevertheless, since potential (but rare) adverse effects associ-
ated with the use of IVIg can not be ruled out, the authors call for more caution when using IVIg 
in neonates with Rhesus hemolytic disease. IVIg is a blood product prepared by separating the 
gamma-globulin fraction from the plasma pooled from multiple donors. The manufacturing 
of IVIg, including fractionation and filtration of viruses is an extremely intensive and expensive 
process. Therefore, the use of IVIg for indications that are not confirmed by well-designed RCTs 
should be restricted.22
Conclusion
Prophylactic treatment with IVIg (in a dosage of 0.75 g/kg) did not reduce the need for ET nor 
the rates of other adverse neonatal outcomes. Our findings do not support the current recom-
mendations of the AAP to use IVIg in neonates with Rhesus hemolytic disease. In view of the 
absence of beneficial effects, the use of IVIg for this indication should be discouraged.
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Exchange transfusion (ET) is the most effective method for treatment of severe hyperbiliru-
binemia and is often required in Rhesus hemolytic disease of the newborn (RHDN). The use 
of ET is also associated with adverse reactions, including severe catheter-related infectious 
complications. We report a term neonate with RHDN treated with an ET through an umbili-
cal venous catheter who developed brain abscesses due to a Bacillus cereus sepsis. This 
severe complication has not previously been reported. We discuss possible causes for this 
severe infection and provide suggestions on prevention.
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Introduction
Exchange transfusion (ET) plays an important role in the treatment of hyperbilirubinemia 
of the newborn. Rhesus associated hemolytic disease of the newborn (RHDN) is one of the 
most common indications for ET. The main therapeutic effect of ET is removal of excess bili-
rubin and maternal red blood cell antibodies in order to prevent kernicterus and to reduce 
hemolysis. Despite improvement in neonatal intensive care, ET still remains a high-risk inva-
sive procedure associated with a significant rate of adverse reactions. Although the mortal-
ity rate associated with ET is nowadays less then 0.3% in term infants, morbidity rates may 
reach 5%.1 Morbidity includes in particular catheter-related complications such as thrombo-
sis, sepsis and necrotizing enterocolitis.1
We report a term neonate with RHDN treated with an ET who developed a rare but severe 
cerebral infection after umbilical cord catheterization. 
Case report
A 36-year-old gravida 2 para 1 with severe Rh D alloimmunization required 3 intrauterine 
transfusions with filtered red blood cell concentrate for fetal anemia. These procedures 
were uncomplicated. The last transfusion before birth was done at 34 weeks’ gestation, 
with a post-transfusion hemoglobin level of 15.1 g/dl. The first labour had been protracted 
and was complicated by a complete perineal laceration after vacuum assisted delivery. For 
this reason the parents required a caesarean delivery, which was planned 3 weeks after 
the final intrauterine transfusion at a gestation of 37 weeks. A male infant was born with 
a birth weight of 2400 grams (25th percentile for gestational age) and Apgar scores of 10, 
10 and 10 at 1, 5 and 10 min, respectively. No abnormalities were detected on physical 
examination, except a pale skin color. Laboratory investigations at birth showed a hemo-
globin value of 9.6 g/dL, a total bilirubin concentration of 11.8 mg/dL and a conjugated 
bilirubin concentration of 11.3 mg/dL. Treatment with intensive phototherapy was started 
immediately after birth. After obtaining parental informed consent, the infant was included 
in a randomized placebo controlled trial to assess the short and long term effects of pro-
phylactic use of intravenous immunoglobulin (IVIg) in neonates with RHDN (LIVIN trial: 
http://www.controlled-trials.com/ISRCTN14013064/). For this study a ready for use 5% IVIg 
solution (Nanogam® Sanquin, The Netherlands) or glucose 5% (placebo) was used. Our 
patient was randomized for IVIg which he received within four hours after birth. Due to per-
sisting elevated bilirubin concentrations and possible need for an ET an umbilical venous 
catheterization was performed. Despite intensive phototherapy, the total serum bilirubin 
Chapter 4
52
level increased gradually to a maximum level of 21.2 mg/dL, exceeding the threshold for ET, 
which was performed on day 3 through the umbilical vein catheter. 
On day 6, the infant became acutely ill, his body temperature rose to 39.0°C and he became 
irritable. The white blood cell count was 8,100/μL (with 10% band forms) and the C-reactive 
protein concentration was 59 mg/L. Cerebrospinal fluid (CSF) analysis showed pleocytosis 
(10,513 cells/μL) and an elevated protein content (137 mg/dL), but the volume of CSF was 
not sufficient for culture. A peripheral blood culture was obtained and processed according 
to standard protocol, using culture vials for pediatric blood specimens (BACTEC culture vials 
type PED PLUSTM /F, enriched soybean-casein digest broth with resins). Meningitis therapy 
was initiated with vancomycin and ceftazidim intravenously. Subsequently, a lumbar punc-
ture was repeated and CSF was collected for culture. Urinalysis was normal. On day 7, the 
blood culture came back positive (after 24 h incubation) for a Gram-positive, rod-shaped, 
beta-hemolyticum bacterium, identified as Bacillus cereus. It was found susceptible to van-
comycin, meropenem and clindamycin, but resistant to penicillin. Bacterial and viral CSF 
cultures remained negative. Cultures of the packed cells used for the intrauterine blood 
transfusions and for the ET were sterile. 
Cranial ultrasound on day 7 revealed a lesion in the right frontal region with signs of central 
necrosis and a rim of hyperechogenicity around it, suspect for a cerebral abscess, whereas a 
cranial ultrasound performed on day 1 had shown no abnormalities. 
Monotherapy with meropenem was started because of a better passage through the blood- 
brain barrier. Magnetic resonance imaging (MRI) on day 11 showed multiple hemorrhagic 
cerebral abscesses in the right frontal, temporal and occipital lobe (Figure 1) and a few small 
abscesses in the cerebellum. 
Figure 1  T2-weighted MRI showing 
a large hemorrhagic abscess in the 
right frontal lobe
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On day 21 the child again became irritable and developed a seizure (stretching of both arms 
and legs). Because of the short duration of the seizure (less than 1 min) and a normal elec-
troencephalogram (EEG), anticonvulsant medication was not required. On day 29 the infant 
had a recurrent generalized convulsion and anticonvulsant treatment (phenobarbital) was 
initiated. Again, the EEG showed no epileptic activity. A MRI performed a few days after the 
seizures showed no changes in the cerebral lesions. 
After 6 weeks of intravenous meropenem administration, antibiotic treatment was discon-
tinued. The infant was discharged home on day 61 with anticonvulsant therapy. At 2 years 
of age, the infant had no neurologic sequelae on physical examination. Mental and psy-
chomotor development indexes, assessed at 2 years of age with the Bayley Scales of Infant 
Development, were within normal ranges.
Discussion
ET has been used in neonatal intensive care units for more than 50 years and is still the 
most effective method for treatment of severe hyperbilirubinemia. However, ET is also asso-
ciated with severe adverse reactions, including catheter-related infectious complications.2 
We report a term infant with cerebral abscesses due to a Bacillus cereus sepsis, a severe 
complication which has not previously been reported.
Bacillus cereus is a probably ubiquitous soil bacterium and an opportunistic pathogen 
that is a common cause of food poisoning. In (premature) neonates, toxins produced by 
Bacillus cereus can cause necrosis of infected tissue. Bacillus cereus infections in neonates 
include meningoencephalitis and brain abscesses, characterized by liquefactive necrosis. 
A few sporadic cases have been reported in the literature and usually involved premature 
infants, suggesting an association with decreased immune response. Most cases of neo-
natal meningoencephalitis and cerebral abscesses with Bacillus cereus described in the 
literature resulted in neonatal death.3-7
Several potential risk factors may have led to the Bacillus cereus infection in this infant. 
Because of severe RHDN, three intrauterine blood transfusions and one ET were required. 
Multiple blood transfusions are associated with an increased risk of infection. However, cul-
tures of all donor blood used for the transfusions were sterile. Intrauterine transfusions have 
also been associated with several procedure-related complications, including, although 
rarely, intrauterine infections. In the largest published series on complications of intrauter-
ine transfusions, only two infections with E. Coli, both resulting in fetal distress within 48 h 
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after the procedure, were found in 740 procedures.8 In the current case, no signs of infection 
were present prenatally, and there was no premature rupture of membranes prior to the 
elective caesarean section. It seems therefore highly unlikely that the Bacillus cereus infec-
tion had a prenatal origin. Moreover, cranial ultrasound on day 1 showed no abnormalities, 
excluding a link between the cerebral abscesses and antenatal invasive procedures. 
Although very unlikely, another potential cause for infection in this case could be the IVIg 
solution. All IVIg preparations are routinely tested for sterility. The production of IVIg is an 
aseptical process. Up till now more than 80 batches resulting in approximately 100.000 vials 
of Nanogam® have been produced. Sterility tests on all these batches were negative.  
Lastly, the most probable cause for infection in this case was the umbilical venous catheter-
ization. Although umbilical venous catheterization is a common procedure in the manage-
ment of sick neonates, it can lead to serious complications. Sequelae include thrombosis, 
embolization, hemorrhage, arrhythmias, (pericardial) effusions, portal hypertension and 
infection.9 In the literature the incidence of sepsis related to umbilical venous catheteriza-
tion is reported between 6% and 24%.2
Umbilical venous catheterization was required in this case because an ET was deemed 
necessary to reduce the elevated bilirubin levels and the risk of bilirubin encephalopathy. 
However, whether catheterization and ET was strictly unavoidable is questionable. 
First, hyperbilirubinemia was mainly due to elevated levels of the conjugated bilirubin frac-
tion. Elevated levels of conjugated bilirubin are not a rare phenomenon in neonates with 
RHDN, although the etiology is not clear. The current AAP guidelines state that thresholds 
for treatment in hyperbilirubinemia should be based on the total bilirubin levels, without 
subtracting the conjugated bilirubin fraction.1 Nevertheless, when conjugated bilirubin is 
significantly elevated (i.e. > 50%) there is no bilirubin threshold at which intervention is rec-
ommended. Bilirubin encephalopathy is due to unbound, unconjugated bilirubin. Whether 
neonates with increased conjugated bilirubin are at increased risk for kernicterus is not 
known and management remains controversial. Management should ideally be based on 
the measurement of unbound, unconjugated bilirubin, but these measurements have not 
yet been adapted to clinical use. 
Second, the AAP guidelines recommend the use of IVIg in case of failure of intensive photo-
therapy in order to reduce the need for ET.1 The evidence to recommend routine prophy-
lactic treatment with IVIg is considered insufficient.10,11 A recent Cochrane review suggests 
that the results of further trials of higher quality should be awaited.10 Although the risk for 
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adverse effects of umbilical venous catheterization and ET may decrease in the future, it will 
never completely disappear. The best way to prevent procedure-related complications in 
RHDN is to reduce the need for ET.
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Objective: Our aim was to study the type and rate of complications associated with exchange 
transfusion (ET) in a large series of neonates with hemolytic disease of the newborn (HDN) 
due to red cell alloimmunization.
Patients and Methods: All neonates with HDN due to red cell alloimmunization admitted 
to our center between January 2001 and June 2011 were eligible for this study. We recorded 
the number and rate of complications during admission in the group of neonates treated 
with (ET-group) and without ET (no-ET-group). Multivariate logistic regression analysis was 
performed to measure independent risk of complications of ET treatment.
Results: A total of 347 infants with red cell alloimmune hemolytic disease were included, 
39% (134/347) was treated with at least one ET during admission (ET-group) and 61% 
(213/347) did not require ET (no-ET-group). Comparison between the ET-group and no-ET-
group showed that ET treatment was independently associated with : proven sepsis (8% 
versus 1% respectively, odds ratio (OR) 8.3, 95% confidence interval (CI) 1.7-40.3, p = 0.009), 
leukocytopenia (88% versus 23% respectively, OR 36.0, 95% CI 17.5-73.8, p < 0.001), severe 
thrombocytopenia (platelet count < 50×109/L) (63% versus 8% respectively, OR 31.4, 95% CI 
14.0-70.4, p < 0.001), hypocalcemia (22% versus 1% respectively, OR 27.4, 95% CI 5.9-126.8, 
p < 0.001) and hypernatremia (8% versus 0% respectively, p < 0.001). Neonatal death did 
not occur in the group treated with ET.
Conclusion: ET in neonates with HDN is associated with increased risk of sepsis, leukocyt-
openia, thrombocytopenia, hypocalcemia and hypernatremia.
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Introduction 
Hemolytic disease of the newborn (HDN) due to red cell alloimmunization may lead to 
excessive unconjugated hyperbilirubinemia. Neonatal treatment consists of intensive pho-
totherapy and exchange transfusion (ET) to prevent kernicterus. After introduction in the 
late 1940s1-3 neonatal treatment with ET became one of the most commonly performed 
neonatal procedures. However, ET is a high-risk invasive procedure requiring the use of 
central lines and is associated with a significant rate of adverse events. Several studies have 
reported on mortality and morbidity rates associated with ET. Although the contemporary 
mortality rate is reported to be less than 2%, rates of morbidity and ET-related adverse 
events can reach 74%.4-11 Reported adverse events include mainly catheter-related com-
plications (malposition, sepsis), complications related to the use of blood products (throm-
boembolization, graft versus host reactions, infection), metabolic derangements (acidosis, 
disturbance of serum levels of sodium, calcium, potassium and glucose) and cardio-respira-
tory reactions (including cardiac arrhythmias, cardiac arrest and apnea).4-11
In nearly all previous studies a heterogeneous group of infants with HDN treated with ET was 
included, varying from red cell alloimmunization to ABO-incompatibility.4-6,8,10,11 Hemolysis 
caused by ABO-incompatibility is usually less severe compared to red cell alloimmunization 
and therefore associated with a reduced rate of neonatal morbidity. Furthermore, different 
indications for ET were used, including anemia, idiopatic hyperbilirubinemia and metabolic/
intrinsic erythrocyte disorders (pyruvate kinase deficiency, glucose-6-phosphate-dehydro-
genase deficiency and Gilbert’s disease).4,10,11 In addition, most studies were limited by a 
relative small number of included patients.4-11 
The aim of this study was to evaluate the type and rate of complications associated with ET 
in a large series of neonates with HDN due to red cell alloimmunization exclusively.
Patients and methods
All term and preterm neonates with HDN due to maternal red cell alloimmunization treated 
with or without ET, admitted to our center between January 2001 and June 2011 were eligi-
ble for this retrospective observational study. The Leiden University Medical Center (LUMC) 
is the national referral center for the management and intrauterine treatment of red cell 
alloimmunization in the Netherlands. Neonatal outcome in part of this group was reported 
in previous studies.12-16  
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Guidelines for the management of neonates with HDN admitted to our nursery (includ-
ing intensive phototherapy and exchange transfusion) have previously been described.12,13 
The guidelines for ET used in our neonatal center were revised in December 2005. Before 
December 2005, criteria for ET included: (1) bilirubin level at birth > 3.5 mg/dL (so-called 
early criterion) and/or (2) total serum bilirubin level above ET thresholds (rise of bilirubin 
value > 0.5 mg/dL/h despite intensive phototherapy). In neonates not treated with IUT, a 
hemoglobin level at birth of < 12.9 g/dL was also considered as an early criterion for ET.14 In 
December 2005 a new guideline of the American Academy of Pediatrics (AAP) with higher 
bilirubin thresholds for phototherapy and ET was implemented in our nursery.17 The criteria 
for ET after December 2005 were: (1) total serum bilirubin above (higher) ET thresholds17 
and/or (2) rise of bilirubin > 0.5 mg/dL/h despite intensive phototherapy, and/or (3) clinical 
symptoms of acute bilirubin encephalopathy regardless of bilirubin level. 
ET was performed with double-volume transfusion (160 mL/kg). In our center ET was 
performed with heparinized blood until December 2000. As of January 2001 heparinized 
blood was replaced by citrated plasma from a non-transfused male donor, lacking irregular 
erythrocyte antibodies, which was added to irradiated, leukocyte-depleted (< 1×106) and 
thrombocyte-reduced red cell concentrate, compatible with maternal antibodies. Citrated 
plasma contains nearly no free calcium and physiologic levels of potassium and glucose, 
with an increased concentration of sodium (168 mEq/L). Because of the well-known differ-
ences in complications between heparinized and citrated blood,18,19 we started including 
patients from the moment citrated plasma was used (January 2001).
Primary outcome of this study was the rate of complications during admission in the group 
treated with ET (ET-group) and without ET (no-ET-group).
An adverse event was defined as any complication that occurred during admission. The 
following events were recorded (definitions are described between brackets): hypocalce-
mia (total serum calcium < 8 mg/dL), hypoglycemia (serum glucose < 46.8 mg/dL), hyper-
kalemia (serum potassium > 6.5 mEq/L), hypokalemia (serum potassium < 3.0 mEq/L), 
hypernatremia (serum sodium > 150 mEq/L), hyponatremia (serum sodium < 130 mEq/L), 
metabolic acidosis (requiring treatment with bicarbonate), respiratory failure (requiring 
respiratory support with continuous positive airway pressure (CPAP) and/or mechanical ven-
tilation), apnea (cessation of respiration for > 20 seconds), pulmonary hemorrhage, cardiac 
arrest (sudden cessation of heartbeat and cardiac function treated with cardiac resuscita-
tion with either epinephrine and/or chest compressions), hypertension (high blood pres-
sure requiring treatment with antihypertensive medication), hypotension (low blood pres-
sure requiring treatment with intravenous fluids or vasopressors), necrotizing enterocolitis 
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(classified according to Bell’s criteria20), proven sepsis (clinical and/or biochemical signs of 
infection with a positive blood culture), suspected sepsis (clinical and/or biochemical signs 
of infection without a positive blood culture), disseminated intravascular coagulation (DIC) 
(requiring treatment with fresh frozen plasma), seizures (clinical evidence of seizure-like 
activity treated with anti-epileptic medication), leukocytopenia (leukocyte count in the first 
24 hours after birth < 9x109/L and after 24 hours < 5×109/L)21, thrombocytopenia (platelet 
count < 150×109/L, defined as severe if platelet count < 50×109/L and very severe if platelet 
count < 20×109/L), intraventricular hemorrhage (classified according to Volpe22) or other 
cerebral hemorrhage and neonatal death. In our center, platelet transfusions are given 
when platelet counts fall below the following thresholds: 1) < 100×109/L before planned ET 
and 2) < 50×109/L after ET.
We recorded the following obstetric and neonatal data: type of red cell alloimmunization, 
number of intrauterine red cell transfusions (IUT), gestational age at birth, birth weight, 
presence of hydrops at birth, hemoglobin level, reticulocyte count, leukocyte count and 
bilirubin level at birth, days of admission, occurrence of the above mentioned complicati-
ons during admission and time of occurrence in relation to ET, number of ETs and presence 
of umbilical venous catheter.   
 
Data are reported as means and standard deviations (SD) or as medians and interquartile 
ranges (IQR). Statistical analysis was performed using Student-t test and Mann-Whitney test 
for continuous variables. Chi-square and Fisher’s-exact test were used for categorical vari-
ables. A p-value < .05 was considered to indicate statistical significance. Of all statistically 
significant complications identified with univariate analysis between the ET-group and no-
ET-group a multivariate logistic regression analysis was performed to measure the indepen-
dent effect of ET(s). The results of the logistic regression models were expressed as odds 
ratios (OR) and 95% confidence intervals (CI). Statistical analysis was performed using SPSS 
17.0 (SPSS Inc., Chicago, IL, USA).
Results
During this 10-year study, 348 neonates with HDN due to red cell alloimmunization were 
admitted to our neonatal nursery. We excluded one preterm neonate (born at 29 weeks’ 
gestation) because he died immediately after caesarean section due to severe perinatal 
asphyxia following unsuccessful IUT. A total of 347 patients were included in this study, 134 
(39%) in the group with at least one ET during admission (ET-group) and 213 (61%) in the 
group without ET (no-ET-group). Baseline characteristics of both groups are summarized in 
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Table 1. The mean (± SD) number of ETs in the ET-group was 1.55 ± 1.01 (median 1, range 
1-9). Neonates with Rhesus D type of red cell alloimmunization were more likely to require 
treatment with ET (91% (122/134) versus 65% (138/213), p < 0.001), whereas treatment with 
ET was only sporadically required in neonates with Kell alloimmunization (1% (1/134) versus 
22% (46/213), p < 0.001).
Complications
Detailed information on complications during admission in the ET-group and the no-ET-
group is summarized in Table 2.
Univariate logistic regression analysis
Metabolic derangements/complications
Two metabolic complications had a significantly higher incidence in the ET-group than in 
the no-ET-group: hypocalcemia (22% versus 1%, OR 29.1, 95% CI 6.8-124.5) and hypernatre-
mia (8% versus 0%, OR not calculated, p < 0.001). Four of 31 (13%) neonates with hypocalce-
Table 1  Baseline characteristics in ET-group and no-ET-group
ET 
 (n = 134)
no-ET
 (n = 213)
p-value
Type of red cell alloimmunization
     Rh D - n (%) 122 (91) 138 (65) < 0.001
     Rh c - n (%) 11 (8) 16 (8) 0.813
     Kell - n (%) 1 (1) 46 (22) < 0.001
     Other types than Rh D, Rh c or Kell - n (%) 0 (0) 13 (6)
Neonates treated with IUT - n (%) 99 (74) 141 (66) 0.131
Birth weight - kga 2.9 ± .6 2.9 ± .6 0.591
Gestational age at birth - weeksb 36 (36-37) 36 (36-37) 0.247
Male - n(%) 89 (66) 130 (61) 0.311
Hydrops at birth - n (%) 2 (2) 4 (2) 1.000
Hemoglobin level at birth - g/dLa 11.6 ± 2.6 12.7 ± 2.9 < 0.001
Reticulocyte count at birth – ‰b,c 49 (6.8-83.3) 39 (3-75.5) 0.089
Leukocyte count at birth – 109/La,d 14.1 ± 5.6 13.4 ± 5.7 0.270
Thrombocytopenia at birth - n (%) 39 (29) 48 (23) 0.169
Bilirubin level at birth - mg/dLa 7.1 ± 3.1 4.8 ± 2.3 < 0.001
Umbilical venous catheter – n (%) 133 (99) 64 (30) < 0.001
Days of admissiona 6.6 ± 3.8 6.2 ± 3.9 0.009 
a  Value given as mean ± SD
b Value given as median (IQR)
c assessed in 78/134 and 149/213 neonates
d assessed in 130/134 and 207/213 neonates
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mia needed calcium replacement therapy and 3 of 11 (27%) needed treatment (additional 
sodium-free intravenous fluid) for hypernatremia. Severe symptoms of hypernatremia (sei-
zures) did not occur.
Cardio-respiratory complications
No significant differences were seen between the two groups in respiratory support, apneas, 
cardiac arrest, and hypotension (Table 2). No cases of cardiac rhythm disorders, pulmonary 
hemorrhage and hypertension (requiring treatment) occurred. 
Infectious complications
Proven sepsis occurred significantly more often in the ET-group than in the no-ET-group (8% 
versus 1%, OR 6.3, 95% CI 1.7-22.9). In the 14 neonates with proven sepsis, bacterial cultures 
were positive for Staphylococcus aureus in 7/14 (50%), coagulase-negative Staphylococcus 
in 3/14 (22%), beta-hemolytic Streptococcus in 1/14 (7%), Klebsiella pneumonia in 1/14 (7%), 
Escherichia coli in 1/14 (7%) and Bacillus cereus in 1/14 (7%). This last patient de veloped 
a Bacillus cereus sepsis with brain abscesses after an ET performed through an umbilical 
venous catheter. This exceptional case has previously been reported.23
The rate of leukocytopenia was significantly higher in the ET-group than in the no-ET-group 
(88% versus 23%, OR 24.7, 95% CI 13.4-45.5). All ET-treated neonates with proven sepsis had 
leukocytopenia during admission and in 55% (6/11) leukocytopenia occurred after ET.
Umbilical venous catheterization was performed significantly more often in the ET-group 
than in the no-ET-group (99% versus 30%) (Table 1).
Hematological complications
The rate of thrombocytopenia (platelet count < 150×109/L) was significantly higher in the 
ET-group than in the no-ET-group (99% versus 32%, OR 143.8, 95% CI 34.6-598.6), and this 
was also true for severe thrombocytopenia and very severe thrombocytopenia (Table 2). 
Seventy-five of 134 ET-treated neonates (57%, 2 missing values) were treated with at least 
one platelet transfusion. One near-term neonate with Rhesus D alloimmunization born at 
36 weeks’ gestation received a platelet transfusion after ET on day one because of a post-ET 
platelet count of 39×109/L. On day 2 a cranial ultrasound showed a hemorrhage in the right 
parieto-occipital periventricular white matter. This hemorrhage was not seen on antenatal 
ultrasounds. Magnetic resonance imaging showed no signs of sinus thrombosis and coa-
gulation was normal. At one year of age, the infant had no neurologic sequelae on phy-
sical examination. In the no-ET-group 3 neonates had signs of intracerebral hemorrhage 
on cranial ultrasound and/or MRI of whom one neonate had severe thrombocytopenia for 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Only one of the 347 neonates died during admission. This neonate from the no-ET-group, 
born at 30 weeks’ gestation, suffered from severe fetal hydrops and died on day 11 due to 
multiple organ failure including respiratory failure due to respiratory distress syndrome and 
severe pulmonary hypertension, bilateral intraventricular hemorrhage grade 2 and renal 
failure. 
ET guideline change
To measure the possible effect of ET guideline change12 on the rate of the previously men-
tioned complications (Table 2) we performed a sub-analysis of ET treated neonates before 
and after guideline change. The rates of complications were not significantly different 
between both groups (data not shown). 
Multivariate logistic regression analysis
Complications during entire admission 
On multivariate logistic regression analysis we corrected for the following covariates: hemo-
globin level at birth, type of red cell alloimmunization, days of admission, and gestational 
age at birth. We corrected for the first two because of the significant differences at baseline 
(Table 1) and for the latter because preterm neonates are more susceptible for ET-related 
complications.10,24 Since the presence of an umbilical venous catheter and ET are correlated 
(Spearman correlation coefficient r = 0.680, p = <0.001), we did not correct for the presence 
of an umbilical venous catheter. Multivariate regression analysis demonstrated that four 
complications, i.e. proven sepsis (OR 8.3, 95% CI 1.7-40.3), severe thrombocytopenia (OR 
31.4, 95% CI 14.0-70.4), leukocytopenia (OR 36.0, 95% CI 17.5-73.8) and hypocalcemia (OR 
27.4, 95% CI 5.9-126.8), had a higher incidence in the ET-group than in the no-ET-group 
(Table 2). Because none of the neonates in the no-ET-group had hypernatremia, additional 
multivariate logistic regression analyses could not be performed.
Complications after first ET 
In Table 2 all complications during entire admission in both groups are reported. Since our 
main interest is in ET-related complications, we performed a sub-analysis excluding all com-
plications in the ET-group that were observed before (first) ET (adjusted-ET-group). Results 
are shown in Table 3.
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Discussion
This study demonstrates that treatment with ET in neonates with HDN is associated with an 
increased risk of sepsis, thrombocytopenia, leukocytopenia, hypocalcemia and hypernatre-
mia. Treatment with ET was not associated with neonatal death in our cohort.
In the last three decades several studies have been published on neonatal morbidity due 
to treatment with ET.4-11 One of the known risk factors associated with ET is development 
of invasive bacterial infections. The reported incidence of ET-related sepsis ranges from 0% 
to 11%.6,8,10 The incidence of proven sepsis detected in this study (8%) is in accordance with 
these previous reports. We found that the independent risk of sepsis was more than eight 
times higher in the ET-group than in the no-ET-group. The exact cause of the increased risk 
of infection is not fully understood, but is most probably related to the use of umbilical lines 
for ET. Umbilical catheters are a well known risk factor for nosocomial infection.25 Sepsis in 
the ET-group may also be caused by administration of infected blood products. Although 
the current risk of transmission of infectious diseases is relatively low, it is not completely 
negligible.7,26 Furthermore, ET-related wash out of leukocytes may also play a role in the 
higher incidence of sepsis in the ET-group, since in double volume ET more than 90% of cir-
culating blood is replaced by leukocyte-depleted donor-blood.19,26-28 Finally, limited data on 
leukocytopenia in neonates with HDN due to red cell alloimmunization show that the risk of 
leukocytopenia is increased in severe Rhesus HDN.29-32 In this study 86% (12/14) of neonates 
with proven sepsis had leukocytopenia of whom 11 were treated with ET. In 55% (6/11) leu-
kocytopenia occurred after treatment with ET. In the remaining 45% leukocytopenia might 
be caused by bone marrow suppression due to increased erythropoiesis.
Another reported risk associated with ET is thrombocytopenia due to the use of a blood 
product which consists of thrombocyte-free erythrocytes.18,19,33 Previous studies reported 
incidences of ET-related thrombocytopenia ranging from 6% to 44%.4-6,8,10,11 In our study, 
the incidence of thrombocytopenia (< 150×109/L) in the ET-group was much higher, almost 
all neonates (99%) had low platelet counts and 63% had severe thrombocytopenia (plate-
lets < 50×109/L). The differences in incidence can be explained by several factors including 
methodological differences and differences in study population. We only included neo-
nates with red cell alloimmune HDN which is known to be associated with an increased 
risk for thrombocytopenia, even without ET.16,34-36 Because other studies included neo-
nates with ABO-incompatibility, their incidence of thrombocytopenia should be lower. In 
this study, the risk of severe thrombocytopenia is 21-fold higher in the group treated with 
ET. Neonatologists must be aware of this potentially devastating complication as massive 
hemorrhage may arise after ET. Complications can be prevented by prophylactic platelet 
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transfusion before, during or after ET in case of low platelet counts. In our study, platelet 
transfusions were administered in 57% of neonates before, during or after ET. 
A third known complication of ET is hypocalcemia, resulting from the use of citrated blood 
which contains almost no free calcium.18,19,33,37 Previous studies reported incidences of 
hypocalcemia ranging from 3% to 42%.4,8,10,11 In our study, 22% of neonates in the ET-group 
had a serum calcium < 8 mg/dL, and 13% of all hypocalcemic infants needed replacement 
therapy. We found that treatment with ET was independently associated with an almost 
30-fold increased risk of hypocalcemia. If left untreated, hypocalcemia can lead to poten-
tially devastating complications such as seizures and cardiac arrhythmias. It is therefore 
crucial to measure calcium levels during the ET-procedure and act accordingly.  
Another metabolic complication which appears to be related to ET is hypernatremia. 
Hypernatremia probably results from an increased level of sodium in citrated blood (in our 
center 168 mEq/L). Only few studies have reported hypernatremia resulting from ET, and 
the exact incidence is unknown.38,39 Because hypernatremia can lead to serious complica-
tions, we recommend frequent measurements of serum sodium levels during and after ET.
Finally, previous studies have reported that ET may also lead to neonatal death. Neonatal 
mortality attributable to ET ranges between 0.5% and 2%.4,8-10 In accordance with our find-
ings, three recent studies reported no neonatal deaths after ET.5,6,11 However, all these studies 
(as well as ours) were not powered to detect a difference in neonatal mortality. Differences 
between the reported rates can be explained by methodological differences such as dif-
ferent sizes of the study cohorts and differences in disease-severity between the cohorts. 
Neonates included in previous studies were often more premature than the near term-age 
population in our cohort.9-11 Another explanation could be that our center is the national 
referral center for intrauterine treatment of red cell alloimmunization. Consequently nearly 
all severely affected neonates with HDN due to red cell alloimmunization are born and 
treated in our center. As a result, ET is a frequently performed and standardized procedure 
in our unit and part of routine practice. We speculate that this may have contributed to the 
low level of severe morbidity or mortality in the ET-group. 
To our knowledge this is the first large study comparing neonatal complications in a group 
of infants with red cell alloimmunization treated with ET and a control-group without ET. 
Nevertheless, the results of this study should be interpreted with care because of the retro-
spective study design. 
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In conclusion, sepsis, leukocytopenia, thrombocytopenia, hypernatremia and hypocalce-
mia are common complications in neonates with HDN due to red cell alloimmunization 
treated with ET. In experienced hands severe permanent morbidity and mortality rates due 
to ET-procedures can be reduced to a minimum.
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Cholestasis in neonates with red cell alloimmune 
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Background: Etiology of cholestatic liver disease in neonates with hemolytic disease of the 
newborn (HDN) has been associated with iron overload due to intrauterine red cell transfu-
sions (IUTs). Data on the incidence and severity of cholestasis in neonates with HDN is scarce, 
and little is known about pathogenesis, risk factors, neonatal management and outcome.
Objective: To evaluate incidence, risk factors, management and outcome of cholestasis in 
neonates with red cell alloimmune hemolytic disease.
Methods: All (near-) term neonates with HDN due to red cell alloimmunization admitted to 
our center between January 2000 and July 2010 were included in this observational study. 
Liver function tests (including conjugated bilirubin) were routinely performed in the neo-
natal period. We recorded the presence of cholestasis, investigated several potential risk 
factors and evaluated the management and outcome in affected neonates. 
Results: A total of 313 infants with red cell alloimmune hemolytic disease treated with or 
without IUTs were included. The incidence of cholestasis was 13% (41/313). Two risk fac-
tors were independently associated with cholestasis: treatment with at least one IUT (OR 
5.81, 95% CI 1.70-19.80, p=0.005) and Rhesus D type of alloimmunization (OR 4.66, 95% CI 
1.05-20.57, p=0.042). Additional diagnostic tests to investigate possible causes of cholesta-
sis were all negative. In five infants (12%) supportive medical and nutritional therapy was 
started and one neonate required iron chelation therapy.
Conclusion: Cholestasis occurs in 13% of neonates with HDN due to red cell alloimmuniza-
tion and is independently associated with IUT treatment and Rhesus D type of alloimmu-
nization.
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Introduction
Hemolytic disease of the newborn (HDN) due to red cell alloimmunization may lead to 
excessive unconjugated hyperbilirubinemia, anemia and iron overload.1 A few studies have 
reported an association between HDN and the development of conjugated hyperbilirubine-
mia, i.e. cholestasis.2-5 Some of these studies (mostly case reports) describe that cholestasis 
in neonates with HDN is uncommon and usually mild and transient.3-5 Other reports how-
ever detail severe and protracted courses of cholestasis.2,4,6,7 The etiology of cholestatic liver 
disease in neonates with HDN has been associated with iron overload due to intrauterine 
transfusions (IUTs).6,8-10 Data on the incidence and severity of cholestasis in neonates with 
red cell alloimmune hemolytic disease is scarce, and little is known about pathogenesis, risk 
factors, neonatal management and outcome. 
The aim of this study was to evaluate incidence, potential risk factors, management and out-
come of cholestasis in a large series of neonates with HDN due to red cell alloimmunization. 
Methods
All consecutive cases of (near-) term neonates (≥35 weeks of gestation) with HDN due to 
maternal red cell alloimmunization admitted to our center between January 2000 and July 
2010 were included in this retrospective study. Neonatal outcome in part of this group 
was described in previous studies.11-14 The Leiden University Medical Center (LUMC) is the 
national referral center for the management and intrauterine treatment of red cell allo-
immunization in the Netherlands. We excluded all preterm neonates (<35 weeks of gesta-
tion) and neonates in whom conjugated bilirubin tests were not performed. The guidelines 
for the management of neonates with HDN admitted to our nursery (including intensive 
phototherapy and exchange transfusion (ET)) have previously been described.12,13 
In addition to frequent total bilirubin levels, extensive diagnostic evaluations are routinely 
performed at birth and during the first week of life in infants with red cell alloimmune HDN 
admitted to our neonatal nursery. These evaluations include hematologic tests (complete 
blood counts), liver function tests (liver enzymes and total and conjugated bilirubin) and 
blood group, Coombs and irregular antibody tests. 
Primary outcome of this study was the incidence of cholestatic icterus in neonates with 
HDN due to red cell alloimmunization. Secondary outcomes were management and out-
come of cholestasis. 
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Cholestasis or conjugated hyperbilirubinemia was defined as a conjugated serum bilirubin 
level above 1.0 mg/dL if total serum bilirubin level is less than 5 mg/dL, or a value of conju-
gated bilirubin that represents more than 20% of total bilirubin if the total bilirubin level is 
greater than 5 mg/dL.15 Severe cholestasis was defined as a conjugated bilirubin level >50% 
of the total serum bilirubin concentration. 
In neonates with cholestasis we recorded the following data: symptoms of cholestasis (such 
as discolored stools and dark urine), duration of conjugated hyperbilirubinemia, (type of ) 
therapy (including Ursodeoxycholic acid (15 mg/kg/d), Vitamin A (2500-5000 IU/d, in pre-
matures 1000-1500 IU/kg/d), vitamin D (800 IU/d, in prematures 400 IU/d), vitamin E (5-10 
mg/kg/d, in prematures 10-20 mg/kg/d), vitamin K (1 mg/d, birth weight < 1500 grams: 
0.5 mg/d) and formula with medium chain triglycerides) and investigations performed to 
establish a specific cause for the cholestatic icterus. Possible causes for neonatal cholestasis 
are (1) infections (sepsis, urinary tract infection, toxoplasmosis, rubella, cytomegalo virus, 
human herpes virus 6, syphilis, parvovirus B19, echovirus, adenovirus, coxsackie virus, hep-
atitis B and C); (2) bile duct anomalies, including biliary atresia and choledochal cyst; (3) 
inborn errors of metabolism, including alpha-1-antitrypsin deficiency, galactosemia, cystic 
fibrosis, tyrosinemia and progressive familial intrahepatic cholestasis, and (4) endocrinopa-
thies (hypothyroidism and hypopituitarism).
We recorded the following obstetric and neonatal data: type of red cell alloimmunization, 
number of IUTs, gestational age at birth, birth weight, total bilirubin level and conjugated 
bilirubin level at birth, maximum total bilirubin level and maximum conjugated bilirubin 
level during admission, time until cholestasis disappeared (within 1 week, between 1 week 
and 1 month or after 1 month), maximum ferritin level during admission, duration of photo-
therapy, number of ETs required and number of top up red blood cell transfusions received 
during the first 3 months of life. 
Data are reported as means and standard deviations (SD) or as medians and ranges. Sta-
tistical analysis was performed using Student-t test and Mann-Whitney test for continuous 
variables. Chi-square and Fisher’s-exact test were used for categorical variables. To assess 
the relationship between ferritin level and treatment with IUT a Spearman correlation was 
calculated. A p-value <0.05 was considered to indicate statistical significance. All predicting 
risk factors for cholestasis identified with univariate analysis were included in a multivariate 
logistic regression model to measure independent effects. The results of the logistic models 
were expressed as odds ratios (OR). Statistical analysis was performed using SPSS 17.0 (SPSS 
Inc., Chicago, IL, USA).
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Results
During the study period 357 neonates with HDN due to red cell alloimmunization were 
admitted to our neonatal nursery. We excluded 35/357 (10%) neonates due to prematurity 
(<35 weeks of gestation) and 9/357 (3%) neonates because conjugated bilirubin levels were 
not available. A total of 313 patients were included in this study. Forty-one neonates (13%) 
met the criteria for cholestasis (cholestasis group). Baseline characteristics are summarized 
in Table 1. 
Risk factors for cholestasis
Detailed information on risk factors for cholestasis is summarized in Table 2.16,17
Eighty-eight percent of neonates with cholestasis had both Rhesus D type of alloimmuni-
zation and were treated with IUT.
Univariate analysis
Several risk factors were found to be associated with cholestasis, including: lower birth 
weight (OR 3.70 for each kg less, 95% CI 1.61-8.33, p=0.001 and OR 1.92 for each 500 grams 
less, 95% CI 1.27-2.89, p=0.002), Rhesus D type of alloimmunization (OR 6.89, 95% CI 1.62-
Table 1  Baseline characteristics
Neonates with HDN 
(n=313)
Neonates treated with IUT - n (%) 206 (66)
Number of IUTs in IUT treated neonatesa 3 (1-6)
Gestational age at birth - weeksa 37 (35-42)
Birth weight - kgb 3.0 ± 0.4
Male - n (%) 197 (63)
Type of red cell alloimmunization
       Rhesus D - n (%) 240 (76.7)
       Rhesus C - n (%) 2 (0.6)
       Rhesus c - n (%) 24 (7.7)
       Rhesus E - n (%) 7 (2.2)
       Kell - n (%) 38 (12.1)
       Cw - n (%) 1 (0.3)
       Jk(a) - n (%) 1 (0.3)
a Value given as median (range)
b Value given as mean ± SD
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29.26, p=0.009), treatment with IUT (OR 7.84, 95% CI 2.36-26.05, p<0.001), total serum bili-
rubin level at birth (OR 1.19, 95% CI 1.07-1.33, p=0.004), maximum ferritin level (OR 1.04 per 
100 μg/L more, 95% CI 0.99-1.08, p<0.001) and number of top up transfusions (OR 1.43, 95% 
CI 1.15-1.77, p=0.004).
Multivariate analysis
On multivariate analysis, the following risk factors were independently associated with 
cholestasis: Rhesus D type of alloimmunization (OR 4.66, 95% CI 1.05-20.57, p=0.042) and 
treatment with IUT (OR 5.81, 95% CI 1.70-19.80, p=0.005). 
Because a higher total bilirubin level at birth is part of the definition of cholestasis and 
thus closely related to a higher conjugated bilirubin level, total bilirubin level at birth was 
excluded from multivariate analysis. As ferritin levels were determined only in 89/313 (28%) 
neonates and ferritin level and treatment with IUT were positively correlated (r=0.565, 
p=<0.001), ferritin was not included in the multivariate analysis. 
Clinical characteristics and outcome of cholestasis
In the cholestasis group 11/41 infants (27%) had severe cholestasis with a conjugated bili-
rubin level >50% of the total serum bilirubin concentration. Four neonates (10%) had symp-
toms of cholestasis such as discolored stools or dark urine. In 15% (6/41) the cholestasis dis-
appeared spontaneously within 1 week, in 15% (6/41) between 1 week and 1 month and in 
15% (6/41) within 1 to 3 months. In the remaining 56% (23/41) of infants the time of disap-
pearance of cholestasis is not clear due to incomplete follow up. However, only 9% (2/23) of 
neonates with incomplete follow up had severe cholestasis. In five infants (12%) supportive 
medical and nutritional therapy was started (Ursodeoxycholic acid, Vitamin A, D, E, K and/or 
formula with medium chain triglycerides). In one infant Ursodeoxycholic acid was given for 
a period of 18 days, in the remaining 4 infants duration of therapy is not known since they 
were transferred to other hospitals while they were still on medication.
One patient with Rhesus D alloimmunization, who received 6 IUTs, developed severe 
cholestasis (maximum bilirubin level 41.3 mg/dL and maximum conjugated bilirubin level 
35.1 mg/dL) and severe hyperferritinemia (maximum serum ferritin level 73000 μg/L). Iron 
chelation therapy with desferrioxamine was started and continued for one month to reduce 
the serum ferritin concentration and liver iron contents. After having excluded other causes 
of cholestasis, the most probable explanation for the cholestasis in this case was hyperfer-
ritinemia with iron overload in the liver, due to multiple IUTs. 
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Additional investigations in cholestasis group
In the cholestasis group, laboratory investigations to evaluate possible liver injury were per-
formed in 36/41 infants (88%). Elevated levels for alkaline phosphatase were detected in 6 
(15%), for aspartate aminotransferase (AST) in 17 (41%), for alanine transferase (ALT) in 13 
(32%) and for gamma-glutamyl transpeptidase (γGT) in 8 infants (20%).16
In 18/41 (44%) neonates in the cholestasis group additional tests were performed to inves-
tigate possible causes of cholestasis. Sixteen infants (39%) were screened for infection. In 
all of them bacterial cultures of blood and urine were negative and there were no proven 
infections with toxoplasmosis, rubella, cytomegalovirus, human herpes virus 6, syphilis, par-
vovirus B19, echovirus, adenovirus, coxsackie virus and hepatitis B and C. Additional tests 
to exclude endocrinologic or metabolic disorders were performed in 9/41 (22%) and 7/41 
(17%) of infants, respectively. In none of these infants an endocrinopathy and/or an inborn 
error of metabolism was diagnosed. In 12/41 (29%) neonates an abdominal ultrasound was 
performed to exclude impairments in bile flow. All infants had normal ultrasound findings. 
Discussion
This study shows that cholestasis is a common problem in HDN, occurring in 13% of neo-
nates. Cholestasis is found particularly in neonates with Rhesus D alloimmunization treated 
with IUTs. Although cholestasis was mild and transient in most cases, a few neonates had 
severe cholestatic liver disease with protracted course and required intensive treatment 
and in one case chelation therapy was needed. 
In the past, several studies have been published on the co-occurrence of cholestasis in 
neonates with HDN due to red cell alloimmunization. In 1963, Dunn described a large 
case series of 133 infants with Rhesus HDN and found that 8% of these patients developed 
‘obstructive jaundice’ defined as conjugated bilirubin level > 3 mg/dL.3,4 However, in addi-
tion to the more stringent definition, their study is not fully comparable with contemporary 
care strategies for Rhesus HDN. In 1963 perinatal mortality and morbidity were far higher 
than nowadays, due to the absence of Rh D prophylaxis, Doppler ultrasound to detect fetal 
anemia and in particular treatment with IUTs. Later, Bowman et al., Perez et al. and Allgood 
et al. also published on cholestasis in neonatal HDN, but none of these studies reported an 
exact incidence of cholestasis.2,5,18
We found that treatment with IUT is an independent risk factor for cholestasis. This could 
be due to iron overload which has been reported in neonates with HDN who underwent 
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IUT.6,8-10 In 1990 Berger and colleagues demonstrated elevated ferritin levels in 12 infants 
with Rhesus HDN and suggested that iron overload could be an explanation for cholestatic 
icterus in Rhesus HDN.9 In 1991, Nasrat et al. measured higher fetal plasma ferritin con-
centrations in 23 Rhesus alloimmunized fetuses compared to controls and serial IUTs were 
associated with additional increases in serum ferritin.10 On the contrary, in 2004 Aygun et 
al. found higher cord blood ferritin levels in neonates affected with Rhesus HDN compared 
to birth weight and gestational age matched controls, but IUTs did not affect the ferritin 
status of the babies with Rhesus HDN.8 This finding is in contrast with our observations. 
We found a positive correlation between treatment with one or more IUTs and high ferritin 
levels during admission, both risk factors for cholestasis in this study. Our data support the 
hypothesis of iron overload as a mechanism of cholestasis in HDN.
In addition to iron overload, the following etiologic mechanisms of cholestasis in HDN were 
previously described: overload of pigment causing stasis and blocking of bile canaliculi; liver 
necrosis caused by hypoxia due to anemia; and pressure by extramedullary hematopoiesis 
in the liver caused by anemia leading to damage of intrahepatic canaliculi.19 Hence, the 
finding that IUT treatment is a risk factor for cholestasis could be due to the disease severity 
(more severe anemia necessitating IUT), to transfusion induced iron overload or to a com-
bination of both. Theoretically, other causes such as infection or metabolic diseases or total 
parenteral nutrition may play a role. However, extensive investigations to rule out other 
causes of cholestasis in infants with cholestasis included in this study yielded no additional 
information. 
This study shows that Rhesus D type of alloimmunization is an independent risk factor for 
cholestasis. This finding has not been described before. However, the vast majority (88%) 
of neonates within the cholestasis group had both Rhesus D type of alloimmunization and 
was treated with IUT, preventing reliable distinction between the actual role of both risk 
factors.
In our series cholestasis resolved spontaneously within 1 week to 3 months after birth in 
almost half of the patients, which is comparable with other studies.2,18 In 56% of the included 
infants, conjugated bilirubin levels and liver enzyme levels (AST, ALT, γGT, and alkaline phos-
phatase) were not monitored until they reached normal values. We recommend to measure 
conjugated bilirubin levels and liver enzyme levels during the first three months of life or 
until they reach normal values. 
We suggest that a full work-up to exclude other causes of cholestasis in a child with red cell 
alloimmnune HDN treated with at least one IUT, is not necessary, provided that no other 
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factors are involved and monitoring of ferritin, liver enzymes and conjugated bilirubin levels 
is guaranteed during the first 3 months of life.
The results of this study should be interpreted with care due to the relatively small number 
of neonates in the cholestasis group and the retrospective study design. In addition, our 
conclusions are limited due to incomplete measurements. For example, only 17% of neo-
nates with cholestasis were tested for metabolic conditions and some of them may have 
had alpha-1-antitrypsin deficiency. Larger, multicenter studies are required to confirm our 
findings.
In conclusion, we found a 13% incidence of cholestasis in HDN due to red cell alloimmu-
nization and identified several risk factors for cholestasis, in particular treatment with IUT 
and Rhesus D type of alloimmunization. Larger follow-up studies are required to determine 
the exact course and etiology of cholestasis in infants with red cell alloimmune hemolytic 
disease.
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Objective: To evaluate the incidence and severity of and risk factors for thrombocytopenia 
at birth in neonates with red cell alloimmunization.
Study design: All neonates with hemolytic disease of the fetus/newborn (HDFN) due to 
red cell alloimmunization admitted to our center between January 2000 and September 
2010 were included in this retrospective study. We measured platelet counts at birth and 
determined the incidence of thrombocytopenia (platelet count <150x109/L) and severe 
thrombocytopenia (platelet count <50x109/L). Risk factors for thrombocytopenia at birth 
were evaluated. 
Results: Thrombocytopenia was present in 26% (94/362) of included neonates with HDFN 
at birth. Severe thrombocytopenia was found in 6% (20/362) of neonates. Three risk factors 
were found to be independently associated with thrombocytopenia at birth: treatment 
with intrauterine red cell transfusion (IUT) (OR 3.32, 95% CI 1.67-6.60, p=0.001), small for 
gestational age (SGA) below the 10th percentile (OR 3.32, 95% CI 1.25-8.80, p=0.016), and 
lower gestational age at birth (OR 1.22 per week, 95% CI 1.02-1.44, p=0.025).
Conclusions: Thrombocytopenia at birth occurs in 26% of neonates with HDFN due to red 
cell alloimmunization and is independently associated with IUT treatment, SGA and lower 
gestational age at birth.
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Introduction
Limited studies have shown that fetuses with red cell alloimmunization are at increased 
risk of thrombocytopenia (platelet count <150x109/L).1-3 In Rhesus D hemolytic disease 
treated with intrauterine red cell transfusion (IUT), thrombocytopenia was detected in 26% 
of fetuses at cordocentesis and was associated with fetal hydrops.2 In Kell hemolytic disease, 
the incidence of fetal thrombocytopenia appears to be lower (10%) and less severe com-
pared to fetuses with Rhesus D alloimmunization.2,3 
Incidence and severity of thrombocytopenia in neonates with red cell alloimmunization at 
birth is unclear. In one small study (n=20) thrombocytopenia was detected in 55% of neo-
nates with Rhesus hemolytic disease during the neonatal period.4 However, platelet count 
was not routinely measured at birth and possibly neonatal thrombocytopenia developed 
after birth due to treatment with exchange transfusion for hyperbilirubinemia.5
The exact cause of fetal and neonatal thrombocytopenia in red cell alloimmunization is not 
well known. Decreased production, increased destruction or a combination of both may 
play a role.1,4,6 Common risk factors for fetal and neonatal thrombocytopenia such as pre-
eclampsia, maternal diabetes and intrauterine growth retardation may also play a role in 
pregnancies affected by red cell alloimmunization.7,8 
The aim of this study was to evaluate the incidence and severity of and risk factors for 
thrombocytopenia at birth in a large series of neonates with hemolytic disease of the fetus/
newborn (HDFN) due to red cell alloimmunization. 
Materials and Methods
All neonates with HDFN due to maternal red cell alloimmunization admitted between January 
2000 and September 2010 at the Leiden University Medical Center (LUMC) were included in 
this retrospective observational study. Our center is the single national referral center for the 
management and intrauterine treatment of red cell alloimmunization in the Netherlands. 
Part of the fetuses/neonates has been described in two previous studies on fetal thrombocy-
topenia2,3, two retrospective studies on transfusions in red cell alloimmunization9,10 and in a 
randomized trial on the use of intravenous immunoglobulin.11
Our management guidelines in neonates with HDFN dictate that a full blood count (includ-
ing hemoglobin level, reticulocyte count and platelet count) must be routinely performed 
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in all neonates at birth. In addition, in the subgroup of fetuses treated with IUT, a full blood 
count is routinely performed at cordocentesis before each IUT to determine the desired 
amount of packed donor red cells.  
Primary outcome was the incidence of and risk factors for thrombocytopenia at birth in 
neonates with HDFN. 
Thrombocytopenia was defined as a platelet count <150x109/L and was classified as mild (101 
to 149x109/L), moderate (51 to 100x109/L), severe (21 to 50x109/L) and very severe (≤20x109/L). 
A fully automated cell counter (Sysmex XE-2100), utilizing optical fluorescent platelet count in 
situations where an impedance count is unreliable, was used to determine fetal and neona-
tal platelet counts. A concentrated platelet transfusion (single donor plasma-reduced platelet 
apheresis concentrates) in a dose of 20x109/kg was given at birth if: (1) platelet count was 
<20x109/L (before November 2009 <30x109/L) in clinically stable neonates; (2) platelet count 
was <50x109/L in neonates with a manifest bleeding, those undergoing a procedure with risk 
of bleeding and in clinically unstable neonates with birth weight <1500 gram.
We recorded the following obstetric and neonatal data: type of red cell alloimmunization, 
number of IUTs, presence of fetal hydrops, fetal platelet count before each IUT, number of 
fetal platelet transfusions and neonatal platelet transfusions at birth, gestational age at birth, 
birth weight, small for gestational age (SGA) (defined as a birth weight <10th percentile)12, 
perinatal asphyxia (defined as Apgar score <7 at 5 minutes after birth), the presence of early 
onset neonatal sepsis (defined as clinical symptoms of infection and positive blood culture 
in the first 72 hours of life) and test results for TORCH infection and fetal/neonatal alloim-
mune thrombocytopenia (FNAIT). We recorded the presence of clinical signs of bleeding at 
birth and intracranial hemorrhage on the first cranial ultrasound performed within 24 hours 
after birth. A cranial ultrasound is performed on all IUT treated neonates. We documented 
the following maternal data: PIH (pregnancy induced hypertension)/preeclampsia, HELLP 
syndrome (syndrome of Hemolysis, Elevated Liver enzymes, Low Platelet counts) diabetes 
and TORCH infection.
Statistical analysis was performed using Student-t-test and Mann-Whitney test for continuous 
variables. Chi square and Fisher’s exact tests were used for categorical variables, as appropri-
ate. The following possible risk factors for thrombocytopenia at birth were included in a mul-
tivariate logistic regression model to measure independent effects: Rhesus D type of red cell 
alloimmunization, PIH/preeclampsia, HELLP syndrome, maternal diabetes, gestational age at 
birth, SGA, treatment with IUT, perinatal asphyxia and fetal hydrops. The results of the logistic 
model were expressed as odds ratios (OR). A p-value <0.05 was considered statistically signifi-
cant. Statistical analysis was executed with SPSS 17.0 (SPSS Inc, Chicago, IL, USA).
 Thrombocytopenia at birth in red cell alloimmune HDN
87
Results
During the study period 364 neonates with HDFN of 330 mothers were admitted to our neo-
natal nursery. A flow chart of included neonates and information on severity and causes of 
thrombocytopenia at birth is presented in Figure 1. A full blood count was measured in all but 
2 neonates (99%, 362/364). In IUT treated neonates, a full blood count was measured in all but 
2 fetuses (99%, 242/244) at cordocentesis. Baseline characteristics are summarized in Table 1.
Incidence, cause and severity of thrombocytopenia in HDFN
Incidence and severity of thrombocytopenia at birth
Thrombocytopenia was detected in 26% (94/362) of neonates at birth and was classified as 
mild (49%, 46/94), moderate (30%, 28/94), severe (19%, 18/94) and very severe (2%, 2/94). 
No neonates had clinical signs of bleeding at birth except for one hydropic premature 
neonate (delivered at 30 weeks’ gestation) with intraventricular hemorrhage grade 2 on day 
one. His platelet count at birth was 53x109/L. 
Four percent (14/362) of neonates received a platelet transfusion at birth due to thrombo-
cytopenia.
Table 1  Baseline characteristics of all included neonates with HDFN due to red cell alloimmunization 
Neonates with HDFN 
(n=362)
Neonates treated with IUT – n (%) 244 (67)
Number of IUTs in IUT treated neonatesa  3 (1-6)
Fetal thrombocytopenia before IUT – n (%) 42 (17)
Fetal thrombocytopenia* – n (%) 97 (40)
Gestational age at birth – weeksa 36 (27-42)
Birth weight – gramsb 2904 ± 548
SGA (birth weight < p10) – n (%) 22 (6)
Male – n (%)) 228 (63)
Rhesus D alloimmunization – n (%) 268 (74)
Kell alloimmunization – n (%) 51 (14)
Rhesus c alloimmunization – n (%) 28 (8)
Rhesus E alloimmunization – n (%)  9 (3)
Fy(a) alloimmunization – n (%)  2 (1)
Cw alloimmunization – n (%)  2 (1)
Jk(a) alloimmunization – n (%)  1 (0)
Rhesus C alloimmunization – n (%)  1 (0)
a = median (range), * based on all fetal platelet counts before each IUT, b = mean ± SD, HDFN = hemolytic 
disease of the fetus/newborn; IUT = intrauterine transfusion; SGA = small for gestational age
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*  In 27/80 respectively 9/14 neonates no NAITP/
ITP and (maternal or neonatal) TORCH diagnostic 
tests were performed.
All neonates admitted with HDFN  n=364
362 neonates with HDFN
Thrombocytopenia at birth n=94 (26%) No thrombocytopenia at birth n=268 (74%)





Very severe n=2 (2.5%)
Probable cause of/
risk for thrombocytopenia*





ITP results n=1 (1%)
Probable cause of/
risk for thrombocytopenia*
HDFN with IUT-treatment n=11 (79%)






Very severe n=0 (0%)
Excluded n=2 (platelet count not measured)
Figure 1   Flowchart showing numbers of neonates enrolled and severity and causes of thrombo-
cytopenia at birth
HDFN = hemolytic disease of the fetus/neonate; IUT = intrauterine transfusion; PIH = pregnancy-induced 
hypertension; SGA = small for gestational age; FNAIT = fetal/neonatal alloimmune thrombocytopenia; 
ITP = immune thrombocytopenic purpura
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Fetal thrombocytopenia and IUT in neonates with thrombocytopenia at birth
Eighty of the 94 thrombocytopenic neonates at birth received at least one IUT (Figure 1). 
Thirty-one percent (24/78) and 95% (76/80) of IUT treated neonates with thrombocytope-
nia at birth had fetal thrombocytopenia based on the first fetal platelet count (before the 
first IUT) and all fetal platelet counts, respectively.
Only one (non-hydropic) fetus received an intrauterine platelet transfusion at a platelet 
count of 27x109/L in addition to a single IUT at 33 weeks’ gestation. He was born after 35+4 
weeks’ gestation with a birth weight of 2580 g (p25-p50) and Apgar scores of 4, 7 and 7 
after 1, 5 and 10 min, respectively. Platelet count at birth was 22x109/L and he received one 
platelet transfusion on day one. Screening tests in this patient showed no evidence of FNAIT 
or TORCH congenital infection.
Diagnostic tests in neonates with thrombocytopenia at birth
Fifteen neonates with thrombocytopenia at birth were screened for FNAIT and one neonate 
had FNAIT coinciding with her Rhesus D HDFN. Maternal and/or neonatal serologic screen-
ing tests for congenital TORCH infection were performed in 63% (59/94) of neonates with 
thrombocytopenia. All TORCH screening tests were negative. No cases of early onset neo-
natal sepsis were detected. 
Risk factors for thrombocytopenia at birth
Detailed information on risk factors for thrombocytopenia at birth and blood results of neo-
nates with and without thrombocytopenia at birth are summarized in Table 2. 
Univariate analysis
Type of alloimmunization 
The incidence of thrombocytopenia at birth in neonates with Rhesus D, Kell, Rhesus c and 
other types of red cell alloimmunization was 26% (69/268), 24% (12/51), 36% (10/28) and 
20% (3/15), respectively. Type of red blood cell alloimmunization was not associated with 
thrombocytopenia at birth (Table 2). The incidence of severe thrombocytopenia (platelet 
count ≤50x109/L) at birth was also not statistically different in neonates with Rhesus D, Kell, 
or Rhesus c compared to neonates without Rhesus D, Kell or Rhesus c respectively (p=0.672, 
p=0.434 and p=0.696, respectively). 
Perinatal risk factors 
Several risk factors were associated with thrombocytopenia at birth including: treatment 
with IUT (OR 3.62, 95% CI 1.95-6.73, p<0.001), fetal hydrops (OR 2.97, 95% CI 1.58-5.58, 
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birth (OR 1.33 for each week less, 95% CI 1.16-1.54, p<0.001) and SGA (OR 3.10, 95% CI 1.30-
7.40, p=0.012). 
Only one mother had HELLP syndrome and one mother had diabetes (both neonates had 
normal platelet counts at birth).  
Multivariate analysis
On multivariate analysis, the following risk factors were independently associated with throm-
bocytopenia at birth: treatment with IUT, lower gestational age at birth and SGA (Table 2). 
Fetal hydrops was not significant at the 5% level, but the relatively low p-value (p=0.083) 
is suggestive of a possible independent association with thrombocytopenia at birth.
Maternal diabetes and HELLP syndrome were excluded from multivariate analysis because 
of limited number of cases. As birth weight and gestational age at birth are closely related, 
birth weight was also excluded from multivariate analysis.
Discussion
This study demonstrates that thrombocytopenia at birth is common among neonates with 
HDFN due to red cell alloimmunization, occurring in 26% of neonates compared to 1-5% in 
the general population and 22-35% in the neonatal intensive care unit (NICU) population.13 
Severe thrombocytopenia was present in 6% of all neonates with HDFN compared to 5-10% 
in the NICU population.
This is the first study describing the incidence of neonatal thrombocytopenia at birth in 
HDFN due to red cell alloimmunization. Koenig et al. described neonatal thrombocytope-
nia in 11 of 20 (55%) neonates with Rhesus HDFN during admission.4 In this study, platelet 
count was not routinely measured at birth and in several cases only after exchange transfu-
sion. Exchange transfusion is a known risk factor for thrombocytopenia, independently of 
red cell alloimmunization.5,14
We found a positive association between IUT treatment and thrombocytopenia at birth. The 
cause of this association is not clear and several mechanisms may play a role. Increased eryth-
ropoiesis could theoretically lead to suppression of thrombopoiesis by the hematopoietic 
stem cells.1,4 However, since IUT is known to suppress erythropoiesis15, this theory only sup-
ports fetal thrombocytopenia at the first IUT. Increased incidence of fetal thrombocytope-
nia from 17% to 40% in fetuses treated with several IUTs may be explained by a decreased 
production, increased consumption, increased destruction, or dilution. In addition, IUT with 
packed red cells can cause dilution of platelets.16 However, it is unlikely that this effect is still 
present at the time of a consecutive IUT after two to three weeks. 
Chapter 7
92
We found that type of red cell alloimmunization was not a risk factor for thrombocytope-
nia at birth. In a previous study fetal thrombocytopenia (at first IUT) appeared to be less 
common in Kell HDFN than in Rhesus D HDFN.3 The discrepancy between the results may be 
due to several factors including methodological differences between the two studies. The 
higher rate of thrombocytopenia in Kell HDFN found in this study may be due to the higher 
number of IUTs in the Kell population.10 
Prematurity and intrauterine growth restriction have previously been described as risk 
factors for early-onset (<72 hours) neonatal thrombocytopenia.7,8 In accordance, we dem-
onstrated that lower gestational age at birth and SGA are independent risk factors for 
thrombocytopenia at birth in neonates with HDFN. In addition, we found that lower birth 
weight irrespective of gestational age is a risk factor for thrombocytopenia at birth in red 
cell alloimmunization. 
Perinatal asphyxia (Apgar score <7), maternal PIH/preeclampsia and syndrome of HELLP 
have formerly been described as risk factors for thrombocytopenia at birth.7,17,18 In our 
study population perinatal asphyxia was not associated with thrombocytopenia at birth 
and the number of cases with PIH/preeclampsia was limited.
Interestingly, one case of thrombocytopenia in this cohort was found to be due to FNAIT. 
Four other case reports of thrombocytopenia due to FNAIT have been described in fetuses/
neonates with Rhesus hemolytic disease.19-22 
Fortunately only one neonate had clinical sings of bleeding at birth (intraventricular hemor-
rhage grade 2).  Although this neonate was thrombocytopenic at birth, in this case other 
factors such as prematurity and hydrops could have contributed to this bleeding complica-
tion. Moreover, the causal relation between thrombocytopenia and intraventricular hemor-
rhage is controversial.23  
The results of this study should be interpreted with care because of the retrospective study 
design. We have not systematically investigated all other possible causes of neonatal throm-
bocytopenia such as maternal immune thrombocytopenic purpura, FNAIT and perinatal/
neonatal infection. Hence the incidence of 26% of thrombocytopenia at birth due to red cell 
alloimmunization can be an overestimate. Finally, the number of spurious thrombocytope-
nia because of clotted samples and platelet clumping is unclear. 
In conclusion, this study shows that 26% of neonates with HDFN due to red cell alloim-
munization have thrombocytopenia at birth. Risk for thrombocytopenia is independently 
associated with IUT treatment, SGA and lower gestational age at birth.
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Objective: To study the effect of a restrictive guideline for exchange transfusion (ET) on the 
number of top-up transfusions in neonates with Rhesus hemolytic disease.
Study design: Retrospective study of all (near)-term neonates with Rhesus hemolytic 
disease admitted to our center between 2000 and 2008. In December 2005, policy changed 
from using liberal ET criteria to more restrictive ET criteria. We recorded the number of ETs 
and the number of top-up transfusions in the group of neonates before (group I, n =156) 
and after (group II, n =27) the guideline change.
Results: The percentage of neonates requiring an ET decreased from 66% (103/156) in 
group I to 26% (7/27) in group II (p < 0.01). The percentage of neonates receiving a top-up 
transfusion increased from 68% (105/154) in group I to 81% (22/27) in group II (p = 0.25). The 
median number of top-up transfusions increased from 1 (interquartile range 0-2) in group I 
to 2 (interquartile range 1-3) in group II (p = 0.01).
Conclusion: In this study, restrictive ET criteria in neonates with Rhesus hemolytic disease 
lead to a reduction of the rate of ET but an increase in the number of top-up transfusions 
for neonatal anemia.
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Introduction
The mainstay of antenatal treatment for hemolytic disease of the fetus and newborn due 
to Rhesus alloimmunization (HDFN) is intrauterine transfusions (IUT) to treat severe fetal 
anemia. The mainstay of postnatal treatment for hemolytic disease of the newborn (HDN) 
secondary to Rhesus alloimmunization is (1) intensive phototherapy and exchange transfu-
sion (ET) to treat hyperbilirubinemia and prevent kernicterus, and (2) top-up transfusions 
to treat neonatal anemia. Neonatal anemia secondary to Rhesus alloimmunization can be 
divided into two types: “hyporegenerative anemia” characterized by depressed erythropoi-
esis and “late anemia of hemolytic disease” caused by persisting hemolysis by remaining 
antibodies.1 Both causes of anemia contribute to the necessity of top-up transfusions during 
the first months of life. The percentage of infants with HDN secondary to Rhesus alloimmu-
nization requiring top-up transfusions for neonatal anemia varies from 27 to 83%.2,3
Several risk factors for neonatal anemia secondary to Rhesus alloimmunization have 
been reported, including IUT (due to suppression of fetal erythropoiesis)2 and severity of 
HDN.1,4,5 Use of ET during the neonatal period has been reported to protect against neo-
natal anemia.3.In addition to removing excess bilirubin, ET also removes antibody-coated 
erythrocytes and maternal antibodies, hence reducing the risk for continuing hemolysis 
and neonatal anemia.3,6 However, the protective role of ET for neonatal anemia has only 
been demonstrated in one small study.3
In December 2005, we implemented a new guideline for the management of neonatal 
hyperbilirubinemia and HDN secondary to Rhesus alloimmunization based on the guide-
lines from the American Academy of Pediatrics (AAP).7 The new guideline for ET was more 
restrictive than the previous ones and led to a more than 50% decrease in the rate of ET. 
Restrictive ET criteria may hypothetically lead to an increase in top-up transfusions ascribed 
to ongoing hemolysis due to antibody coated cells not being removed from the circulation. 
Whether the reduction in ET indeed resulted in an increased rate of top-up transfusions was 
not clear. 
The aim of this study was to evaluate the effect of this new guideline on the number of 
top-up transfusions and determine if neonates with hemolytic disease of the newborn 





All neonates with a gestational age ≥ 35 weeks with HDN secondary to Rhesus D, C, c or E anti-
bodies admitted between January 2000 and November 2008 to the neonatal division of the 
Leiden University Medical Center (LUMC) were included in this retrospective observational 
study. LUMC is the national referral center for the management and intrauterine treatment 
of red cell alloimmunization in the Netherlands. Neonates with Kell, Jka or Cw red cell alloim-
munization, and neonates receiving transfusions for unrelated pathology were excluded 
from this study. We also excluded neonates participating in an ongoing randomized double-
blind placebo-controlled trial for the use of immunoglobulin in RHD, which started in August 
2006 at our institution (the LIVIN study: http://www.trialregister.nl/trialreg/admin/rctview.
asp?TC=832 )
In December 2005, we implemented a new guideline for the management of neonatal hyper-
bilirubinemia and HDN secondary to Rhesus alloimmunization based on the guidelines from 
the American Academy of Pediatrics (AAP)7 The differences in phototherapy thresholds before 
and after introduction of the new guideline are shown in Figure 1. The guideline for photo-
therapy administration at our neonatal division has previously been described.2 The bilirubin 
thresholds for ET in the new guideline were higher than in the previous one. The differences in 
ET thresholds of total serum bilirubin before and after guideline change are shown in Figure 
2. The criteria for ET before December 2005 included a total serum bilirubin level at birth > 3.5 
mg/dL (measured in neonatal blood at birth or in a few cases in umbilical cord blood),2 (early 
criterium) and/or a total serum bilirubin level above ET thresholds (rise of bilirubin value > 0.5 
mg/dL/hr despite intensive phototherapy).2 In neonates not treated with IUT, a hemoglobin 
level at birth of < 12.9 g/dL was also considered as an early criterium for ET. 2 Bilirubin levels 
were measured in all neonates every 2 to 3 hours during the first few days after birth.
Early criteria for ET were abandoned after the guideline change. The criteria for ET after Decem-
ber 2005 were: (1) total serum bilirubin above (new) ET thresholds7 (Fig 2) and/or (2) rise of 
bilirubin > 0.5 mg/dL/hr despite intensive phototherapy, and/or (3) clinical symptoms of acute 
bilirubin encephalopathy regardless of bilirubin level. ET was performed with double-volume 
transfusion (160 mL/kg) using irradiated and leukocyte-depleted compatible erythrocytes. 
After initial discharge from the LUMC, top-up transfusions were performed when hemoglo-
bin levels were < 8.0 g/dL or < 9.6 g/dL if clinical symptoms of neonatal anemia (lethargy, 
feeding problems, need for oxygen or failure to thrive) were present. The volume used for 
top-up transfusions during the study period was 15 ml/kg bodyweight. The volume and cri-
teria for top-up transfusion were the same in both groups. Neonatal anemia, often referred to 
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Figure 1  Phototherapy thresholds before and after guideline change in neonates with Rh hemolytic disease
total serum bilirubin (mg/dL)
 _⧫_ ET thresholds after guideline change (gestational age 35-38 weeks)
 _◼_ ET thresholds  thresholds after guideline change (gestational age >38 weeks)
--▲-- ET thresholds  thresholds after guideline change (gestational age <35 weeks)
















 _⧫_ Phototherapy thresholds after guideline change (gestational age 35-38 weeks)
 _◼_ Phototherapy thresholds after guideline change (gestational age >38 weeks)


















as “late anemia” in previous studies3,5,8,9 was defined as a hemoglobin level below thresholds 
requiring a top-up transfusion during the first three months of life. Folic acid 50 mcg/day was 
administered orally during the first three months of life to all neonates with RHD. According to 
our management guidelines, neonates with RHD were not treated with erythropoietin. 
We recorded the following obstetric and neonatal data: fetal hemoglobin at first IUT and 
number of IUTs, gestational age at birth, birth weight, hemoglobin level and reticulocyte 
count at birth, bilirubin level at birth, maximum bilirubin level during admission, duration 
of phototherapy (days), number of ETs required, number of top-up red blood cell transfu-
sions received during the first 3 months of life and hemoglobin levels prior to the top-up 
transfusion. Obstetric data were gathered using a dedicated database for Rhesus compli-
cated pregnancies in which data are prospectively collected. Neonatal data were collected 
using medical files. Data on top-up transfusions and hemoglobin levels prior to the top-up 
transfusion in infants who received follow-up outside the LUMC were gathered through cor-
respondence with the local pediatrician or blood transfusion department. 
Primary outcome was the number of top-up transfusions in the group of neonates admitted 
before (group I) and after (group II) the new guideline implementation in December 2005.
Data are reported as means and standard deviations (SD) or as medians and interquartile 
range (IQR), as appropriate. Statistical analysis was performed using Student-t-test and 
Mann-Whitney test for continuous variables. Chi square and Fisher’s exact test were used 
for categorical variables, as appropriate. To assess the relationship between the number 
of ETs and the number of top-up transfusions, Spearman correlations were calculated. A 
p-value <0.05 was considered statistically significant. Statistical analysis was executed with 
SPSS 16.0 (SPSS Inc, Chicago, IL).
Results
During the study period 270 infants with hemolytic disease delivered ≥ 35 weeks’ gesta-
tion were admitted to our neonatal division. Fifty neonates were excluded because of par-
ticipation in a randomized double-blind placebo-controlled trial for the use of intravenous 
immunoglobulin. Thirty-six neonates were excluded due to hemolytic disease caused by 
Kell (n=34), Jka (n=1) or Cw (n=1). One neonate requiring major cardio-thoracic surgery for 
congenital heart disease was also excluded. A total of 183 patients were included in this 
study, of whom 156 in the group before (group I) and 27 in the group after (group II) the 
implementation of the new guideline in December 2005. Baseline characteristics in both 
groups are summarized in Table 1. 
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Neonates treated with IUT – n (%) 99 (63) 15 (56) 0.52
Number of IUTs per neonatea 2 (0 - 3) 1 (0 - 2) 0.29
Gestational age at first IUT – weeksa 30 (24 – 33) 31 (23 - 32) 0.70
Hemoglobin level at first IUT – g/dLa 6.6 (5.1 – 7.7) 5.8 (5.0 – 7.4) 0.70
Gestational age at birth – weeksa 37 (36 - 37) 37 (36 - 37) 0.89
Birth weight – gramsb 3020 ± 445 2940 ± 396 0.40
Male – n (%) 87 (56) 21 (78) 0.04
Neonates with Rhesus D – n (%) 140 (90) 21 (78) 0.10
Neonates with Rhesus c – n (%) 13 (8) 4 (15) 0.29
Neonates with Rhesus C – n (%) 2 (1) 0 (0) 1.00
Neonates with Rhesus E – n (%) 1 (1) 2 (7) 0.06
aValue given as median (IQR)
bValue given as mean ± SD 
The use of IUT, phototherapy and ET
Detailed information on the use of IUT is presented in Table 1 and on the use of photo-
therapy and ET in group I and group II is presented in Table 2. Serial IUTs were performed in 
99 (63%) infants in group I and 15 (56%) in group II (p = 0.52). At least one ET was required 
in 66% (103/156) of the patients in group I compared to 26% (7/27) of the patients in group 
II (p < 0.01). The rate of ET performed on day 1 dropped from 96% (94/103) in group I to 
57% (4/7) in group II (p < 0.01). The median number of ETs was 1 in group I (IQR 0-1, range 
0-5) and 0 in group II (IQR 0-1, range 0-2) (p < 0.01). No significant relationship was found 
between the number of IUTs and the number of ETs (Spearman correlation coefficient = 
-0.009; p = 0.90). 
The use of top-up transfusions
Complete information on the number of top-up red cell transfusions was obtained for 98% 
(180/183) of neonates. Detailed information on the use of top-up transfusions in group I 
and group II is presented in Table 3. The percentage of neonates in group I and group II 
receiving a top-up transfusion was 68% (105/154) and 81% (22/27), respectively (p = 0.25). 
The median number of top-up transfusions per infant in group I and II was 1 (IQR 0-2, range 
0-6) and 2 (IQR 1-3, range 0-5) (p = 0.01). 
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Neonates receiving top-up transfusions – n (%) 105/154 (68) 22/27 (81) 0.25
Number of top-up transfusions per infanta 1 (0-2)c 2 (1-3) 0.01
Neonates receiving:    
1 top-up transfusion – n (%)
2 top-up transfusions – n (%)
3 top-up transfusions – n (%)
4 top-up transfusions – n (%)
5 top-up transfusions – n (%)



















Days after birth until first 
top-up transfusiona
19.5 (1 - 34.8)c 10 (2.5 – 23.0)d 0.23
Hemoglobin level at first top-up 
transfusion – g/dLb
8.3 ± 1.5e 8.2 ± 1.3f 0.72
a Value given as median (IQR) 
b Value given as mean ± SD
c Assessed in 153/156 neonates
d Assessed in 17/22 neonates
e Assessed in 95/105 neonates
f Assessed in 16/22 neonates 






Hemoglobin level at birth - g/dLa 11.6 ± 2.58 12.6 ± 3.40 0.25
Bilirubin level at birth - mg/dLa 6.0 ± 2.70 6.2 ± 2.85 0.89
Reticulocyte count at birth – ‰b,c 21 (3 - 61) 47.5 (3 - 106) 0.19
Maximum bilirubin – mg/dLb 13.6 (10.3 – 16.8) 15.4 (13.2 -18.0) 0.03
Neonates treated with phototherapy – n (%) 150 (96) 27 (100) 0.59
Phototherapy – daysa 4.1 ± 1.88 4.7 ± 1.59 0.11
Neonates treated with ET – n (%) 103 (66) 7 (26) < 0.01
Number of ETs per neonateb 1 (0 -1) 0 (0 -1) < 0.01
ETs performed on day 1 – n (%) 94 (96) 4 (57) < 0.01
Duration of admission at our center – daysa 6.0 ± 3.3 6.3 ± 3.9 0.47
aValue given as mean ± SD
bValue given as median (IQR)
cReticulocyte count at birth was assessed in 75 and 20 patients of group I and II, respectively
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Combining group I and II, we found a negative correlation between the number of ETs and 
the number of top-up blood transfusions (Spearman correlation coefficient -0.183; p = 0.01). 
This correlation between a lower number of ETs and a higher number of top-up transfusions 
was present mainly in the subgroup of neonates treated with IUT (n = 114) (Spearman cor-
relation coefficient = -0.340; p < 0.01). In the subgroup of neonates without IUT (n = 69), the 
correlation between the number of ETs and the number of top-up blood transfusions was 
not significant (Spearman correlation coefficient = 0.011; p = 0.93). Of the 110 neonates that 
received an ET 73 neonates (66%) were treated with IUT.
Comment
This study shows that after implementation of a more restrictive guideline for ET in neonates 
with RHD, the rate of ETs decreased considerably from 66% to 26%. The reduction in ET rate 
was associated with a significant increase in the number of top-up transfusions for neona-
tal anemia. Neonates in group II required twice more top-up transfusions than neonates in 
group I. Since the criteria for top-up transfusions remained unchanged before and after the ET 
guideline changes, our findings suggest that neonatal anemia in neonates with RHD is more 
likely to occur if restrictive ET criteria are used.
Our findings are in accordance with a previous study by al-Alaiyan et al. in a small group of 
36 (near-) term neonates with RHD treated with IUT.3 Al-Alaiyan et al. reported a similar asso-
ciation between ET rate and top-up transfusions.3 The risk of neonatal anemia in neonates 
treated with and without ET was 36% and 92%, respectively (p = 0.04).3
The reduced rate of top-up transfusions in infants treated with ET can be attributed to the 
removal of antibodies and IgG coated erythrocytes during ET, hence reducing the hemolytic 
process and the risk of neonatal anemia.3,6 However, the effect of ET on the antibody titer on 
the short term is limited. Since the antibodies are distributed in the intravascular as well as the 
extravascular fluid, ET reduces the antibody titer only by about 25 percent.4,10 The beneficial 
effect of ET lies in replacing nearly all of the Rhesus positive red cells by immunologically com-
patible cells, hence surviving cells in the blood stream.4
In contrast with previous studies2,8 we found a significant negative correlation between the 
number of ETs and top-up transfusions. This negative correlation was found only in neonates 
treated with IUT, but was not found in neonates without IUT treatment. Since fetuses requir-
ing IUT treatment are more severely affected by RHD than fetuses without IUT treatment, we 
speculate that the beneficial effect of ET in reducing the number of top-up transfusions occurs 
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primarily in severely affected neonates with high titer antibodies. Washing out antibodies and 
replacing Rhesus positive cells through ET treatment may be particularly more effective in 
severely affected neonates. 
The pathogenesis of neonatal or late anemia in RHD is not completely clarified and can be 
due to either depressed erythropoiesis (“hyporegenerative anemia”) or persisting reduction 
in half-life of the Rhesus positive erythrocytes caused by remaining antibodies (“late anemia 
of hemolytic disease”) if age-appropriate or elevated reticulocytes are present.11,12 “Hypore-
generative anemia” occurs in particular after IUT due to suppression of the erythropoiesis.2,9 
An alternative explanation for failing compensatory reticulocytosis is destruction of bone 
marrow precursors and reticulocytes by antibodies.4,13 Other contributing factors to neonatal 
anemia are reduced survival of transfused red blood cells,5 natural decline of the hemoglobin 
level toward the physiological nadir, and the increasing intravascular volume of the growing 
neonate.1 Finally, erythropoietin deficiency can be a possible contributing factor to neonatal 
anemia.12  Treatment with erythropoietin has been suggested to reduce the number of top-up 
transfusions, but the evidence to recommend routine use of erythropoietin is very limited.14
The data in this study should be interpreted with care due to the retrospective design of the 
study which may have led to a selection bias and influenced by changing transfusion attitudes 
over time. Although both groups were similar in terms of severity of fetal anemia, need of IUT, 
and hemoglobin levels at birth, it is conceivable that neonates in group II were more severely 
affected than neonates in group I, hence requiring more top-up transfusions.2 Importantly, 
the percentage of male infants in group II was higher than in group I. Male infants have a 
higher prevalence of HDN secondary to Rhesus alloimmunization,15 a higher neonatal death 
rate from kernicterus16 and appear to be more severely affected than females in terms of need 
for IUT, development of hydrops fetalis and perinatal mortality.17 A larger study is required to 
determine if this sex difference in baseline characteristic may have influenced our results.   
In conclusion, this study shows that the number of ETs in neonates with HDN secondary to 
Rhesus alloimmunization decreased significantly after the introduction of restrictive ET crite-
ria. Reduction of ET rate resulted in a doubling of the number of top-up transfusions. Restric-
tive ET criteria in HDN secondary to Rhesus alloimmunization during the neonatal period may 
thus lead to an increased rate of neonatal anemia. Nevertheless, the risk of adverse events 
associated with ETs (in particular catheter-related complications) is high (7%)18 compared to 
the transfusion-related risks of blood transfusion in general (< 0.04%).19 A reduction in ETs, 
despite an increase in top-up transfusions may therefore be more beneficial for neonates 
with HDN secondary to Rhesus alloimmunization, although the long-term effects on neuro-
developmental outcome requires longer follow-up.
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Exchange transfusions and top-up transfusions 
in neonates with Kell hemolytic disease 













Objective: To evaluate neonatal outcome in Kell hemolytic disease compared to Rh D 
hemolytic disease.
Study design: Retrospective study of all (near)-term neonates with Kell (n=34) and Rh D 
hemolytic disease (n=157) admitted to our center between January 2000 and December 
2008. We recorded the need for exchange transfusion and top-up transfusions up to three 
months of age.
Results: Neonates in the Kell group required less days of phototherapy than neonates in the 
Rh D group (2.4 versus 4.1 days, respectively (p < 0.01)). The percentage of neonates requi-
ring an exchange transfusion was lower in the Kell group than in the Rh D group (6% (2/34) 
and 62% (98/157), respectively (p < 0.01)). The percentage of neonates in the Kell group and 
Rh D group requiring a top-up transfusion was 62% (21/34) and 72% (113/157), respectively 
(p = 0.20). The median number of top-up transfusions per neonate in the Kell group and Rh 
D group was 1 (interquartile range (IQR) 0-2) and 2(IQR 0-2), respectively (p = 0.07).
Conclusion: Neonates with Kell hemolytic disease require less phototherapy and less 
exchange transfusions compared to neonates with Rh D hemolytic disease, but an equal 
number of top-up transfusions.
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Introduction
Kell alloimmunization is second only to Rh D in causing antibody-mediated fetal anemia. 
Since the introduction of Rh D immunoprophylaxis, Kell antibodies account for 10% of 
antibody-mediated fetal anemia.1 After introduction of routine antibody-screening of all 
pregnant women in the Netherlands in 1998, perinatal survival of fetuses with Kell hemoly-
tic disease of the neonate (HDN) treated with intrauterine transfusion (IUT) increased from 
61% to 100%.2 
In contrast to Rh D HDN, fetal anemia in Kell HDN is often more severe due to concomitant 
suppression of erythropoiesis rather than hemolysis of erythrocytes.3-5 Consequently, the 
immediate neonatal management in Kell HDN is different from Rh D HDN. A previous small 
study showed that neonates with Kell HDN have lower serum bilirubin levels and require 
less phototherapy and exchange transfusions (ETs) than neonates with Rh D hemolytic 
disease.6
In analogy with Rh D hemolytic disease, neonates with Kell HDN may require top-up trans-
fusions for up to several months after birth.7 Whether the incidence and severity of neonatal 
anemia in Kell hemolytic disease differs from neonates with Rh D hemolytic disease, is not 
known. Only a limited number of studies (mostly case reports) have been published on the 
severity of anemia in the postnatal period.6, 8-10
The aim of this study was to evaluate neonatal and hematological outcome in a large series 
of neonates with Kell hemolytic disease compared to neonates with Rh D hemolytic disease. 
Materials and Methods
All (near)-term neonates (gestational age ≥ 35 weeks) with hemolytic disease due to mater-
nal Kell and Rh D alloimmunization, delivered between January 2000 and December 2008 at 
the Leiden University Medical Center (LUMC) were included in this retrospective observatio-
nal study. Part of the neonates included in the Rh D group have previously been described in 
a different study.11 Our center is the national referral center for the management and intrau-
terine treatment of red cell alloimmunization in the Netherlands. We excluded all neonates 
with other types of HDN and neonates participating in an ongoing randomized trial for the 
use of immunoglobulin in Rh D hemolytic disease, which started in August 2006 at our insti-
tution (LIVIN study: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=832).
Chapter 9
110
The guideline for the application of phototherapy at our neonatal division has previously 
been described.11,12 The guidelines for ET used at our neonatal division were changed in 
December 2005. Before December 2005, criteria for ET included: (1) bilirubin level at birth 
> 3.5 mg/dL (so-called early criterion) and/or (2) total serum bilirubin level above ET thres-
holds (rise of bilirubin value > 0.5 mg/dL/hr despite intensive phototherapy). In neonates 
not treated with IUT, a hemoglobin level at birth of < 12.9 g/dL was also considered as an 
early criterion for ET.12 In December 2005 a new guideline of the American Academy of 
Pediatrics (AAP) with higher bilirubin thresholds for phototherapy and ET was implemented 
by our department.13 The criteria for ET after December 2005 were: (1) total serum bilirubin 
above (higher) ET thresholds13 and/or (2) rise of bilirubin > 0.5 mg/dL/hr despite intensive 
phototherapy, and/or (3) clinical symptoms of acute bilirubin encephalopathy regardless of 
bilirubin level. ET was performed with double-volume transfusion (160 mL/kg) using irradi-
ated and leukocyte-depleted compatible erythrocytes. 
We recorded the following obstetric and neonatal data: fetal hemoglobin concentration at 
first IUT and number of IUTs, gestational age at birth, birth weight, hemoglobin level and 
reticulocyte count at birth, bilirubin level at birth, maximum bilirubin level during admis-
sion, duration of phototherapy (days), number of ETs required, number of top-up red blood 
cell transfusions received during the first 3 months of life and hemoglobin levels prior to the 
top-up transfusion. Data on the number of top-up transfusions and hemoglobin levels prior 
to the top-up transfusion in infants who received follow-up outside the LUMC were collec-
ted through correspondence with the local pediatrician or blood transfusion department. 
After discharge from our center, top-up transfusions were performed in referring hospitals 
when hemoglobin levels were < 8.0 g/dL, or < 9.6 g/dL if clinical symptoms of neonatal 
anemia were present (such as lethargy, feeding problems, need for oxygen or failure to 
thrive). Folic acid (50 mcg/day) was administered orally during the first three months of life 
to all neonates with hemolytic disease.
Primary outcome was the number of ETs and the number of top-up transfusions. Outcome 
was compared between neonates with Kell hemolytic disease (Kell group) and neonates 
with Rh D hemolytic disease (Rh D group).
Data are reported as means and standard deviations (SD) or as medians and interquartile 
range (IQR), as appropriate. Statistical analysis was performed using Student-t-test and 
Mann-Whitney test for continuous variables. Chi square and Fisher’s exact test were used 
for categorical variables, as appropriate. Linear regression analysis was performed using 
the Pearson Correlation coefficient. A p-value < 0.05 was considered statistically significant. 
Statistical analysis was executed with SPSS 16.0 (SPSS Inc, Chicago, IL, USA).
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Results
During the study period, 309 neonates with hemolytic disease were admitted to our neo-
natal nursery. Two hundred and seventy-seven (90%) of these neonates were delivered at 
a gestational age ≥ 35 weeks. Fifty-five neonates were excluded because of participation in 
a randomized trial for the use of intravenous immunoglobulin. Thirty-one neonates were 
excluded due to HDN caused by Rh c (n=17), Rh C (n=3), Rh E (n=3), Cw (n=2), Jka (n=1), 
presence of both Rh D and Kell antibodies (n=2), and unknown type of irregular antibody 
(n=3). A total of 191 patients were included in this study, 34 (18%) in the Kell group and 157 
(82%) in the Rh D group. Baseline characteristics in both groups are summarized in Table 1. 
Intrauterine transfusions (IUTs) were performed in 82% of neonates in the Kell group and 
66% of neonates in the Rh D group (p = 0.07). The median number of IUTs in the Kell group 
and Rh D group was 3 (IQR 2-4, range 0-5) and 2 (IQR 0-4, range 0-6) respectively (p = 0.01). 
In the Kell group the median antibody titer at first IUT was 1:128 (range 1:2-8000).






Neonates treated with IUT – n (%) 28 (82) 104 (66) 0.07
Number of IUTs per neonate a 3 (2-4) 2 (0-3.5) 0.01
Gestational age at first IUT – weeks a 27 (23-29) 29 (24-33) 0.07
Hemoglobin level at first IUT – g/dL a 5.3 (3.5-7.3) 6.4 (5.0-7.4) 0.16
Gestational age at birth – weeks a 36 (36-37) 37 (36-37) 0.52
Birth weight – grams b 3190 ± 348 2947 ± 418 <0.01
Male – n (%) 25 (74) 92 (59) 0.11
a Value given as median (IQR)
b Value given as mean ± SD 
Phototherapy and ET
Detailed information on neonatal outcome in both groups, in particular treatment with 
phototherapy and ET is presented in Table 2. Mean bilirubin level at birth and maximum 
bilirubin level during admission were significantly lower in the Kell group than in the Rh 
D group, 3.1 versus 6.0 mg/dL (p < 0.01) and 8.0 versus 14.3 mg/dL (p < 0.01), respectively. 
Neonates in the Kell group required significantly less days of phototherapy than neonates in 
the Rh D group (2.4 and 4.1 mean days, respectively, (p < 0.01)). At least one ET was required 
in 6% (2/34) of the patients in the Kell group compared to 62% (98/157) of the patients in 
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the Rh D group (p < 0.01). The median number of ETs was 0 in the Kell group (IQR 0-0, range 
0-1) and 1 in the Rh D group (IQR 0-1, range 0-5) (p < 0.01). None of the infants in the Kell 
group without IUT required an ET.
Top-up transfusions
Complete information on the number of top-up red cell transfusions was obtained for 
98% (188/191) of neonates. The percentage of neonates requiring a top-up transfusion 
was similar in the Kell group and Rh D group (62% (21/34) and 72% (113/157), respectively 
(p = 0.20). The median number of top-up transfusions per neonate in the Kell group and Rh 
D group was 1 (IQR 0-2, range 0-4) and 2 (IQR 0-2, range 0-6), respectively (p = 0.07). Mean 
hemoglobin level at first top-up transfusion and median number of days until first top up 
transfusion were similar in both groups. Detailed information on the use of top-up transfu-
sions in the Kell group and Rh D group is presented in Table 3.
In the sub-group analysis of neonates treated with IUT (n=132), we found that neonates 
with Rh D HDN required significantly more top-up transfusions than neonates with Kell HDN 
(median of 2 range 0-6 and median of 1 range 0-4), respectively (p = 0.02). We performed a 
linear regression analysis between the number of IUTs and the reticulocyte count at birth 
in both groups. A higher number of IUTs was correlated with a lower reticulocyte count at 
birth in the Rh D group (Pearson Correlation coefficient -0.49; p < 0.001). This negative cor-
relation was not found in the Kell group (Pearson Correlation coefficient -0.05; p = 0.85). 






Hemoglobin level at birth - g/dL a 7.9 ± 1.8 7.2 ± 1.6 0.01
Bilirubin level at birth - mg/dL a 3.1 ± 1.7 6.0 ± 2.3 <0.01
Reticulocyte count at birth – ‰ b,c 12 (8-49) 21 (3-66) 0.90
Maximum bilirubin – mg/dL b 8.0 (3.9-10.7) 14.3 (10.8-16.9) <0.01
Neonates treated with phototherapy – n (%) 31 (91) 154 (98) 0.07
Phototherapy – days a,d 2.4 ± 1.3 4.1 ± 1.7 <0.01
Neonates treated with ET – n (%) 2 (6) 98 (62) <0.01
Number of ETs per neonate b 0 (0-0) 1 (0-1) <0.01
a  Value given as mean ± SD
b Value given as median (IQR)
c Reticulocyte count at birth was assessed in 15/34 and 81/157 neonates in the Kell and Rh D-group, 
 respectively
d Days of phototherapy was assessed in 134/157 neonates with Rh D
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Comment
This study shows that fetuses with severe Kell hemolytic disease are more often treated with 
IUT compared to fetuses with Rh D hemolytic disease. Subsequently, infants with HDN due 
to Kell-antibodies  need less phototherapy and ETs in the neonatal period than neonates 
with Rh D hemolytic disease. However, the need for top-up transfusions was similar in both 
groups.
Various researchers have suggested that anemia in Kell hemolytic disease is caused prima-
rily by erythroid suppression rather than hemolysis, as in Rh disease.3,4 An alternative theory 
is that anti-Kell-antibodies are responsible for the destruction of early erythroid progenitor 
cells, which lack hemoglobin.5,14 A lower amniotic fluid bilirubin and only mild neonatal 
hyperbilirubinemia in Kell hemolytic disease compared to Rh D are consistent with this 
theory. In addition, an in vitro study by Vaughan et al. demonstrated that human monoclo-
nal anti-Kell antibodies and the serum of women with anti-Kell antibodies specifically inhibit 
the growth of Kell-positive erythroid progenitor cells.5 Vaughan et al. found no correlation 
between the anti-Kell antibody titer and the degree of inhibition.5 Poor correlation between 
antibody titer and disease severity in Kell supports the theory that Kell alloimmunization 






Neonates requiring top-up transfusions – n (%) 21 (62) 113 (72) 0.20
Number of top-up transfusions per neonate a 1 (0-2) 2 (0-2) 0.07
Neonates requiring:                
1 top-up transfusion – n (%)
2 top-up transfusions – n (%)
3 top-up transfusions – n (%)
4 top-up transfusions – n (%)
5 top-up transfusions – n (%)



















Days after birth until first top-up transfusion a 16 (1-31.5) 17.5 (1-33.5) 0.56
Hemoglobin level at first top-up transfusion – g/dL b 8.2 ± 1.4 8.4 ± 1.5 0.73
Number of top-up transfusions (per neonate) in the 
subgroup treated with IUT a 1 (0-2) 1.9 (1-3) 0.02
a Value given as median (IQR) 
b Value given as mean ± SD
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has a different pathogenesis than Rh alloimmunization. In a recent study of 43 pregnancies 
with Kell alloimmunization, we found that the vast majority of severely affected cases had 
antibody titers of 1:32 or more. Nevertheless, to be on the safe side, we recommended that 
all pregnancies with Kell titers of 1:2 or higher (and a proven Kell positive fetus) should be 
closely monitored.2  
In accordance with previous studies from the group of Weiner4 and our group15 we found 
that antenatal course of fetuses with Kell alloimmunization is different from Rh D hemolytic 
disease. Fetuses with Kell alloimmunization have lower hemoglobin levels at first IUT and 
require more IUTs. Moreover, the first IUT was performed at an earlier gestational age than 
in Rh D fetuses.15 These findings underscore that fetal anemia is more severe in Kell sen-
sitized fetuses than in Rh D sensitized fetuses. Weiner et al. also found a significant lower 
reticulocyte count, reflecting the destruction of Kell expressing erythroid progenitor cells 
in Kell hemolytic disease.4
In terms of neonatal management and outcome, this study shows that neonates with Kell 
hemolytic disease have milder hyperbilirubinemia, requiring less phototherapy and ETs 
than infants with Rh D hemolytic disease. In our study we found no relation between lack 
of IUT and number of ETs or top-up transfusions. Our findings are consistent with previous 
reports6,8,16-18 and reflect the observation that hemolysis of mature (hemoglobinised) ery-
throcytes in Kell hemolytic disease is less than in Rh D hemolytic disease.3,4
Given the significantly higher number of IUTs in the Kell group, one could expect an 
increased incidence of postnatal anemia (and top-up transfusions). As shown in previous 
studies, repeated IUTs result in a decreased reticulocyte count, indicating a suppression of 
fetal erythropoiesis.12,19 In contrast, we found a trend towards less top-up transfusions in 
neonates with Kell hemolytic disease compared to neonates with Rh D hemolytic disease, 
however this difference was not significant (p = 0.07). This finding could support the fact 
that fetal and neonatal anemia due to Kell alloimmunization has a different pathogenesis 
than Rh alloimmunization. Larger studies are required to confirm these findings. In contrast 
to anti-D, most anti-Kell antibodies have a strong lytic potential which also affects red cell 
precursor cells,3,4,19  Vaughan and colleges found no correlation between the  antibody titer 
and the degree of inhibition of Kell-positive erythroid progenitor cells. The titers of anti-Kell 
antibodies associated with fetal anemia are generally substantially lower compared to ten 
to 100 fold higher titers in case of Rh D hemolytic disease. Consequently anti-D antibodies 
may circulate in the newborn for a longer period after birth, whereas Kell antibodies disap-
pear sooner, which may explain the more moderate late anemia in Kell hemolytic disease, 
despite concomitant suppression of the erythropoiesis.5
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This is the first study comparing the degree of postnatal anemia in a relatively large number 
of infants with Kell- and Rh D hemolytic disease. Santiago et al. described three neonates 
with Kell HDN of whom only one required a top-up transfusion.17
Collinet et al. reported a case of severe fetal anemia due to Kell alloimmunization, which 
was postnatally treated with two top-up transfusions and recombinant erythropoietin and 
iron supplementation.7
The results of this study should be interpreted with care due to the small number of neo-
nates with Kell hemolytic disease in this study which is inherent to the low incidence of this 
disease. Larger, multicenter studies are required to confirm our findings. 
In conclusion, although neonates with Kell hemolytic disease require less phototherapy 
and exchange transfusions, the equal need for top-up transfusions justifies similar follow-
up management as in Rh D hemolytic disease. Finally, because of the destruction of red cell 
precursor cells as well, treatment with erythropoietin may be more effective in neonates 
with Kell hemolytic disease than in neonates with Rh D hemolytic disease.9,10 
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Objective: To determine the incidence and risk factors for neurodevelopmental impairment 
(NDI) in children with hemolytic disease of the fetus/newborn treated with intra uterine 
transfusion (IUT).
Study Design : Neurodevelopmental outcome in children at least 2 years of age was as-
sessed using standardized tests, including the Bayley Scales of Infant Development, the 
Wechsler Preschool and Primary Scale of Intelligence and the Wechsler Intelligence Scale 
for Children, according to the children’s age. Primary outcome was the incidence of NDI 
defined as at least one of the following: cerebral palsy, severe developmental delay, bilateral 
deafness and/or blindness. 
Results: A total of 291 children were evaluated at a median age of 8.2 years (range 2 to 17 
years). Cerebral palsy was detected in six (2.1%) children, severe developmental delay in 
nine (3.1%) children and bilateral deafness in three (1.0%) children. The overall incidence 
of NDI was 4.8% (14/291). In a multivariate regression analysis including only pre-operative 
risk factors, severe hydrops was independently associated with NDI (OR 11.2, 95%, CI 1.7-
92.7).
Conclusions: Incidence of NDI in children treated with IUT for fetal alloimmune anemia is 
low (4.8%). Prevention of fetal hydrops, the strongest pre-operative predictor for impaired 
neurodevelopment, by timely detection, referral and treatment may improve long-term 
outcome. 
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Introduction
Fetal and neonatal hemolytic disease results from maternal alloimmunization to red cell 
antigens, for which mother and fetus are incompatible. Maternal IgG antibodies pass the 
placenta into the fetal circulation and cause destruction of fetal red cells. The resulting pro-
gressive fetal anemia leads, when untreated, to fetal hydrops and perinatal death.1 
Before 1970, hemolytic disease due to antibodies against the Rhesus-D antigen was the 
most important cause of perinatal death.2 Several interventions have drastically reduced 
the incidence and severity of the disease, including postnatal and more recently antena-
tal anti-D prophylaxis programs,3,4 improved diagnostic management and neonatal treat-
ment.1,5-7 One of the major advances was the introduction in 1963 of intrauterine blood 
transfusions (IUTs),1 first performed by Liley using the intraperitoneal technique.8 In the 
1980’s, this technique was replaced by the intravascular IUT.1 Nowadays, this treatment is 
the most successful procedure in fetal therapy, with perinatal survival rates exceeding 95% 
in experienced centers.1,7 However, one of the concerns of the more widespread and suc-
cessful use of fetal therapy is that a decrease in perinatal mortality may lead to an increase 
of children with long-term handicaps. Only a few studies with small patient numbers have 
reported on long-term neurodevelopmental outcome after IUT, with an incidence of adverse 
outcome ranging from 4.5 to 12%.9-16 The aim of our study was to determine the incidence 
and risk factors for adverse neurodevelopmental outcome after IUT treatment in the largest 
cohort of children worldwide. 
Methods
In 2008 we designed a large national cohort study to evaluate the long-term neurodevelop-
mental outcome in children treated with IUT: the LOTUS study (LOng-Term follow-up after 
intra-Uterine transfusionS).17 All mothers with red cell alloimmunization treated with IUT 
between January 1st 1988 and January 1st 2008 at the Leiden University Medical Center and 
their children were invited to participate in this large follow-up study. For the purpose of this 
study we included all children of 2 to 17 years of age who had complete follow-up including 
a cognitive development test. Children with severe congenital anomalies and syndromal 
disorders were excluded. This study was approved by the ethics committee of the Leiden 
University Medical Center. Informed consent was obtained from all participating families. A 
limited outcome evaluation in a small part of our study group (11 children treated between 
1991 and 1993) was described before.9 Primary outcome was a composite outcome termed 
neurodevelopmental impairment (NDI) defined as at least one of the following; cerebral 
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palsy (CP), severe cognitive developmental delay (< –2 Standard Deviation (SD)), bilateral 
deafness requiring hearing amplification and/or bilateral blindness. 
The Leiden University Medical Center serves as the single national reference center for 
the management of red cell alloimmunization in pregnancy in the Netherlands. IUTs are 
performed when signs of fetal anemia are detected on Doppler ultrasound examinations. 
Details on our management guidelines for alloimmunized pregnancies were previously 
described.18 Since the implementation of the IUT program using the ultrasound-guided 
intravascular transfusion technique at our center in 1987, all relevant perinatal data have 
prospectively been collected in a computerized database. Data included are: type of alloim-
munization, gestational age at IUT, hemoglobin level, presence and severity of hydrops at 
the start of the intrauterine treatment, number of IUTs, gestational age at birth, gender, 
birth weight and neonatal outcome. Neonatal outcome data included: number of exchange 
transfusions due to severe hyperbilirubinemia, respiratory distress syndrome, necrotizing 
enterocolitis (classified according to Bell19), sepsis (defined as clinical symptoms of infection 
and a positive bacterial blood culture) and severe cerebral injury detected either on cranial 
ultrasound, Computed Tomography scan (CT) or Magnetic Resonance Imaging (MRI). Severe 
cerebral injury was defined as the presence of intraventricular hemorrhage ≥ grade 3 (classi-
fied according to Volpe20), cystic periventricular leukomalacia ≥ grade 2 (classified according 
to de Vries21) and/or ventricular dilatation (defined according to Levene et al22). Other major 
cerebral abnormalities associated with adverse neurological outcome were also recorded 
and classified as severe cerebral lesions. We recorded the presence of perinatal asphyxia, 
defined as three or more of the following five criteria: non-reassuring cardiotocogram pat-
terns, umbilical cord arterial pH < 7.10, Apgar score < 5 at 5 minutes after birth, failure of 
spontaneous breathing at 5 minutes after birth and onset of multiple organ failure.
Parental education was determined by the level of education of each parent individually. 
A score of 1 was given if the parent’s education was low, a score of 2 for an average educa-
tional level, and a score of 3 for higher levels of education. Education scores of both parents 
were then added (score range from 2 to 6). Ethnicity was recorded as Caucasian or non-
Caucasian. Children were considered to be Caucasian when one or both parent(s) were of 
Caucasian ethnicity.
Follow-up
All participating families visited our out-patients clinic from August 2008 to November 
2010. At this visit, a physical and neurological examination according to Touwen23 and an 
assessment of cognitive development using standardized tests were performed.17 All chil-
dren were assessed by one of the three investigators specialized in developmental assess-
ment (IL, VS and EL). 
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Presence of CP was assessed according to the criteria of the European CP Network and clas-
sified as diplegia, hemiplegia, quadriplegia, dyskinetic or mixed.24 Minor neurological dys-
function (MND) was defined as a moderate abnormality of tone, posture, and movement 
leading to only minor functional impairment or minor developmental delay.23
Cognitive development in children aged 2 to 3 years was assessed according to the Dutch 
version of the Bayley Scales of Infant Development, 2nd edition (BSID-II).17 BSID-II scores 
provide a mental developmental index (MDI). Children between 3 and 7 years of age were 
tested with the Dutch version of the Wechsler Preschool and Primary Scale of Intelligence, 
3rd edition (WPPSI-III-NL).17 Cognitive development in children between 7 and 17 years of 
age was assessed with the Dutch version of the Wechsler Intelligence Scale for Children, 3rd 
edition (WISC-III-NL).17 Both the WPPSI and the WISC provide a full scale IQ score. BSID-MDI, 
WPPSI and WISC scores follow a normal distribution curve with a mean score of 100. A score 
of 70-84 indicates mild delay (i.e. < -1 SD) and a score < 70 indicates severe delay (i.e. < -2 
SD). A trained psychologist (JK), blinded to the antenatal course and neonatal outcome, 
performed the tests in all children. 
Risk factors
Potential risk factors for NDI were investigated including severity of fetal anemia (actual 
hemoglobin level and Z-hemoglobin), presence and severity of fetal hydrops (classified 
according to van Kamp et al.25) at start of the intrauterine treatment, number of IUTs, ges-
tational age at birth (divided in three groups: neonates born before 32 weeks’ gestation, 
between 32 and 35 weeks’ gestation and after 35 weeks’ gestation), severe neonatal mor-
bidity and perinatal asphyxia. Standardized Z scores of hemoglobin (Z-hemoglobin) were 
defined as the number of standard deviations (SDs) that an actual value deviated from the 
normal mean for gestational age. Reference values for hemoglobin were derived from the 
literature.26 Severe neonatal morbidity was defined as the presence of one or more of the 
following: respiratory distress syndrome, necrotizing enterocolitis ≥ grade 2, sepsis and/or 
severe cerebral injury. 
Statistical analyses
We used univariate logistic regressions to test the association between NDI and the poten-
tial risk factors. We entered the risk factors into a multivariate logistic regression model and 
included additional potential confounders including gender, parental education and eth-
nicity. Multiple logistic regression analysis was used to measure the independent effect of 
the potential risk factors for NDI. Results of logistic regression were considered significant at 
p-values < 0.05. We used the Pearson correlation test to calculate the correlation between 
hemoglobin at first IUT and IQ score. Analyses were performed using SPSS version 16 (SPSS 




During the study period 1284 IUTs were performed in 451 fetuses. Thirty-one fetuses died 
in utero and 11 in the neonatal period resulting in a perinatal survival rate of 91% (409/451). 
Two more children died during childhood due to causes unrelated to hemolytic disease 
of the fetus/newborn (one accidental infant death occurred due to incorrect construction 
of the bedframe and one infant death was due to acute cardiomyopathy and pulmonary 
hypertension). Thus, the overall survival rate was 90% (407/451). Three children were diag-
nosed with congenital anomalies including Kinsbourne’s syndrome, congenital cerebel-
lar hypoplasia and Phelan-McDermid syndrome and were excluded from further analysis. 
A total of 342 children were 2 to 17 years of age and thus eligible for the study. Fifty-one 
(15%) children were lost-to-follow-up, due to declined consent (6%, 21/342) or loss of 
contact address (9%, 30/342). Complete follow-up data were obtained from 291 children by 
a visit at our out-patient clinic. A flowchart showing the derivation of our study population 
is shown in Figure 1. 
Fetuses treated with IUT
n = 451
Death
n = 44 (10%)
Severe congenital anomalies
n = 3 (1%)
Children 2-17 years old
n = 342 (85%)
Children >17 years old




n = 291 (85%)
Lost-to-follow-up
n = 51 (15%)
Figure 1  Flowchart showing the derivation of our study population
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Perinatal outcome
Detailed information on the baseline perinatal characteristics on 291 long-term survivors is 
summarized in Table 1. The mean hemoglobin level at first IUT was 5.5 g/dL (± 2.4 SD), and 
the Z-hemoglobin -7.3 SDs. Both the mean hemoglobin level and Z-hemoglobin in fetuses 
with hydrops (mild or severe) were significantly lower than in fetuses without hydrops, 3.3 
versus 6.3 g/dL (p < 0.001) and -9.1 versus -6.7 (p < 0.001). 
The percentage of neonates born < 32 weeks’, between 32 and 35 weeks’, and ≥ 35 weeks’ 
gestation was 2% (6/291), 15.5% (45/291) and 82.5% (240/291).
Exchange transfusions during the neonatal period were performed in 58% (168/291) of 
children. The following severe neonatal morbidities were recorded: respiratory distress syn-
drome (2.4%, 7/291), necrotizing enterocolitis (1.0%, 3/291), sepsis (5.8%, 17/291), perina-
tal asphyxia (3.8%, 11/291) and severe cerebral injury (1.7%, 5/291). Severe cerebral injury 
detected on cranial ultrasound included ventricular dilatation (n = 2), hemorrhagic periven-
tricular leukomalacia (n = 1), cystic periventricular leukomalacia (n = 1) and extensive cere-
bral abscess (n = 1). In both children with ventricular dilatation, cerebral abnormalities were 
already detected antenatally. The incidence of severe neonatal morbidity was significantly 
higher in the group neonates born before 32 weeks’ gestation (OR 32.1, 95% CI 5.4-190-8, 
p < 0.001). No significant differences in antenatal and neonatal characteristics were found 
between the follow-up (n = 291) and lost-to-follow-up group (n = 51). 
Table 1  Baseline characteristics
Rhesus D alloimmunization – n (%)
Kell – n (%)
Rhesus c – n (%)




  6 (2)
Gestational age at first IUTa – weeks 26 ± 4.2 (16-35)
Number of IUTs per fetusa 3 ± 1.1 (1-6)
Hemoglobin at first IUTa – g/dL 5.5 ± 2.4 (1.1-13.2)
Hydrops – n/N (%)
    Mild hydrops – n/N (%)




Gestational age at birthb – weeks 36 (35-37)
Birth weightb – grams 2812 (2520-3159)
Neonates requiring an exchange transfusion – n (%) 168 (58)
a Values are given in mean ± 1 SD (range)




The median age at follow-up was 8.2 years (range 2-17 years). The incidence of CP was 
2.1% (6/291) (spastic quadriplegia: n = 3, spastic diplegia: n = 2, dyskinetic: n = 1). MND was 
recorded in 11.0% (32/291). None of the children had kernicterus. Nineteen children were 
evaluated using BSID-II tests, the average MDI score was 93 ± 14. A total of 89 children were 
tested using the WPPSI and 183 were tested using the WISC. The average full scale IQ in the 
WPPSI-group and WISC-group was 100 ± 14.8 and 101 ± 13.5, respectively. We found no cor-
relation between hemoglobin level at first IUT and full scale IQ score (r = 0.1, p = 0.1) (Figure 
2). Severe developmental delay (< -2 SD) was detected in 3.1% (9/291) of children. Moderate 
developmental delay (< -1 SD) was detected in 14.4% (42/291) of children. Bilateral deafness 
was present in three children (1.0%). None of the children had bilateral blindness. Table 2 
summarizes the long-term neurodevelopmental outcome.
Figure 2. Relation between hemoglobin level at first IUT and full scale IQ score, in children 




IQ, intelligence quotient 
IUT, intrauterine transfusions 
                                    Q, intelligence quotient      IUT, intrauterine transfusions 
Figure 2   Relation between hemoglobin level at first IUT and full scale IQ score, in children with (red 








 Long-term outcome after IUT: the LOTUS study
125
Overall, the incidence of NDI (CP, severe developmental delay, deafness and/or blind-
ness) was 4.8% (14/291). Details on the combinations of abnormal findings in the children 
with adverse outcome are presented in Table 3. One infant with CP (#14 in Table 3) had 
no cranial ultrasound examination in the neonatal period, but a MRI performed at 2 years 
of age showed signs of cerebral atrophia, suggestive for periventricular leukomalacia. One 
infant with severe cerebral injury detected on ultrasound and MRI (hemorrhagic periven-
tricular leukomalacia) in the neonatal period had a favorable outcome. Another infant with 
extensive Bacillus Cereus cerebral abscess had also a favorable outcome and was previously 
reported.27
The incidence of NDI was significantly higher in children with a history of mild and severe 
hydrops. Mild hydrops was present in 36% (5/14) of children with NDI compared to 18% 
(49/277) of children without NDI (OR 4.3, 95% CI 1.2 – 15.3, p = 0.025). Severe hydrops was 
present in 29% (4/14) of children with NDI compared to 6% (17/277) of children without NDI 
(OR 9.9, 95% CI 2.4 – 40.5, p = 0.001). 
The risk of NDI was significantly increased in the group of neonates born prematurely (ges-
tational age at birth < 32 weeks) (OR 12.8, 95% CI 2.1-79.5, p = 0.006) (Table 4), but was not 
increased in the group of neonates born between 32 and 35 weeks (OR 1.8, 95% CI 0.5-7.0, 
p=0.38) and ≥ 35 weeks’ gestation (OR 0.4, 95% CI 0.1-1.3, p = 0.08).
Univariate analysis of potential risk factors for NDI was performed (Table 4). Several risk 
factors were found to be associated with NDI, including fetal hydrops, hemoglobin level, 
number of IUTs, prematurity and severe neonatal morbidity. 
We found no difference between the groups with and without NDI for gender 57% (8/14 
male) versus 55% (151/277 male) (p = 0.85) and ethnicity (Caucasian) 14% (2/14) versus 6% 
Table 2  Long-term neurodevelopmental outcome in 291 long-term survivors after intrauterine 
transfusions
Age at follow-upb – years 8.2 (2-17)
Isolated severe development delay – n (%)   5 (1.7)
Isolated cerebral palsy – n (%)   2 (0.7)
Isolated bilateral deafness – n (%)   3 (1.0)
Cerebral palsy and severe developmental delay – n (%)   4 (1.4)
Neurodevelopmental impairmentb – n (%) 14 (4.8)
a Value given as median (range)
b Neurodevelopmental impairment is defined as at least one of the following: cerebral palsy, severe 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(18/277) (p = 0.24). Mean parental education was significantly lower in the NDI group com-
pared to the no-NDI group 3.2 ± 1.1 vs. 4.2 ± 1.4, respectively (p = 0.016). Post-hoc analysis 
showed no difference in the incidence of exchange transfusion between the group with 
(57%, 8/14) and without NDI (58%, 160/277) (p = 0.96).
Potential risk factors and the possible confounder parental education were entered in a mul-
tivariate logistic regression model to assess the independent association with NDI (Table 4). 
We excluded hemoglobin at first IUT from this multivariate analysis model, as this variable 
is strongly associated with the presence of hydrops and could possibly bias our results. In a 
multivariate regression analysis including prenatal and postnatal factors, the following risk 
factors were independently associated with NDI: number of performed IUTs (OR 2.3 per IUT, 
95% CI 1.1-4.6, p = 0.02), severe neonatal morbidity (OR 85.6, 95% CI 9.7-755.3, p < 0.001) 
and parental education (OR 8.4, 95% CI 2.2-31.5, p = 0.002).
To determine the predictive role of prenatal risk factors, we entered the following factors 
in a separate multivariate regression model using only the following prenatal factors: mild 
hydrops, severe hydrops, level of hemoglobin at first IUT and number of IUTs. We found that 
only severe hydrops (OR 11.2, 95% CI 1.7-92.7, p = 0.011) was significantly independent 
associated with NDI.
Comment
This is the largest study to date on long-term neurodevelopmental outcome in children 
surviving a high-risk pregnancy thanks to invasive fetal therapy. The vast majority (over 
95%) of children treated with IUT for severe fetal anemia had a normal neurodevelopmental 
outcome. The incidence of severe developmental delay (3.1%) was in line with the Dutch 
normative population (2.3%).28 In addition, the incidence of bilateral deafness in the general 
population was similar to what we found in our cohort.29 However, the rate of CP (2.1%) in 
our study was higher compared to the general population (0.7% at 32 to 36 weeks’ gesta-
tion30 and 0.2% at 37 weeks’ gestation31).
A few small studies on the long-term neurodevelopmental outcome in children treated 
with IUT have been reported.9-16 The two largest studies to date reveal higher incidences 
of NDI when compared to our results, 10% (7/69) and 8% (3/38) respectively9,10 Differences 
in long-term outcome may be explained by methodological differences and heterogeneity 
between the studies.
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Apart from the reassuring results valuable for counseling pregnant women with red cell 
alloimmunization, the importance of our analysis lies in the identification of potentially 
avoidable risk factors for adverse outcome. The current study shows a clear association with 
long-term impairment and the presence of hydrops and number of IUTs performed. Severe 
fetal hydrops was already known to be associated with increased perinatal mortality.25 
The underlying mechanism causing cerebral damage and long-term NDI in hydropic and 
severely anemic fetuses is not yet known. Cerebral lesions may result from hypoxic injury 
related to severe anemia. Since short- and long-term outcome appears to be better in non-
hydropic fetuses, clinicians should try to prevent or reduce the development of hydrops in 
fetuses at risk for fetal anemia. Interestingly, the actual hemoglobin concentration was more 
strongly associated with NDI than the hemoglobin Z-score. This concurs with the concept 
that tissue oxygenation depends more closely to the number of circulating red cells then on 
deviation of the hemoglobin level from the mean for gestational age. Whether more timely 
detection and treatment of fetal anemia, and prevention of hydrops improves outcome, 
and what degree of anemia actually requires transfusion needs further study.  
Another risk factor for NDI was severe neonatal morbidity. As shown in our results, both the 
incidence of severe neonatal morbidity and the incidence of NDI were associated with the 
severity of prematurity. Severe prematurity is a well-known risk factor for neonatal morbid-
ity, cerebral injury and long-term adverse outcome.32,33 We did not find a relation between 
NDI and exchange transfusions, which we interpret as confirmation of our relatively aggres-
sive neonatal management protocol aimed at reducing the rate of severe hyperbilirubine-
mia. None of the children had kernicterus.
Finally, parental education was independently associated with NDI. Socioeconomic status 
(SES) and parental educational level are well known determinants of child cognitive devel-
opment.28,34-37 Both factors may influence child cognitive functioning for a variety of 
reasons, including reduced access to essential material resources (such as cognitively stimu-
lating materials) and/or non-material resources (such as education, information and skills). 
Moreover, genetic conditions may account for up to 72% of the variance in intelligence.38 
The two most important limitations of our study were the relatively incomplete follow-up 
and the lack of a control group. We were not able to trace 9% of children, mainly due to the 
long time-lap since IUT treatment. In addition, 6% of families declined to participate to the 
study. The risk for an adverse outcome has been shown to be higher in the lost-to-follow 
group as children at increased risk for severe neurodevelopmental compromise may not 
return for evaluation.39 Nevertheless, comparisons of antenatal and perinatal characteristics 
between the study group and the lost-to-follow-up showed no significant differences, sug-




The high rate of intact survival in this high-risk group of severely anemic fetuses confirms 
the success of this antenatal treatment. Although hemolytic disease of the fetus/newborn 
was the main cause of perinatal death for many years, the chance of successful recovery 
with adequate antenatal management can nowadays be considered as excellent. However, 
several factors were associated with increased risk for NDI including fetal hydrops, number 
of IUTs and severe neonatal morbidity. Future studies to reduce the incidence of these 
risk factors in children treated with IUT may help decrease the rate of adverse long-term 
outcome.
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Discussion
Fetal and neonatal red cell alloimmune hemolytic disease results from alloimmunization to 
red cell antigens, for which mother and fetus are incompatible. Production of maternal IgG 
antibodies directed against the fetal red blood cells occurs when fetal red blood cells posi-
tive for a certain antigen, pass into the blood circulation of a mother lacking that particular 
antigen. These maternal IgG antibodies may then cross the placenta into the fetal circula-
tion and cause a wide scale of symptoms in the fetus, ranging from mild to severe hemolytic 
anemia and fetal hydrops.1 Maternal immunization to the Rh D-antigen is the most common 
cause of severe fetal and neonatal disease.2 However, more than 50 other (non-Rh D) red cell 
antigens have been reported to be associated with HDFN. Anti-Rh c and anti-Kell antibodies 
constitute the major causes of severe fetal and neonatal disease, whereas anti-Rh E, e, C, Cw 
and a few rare other antibodies are seen less frequently.2-4 Non-Rh D-immunizations mostly 
result from incompatible red blood cell transfusions, if not precautionary measures e.g. Kell-
matched transfusions for female in (pre)fertile age are applied.2 
In the Netherlands, the post-delivery Rh D prophylaxis program (introduced in 1969) resulted 
in a decline of new Rh D immunizations from 3.5%  in 1969 to 0.6% in 1995.5 These rates were 
comparable with international studies on this subject.6 In the Netherlands, around 170 preg-
nancies are affected each year with Rh D immunization and 380 with non-Rh D immunization. 
In approximately 30 of these cases severe fetal hemolytic disease will occur, requiring antena-
tal treatment with IUT in the LUMC. 
In this chapter we summarize the recent evidence and opinions on management and outcome 
of HDFN due to red cell alloimmunization and discuss future research perspectives.
Management 
HDN due to red cell alloimmunization can lead to severe hyperbilirubinemia, acute bilirubin 
encephalopathy and subsequently chronic bilirubin encephalopathy, also known as kernict-
erus.7 Prevention of kernicterus is considered to be the primary goal of postnatal management 
of red cell alloimmune HDN.8 Treatment of hyperbilirubinemia consists primary of intensive 
phototherapy and ET.1 Phototherapy lowers serum bilirubin levels through photo-oxidation 
and converts bilirubin to a water-soluble substance.7 Phototherapy was first introduced in the 
late 1950s, when white light was the mainstay of treatment.9 Since then significant improve-
ments have been made and it has become clear that the efficacy of phototherapy is dependent 
on a number of factors, including spectral quality of the delivered light, irradiance (intensity of 
light), surface area receiving phototherapy, distance from the light to the skin, skin pigmenta-
tion, total serum bilirubin concentration at the start of phototherapy and duration of expo-
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sure.1,7,10,11 In HDN due to red cell alloimmunization, prompt and intensive phototherapy 
should be started immediately after birth (as bilirubin can rise sharply after birth), in order 
to reduce the need for ET.1 Intensive phototherapy implies the use of (1) emission of light in 
the blue-to-green range that overlaps the plasma bilirubin absorption spectrum (460-490 
nm), (2) irradiance of at least 30 µW/cm2/nm  and (3) illumination of maximal body surface 
(diaper should be removed).1,8,12 An exception on this intensive phototherapy regime is 
Kell alloimmunization, in which anemia is more prominent than hyperbilirubinemia. In 
Kell alloimmunization, anemia results mainly from reduced erythropoiesis by destruction 
of progenitor red blood cells rather than hemolysis of erythrocytes.13 Consequently, only 
minimal phototherapy is required, despite severe anemia. Studies reporting on adverse 
effects of phototherapy are limited. In neonates with cholestasis, phototherapy can cause 
the bronze baby syndrome, in which skin, urine and serum evolve a greyish-brown discolor-
ation.7,14 The pathogenesis of this disorder is not fully understood, but it resolves spontane-
ously when phototherapy is discontinued. Recent reports from Swedish research groups 
have suggested an association between phototherapy and type 1 diabetes and childhood 
asthma.15-17 The mechanism behind this association is unknown. However, effects of photo-
therapy on the neonatal gut and gut immune response have been suggested. Other studies 
have been reported on blue light phototherapy as a risk factor for melanocytic nevus devel-
opment.18,19 Additional prospective, multicenter studies are warranted to investigate the 
long-term adverse events of (intensive) phototherapy.
In case of failure of phototherapy, ET is used to remove bilirubin from the circulation. ET has 
the additional benefits of removing maternal antibodies (and consequently limiting further 
hemolysis) and correcting associated anemia.1 Another favourable effect of ET is a decrease 
in plasma ferritin and iron levels.20 ETs are performed with double volume transfusion (160 
ml / kg) using irradiated, leucocyte-depleted compatible erythrocytes via an intravenous 
catheter, usually an umbilical vein. The rate of neonates with HDN requiring treatment with 
ET varies from 20 to more than 70%.21 In 2004 more restrictive ET guidelines were published 
by the American Academy of Pediatrics8 and which led to a decrease in the use of ET.22 This 
reduction in ET has led to an increased need of top-up transfusions due to ongoing hemo-
lysis and remaining antibodies.22 Our center adopted the new guidelines in 2005 and the 
incidence of neonates with red cell alloimmunization requiring treatment with ET dropped 
significantly from almost 70% to less than 20% thereafter.23 
After introduction in the late 1940s,24-26 neonatal treatment with ET became one of the 
most frequently performed neonatal procedures. However, ET remains a procedure with 
a significant risk of adverse effects. The current mortality rate is reported to be less than 
2%, whereas rates of morbidity and ET-related adverse events can reach 74%.27-34 Reported 
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adverse events include mainly catheter-related complications (malposition, sepsis), com-
plications linked to the use of blood products (thromboembolization, graft versus host 
reactions, infection), metabolic derangements (acidosis, disturbance of serum levels of 
sodium, calcium, potassium and glucose) and cardio-respiratory reactions (including 
cardiac arrhythmias, cardiac arrest and apnea).27-34 Our study on morbidity after ET demon-
strates that treatment with ET in neonates with HDN is associated with a 6-fold increased 
risk of sepsis (incidence 8% in the ET-group versus 1% in the no-ET-group, odds ratio (OR) 
6.3, 95% confidence interval (CI) 1.7-22.9), a 25-fold increase in leukocytopenia (incidence 
88% (versus 23%), OR 24.7, 95% CI 13.4-45.5), a 21-fold increase in severe thrombocyto-
penia (incidence 63% (versus 8%), OR 21.4, 95% CI 11.5-39.7), a 29-fold increase in hypo-
calcemia (incidence 22% (versus 1%), OR 29.1, 95% CI 6.8-124.5) and an increased risk of 
hypernatremia (incidence 8% (versus 0% in the no-ET-group)). Treatment with ET was not 
associated with neonatal death in our study population. The remarkably lower incidence 
of ET-related morbidity and mortality in our study compared to previous studies can be 
explained by methodological differences (different sizes of the various study cohorts) and 
differences in disease-severity between the studied cohorts (premature neonates in pre-
vious studies versus (near) term-age neonates in our cohort).28,29,31 Another explanation 
could be that in the Netherlands treatment for intrauterine and postnatal red cell alloim-
munization is centralized in one tertiary center. Subsequently almost all severely affected 
neonates with HDN due to red cell allo immunization are born and treated in our center. As 
a result, ET is a frequently performed and standardized procedure in our unit and part of 
routine practise. We speculate that in experienced hands severe permanent sequelae due 
to ET-procedures can be kept at a minimum. We therefore advocate a centralized manage-
ment of neonatal red cell allo immunization. 
Neonatal treatment with IVIg has been suggested as an alternative therapy for ET in HDN due 
to red cell alloimmunization.8 In many Western countries, including the Netherlands, IVIg is 
widely used.35 In a few small RCTs, IVIg reduced the need for ET and duration of phototherapy 
in neonates with red cell alloimmunization.36-39 However, these studies were restricted by 
several important methodological limitations.23 In 2002 a Cochrane review concluded that 
further well-designed trials are needed before routine use of IVIg can be recommended.40 In 
the last decade, two other study-groups performed a RCT on this topic, favouring the use of 
IVIg. However, these studies were flawed due to with important methodological restrictions 
related to unclear randomization and blinding procedures.41,42 In contrast, our double-blind, 
placebo-controlled  RCT on the prophylactic use of IVIg in neonatal red cell alloimmuniza-
tion demonstrated that IVIg does not reduce the need for ET nor the rates of other adverse 
neonatal outcomes.23 Recently, a research group from Brazil finalized a similar RCT and also 
found no difference between both groups on the rate of ET.43 A possible explanation for the 
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lack of effect of IVIg in our study could be that treatment with intensive and prophylactic 
phototherapy, starting immediately after birth, reduces the risk of severe hyperbilirubine-
mia.23 In view of the absence of beneficial effects and because of rare but potential adverse 
effects,44-46 we do not recommend the use of IVIg in HDN due to red cell alloimmunization.23 
A new meta-analysis of all recently published RCTs is needed to determine the efficacy and 
safety of IVIg in neonatal red cell alloimmunization.
In the past, various other treatment strategies for hyperbilirubinemia in neonatal red cell 
alloimmunization have been investigated, including treatment with albumin, phenobarbi-
tal, metalloporphyrines and clofibrate.47 Administration of albumin before ET might increase 
the efficacy of ET, because more bilirubin will be mobilized and excreted from tissue to 
blood.1,48 In 2009 Shahian et al. performed a RCT to determine the role of administration 
of intravenous albumin prior to ET in term, otherwise healthy neonates. They observed 
that infusion of 20% albumin one hour prior to ET significantly reduced the post-ET total 
serum bilirubin level and duration of phototherapy.48 However, evidence that albumin infu-
sion increases long-term outcome in infants with red cell alloimmunization is not available 
and thus routine use of albumin is not recommended.1 Phenobarbital increases bilirubin 
uptake, conjugation and excretion1 and its potential effect on hyperbilirubinemia has been 
studied for decades.49-53 A recent retrospective study by Trevett et al. showed that antenatal 
maternal administration of phenobarbital significantly reduces the need for ET in neonates 
affected with HDN due to red cell alloimmunization. The incidence of ET in neonates with 
and without antenatal phenobarbital administration was 9% versus 52%, respectively (p < 
0.01).54 Further study in a randomized controlled trial is necessary to confirm these results. 
Recentlt, Chawla et al. performed a meta-analysis to evaluate the role of phenobarbital in 
the management of unconjugated hyperbilirubinemia during the first two weeks of life in 
preterm neonates. The authors reported that phenobarbital reduces peak serum bilirubin, 
duration and need of phototherapy and need of ET in preterm very low birth weight neo-
nates. These impressive findings warrant further studies to evaluate adverse effects and 
neurodevelopmental outcome.55 Metalloporphyrins, synthetic heme analogs, are competi-
tive inhibitors of heme oxygenase, the rate-limiting enzyme in bilirubin production.1,56 Their 
use has been proposed as an alternative strategy for treating severe hyperbilirubinemia by 
preventing the formation of bilirubin.56 However, a recent Cochrane review suggests that 
placebo-controlled RCTs are required to report on outcomes such as severe hyperbiliru-
binemia, kernicterus, ET and long-term neurodevelopmental impairment.52,56-58 Finally, a 
few studies report beneficial effects of clofibrate on hyperbilirubinemia. This drug activates 
peroxisome proliferator-activated receptors and increases bilirubin conjugation and excre-
tion. One single dose of clofibrate has been reported to be effective, safe and cost-effective 
in view of reducing duration of admission.59 However, long-term clofibrate treatment has 
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been associated with serious adverse effects and therefore more research is needed to 
clarify its safety.47
Short-term outcome 
In the past, various postnatal complications in neonatal red cell alloimmunization have 
been reported, including hematological complications (anemia, thrombocytopenia and 
leucopenia) and cholestatic liver disease.1,20 
Anemia
Anemia in red cell alloimmunization results from hemolysis of fetal red blood cells by mater-
nal IgG antibodies. Maternal antibodies usually persist in the infants circulation for several 
months after birth, causing prolonged hemolysis. Anemia in HDN due to red cell alloimmuni-
zation can be divided into early onset anemia (within 7 days after birth), caused by antibody 
dependent hemolysis of red blood cells, and late onset anemia (from 1 week until 3 months 
after birth). Late onset anemia may be secondary to either ineffective erythropoiesis due to 
suppressed bone marrow (‘late hyporegenerative anemia’) and/or persistent hemolysis (‘late 
anemia of hemolytic disease’).20,60 Late anemia is a common problem in infants with red cell 
alloimmunization and we therefore advocate that a full work-up, including invasive diagnostic 
tests to exclude other causes of anemia is generally not necessary. Treatment of anemia exists 
of top-up transfusions, which can be necessary up to the third month of life. Infants must 
therefore be checked for the rate of hemoglobin fall once a week until three months of age. 
Approximately 80% of infants treated with IUT require at least one top-up transfusion for late 
anemia in the first three months of life, compared to around 65% of infants without IUT.1,22,60 
International guidelines for top-up transfusions in the first months of life including transfu-
sion triggers are not available. In our center transfusion triggers include: haemoglobin level 
< 8 g/dL (5 mmol/L) or < 9.6 g/dL (6 mmol/L) when clinical symptoms of anemia are present 
(need of extra oxygen, poor feeding, tachycardia, tachypnea).1,20 Generally, top-up transfu-
sions given to neonates with HDN consist of 10-20 mL/kg irradiated, ABO/Rh type-specific and 
antigen-negative red blood cells.20
Erythropoietin (EPO) can be used to prevent late anemia and reduces the need for top-up 
transfusions. However, there is insufficient evidence to recommend routine use of EPO in HDN 
due to red cell alloimmunization.61-69 Larger RCTs are needed to study this topic. 
Various supplements, including folic acid and iron could theoretically support erythropoiesis. 
However, evidence on optimal dosage and side effects is lacking. Nevertheless, in our center 
we routinely administer folic acid 0.05 mg/day orally to infants with HDN during the first 
three months of life.1,20 Iron supplementation is sporadically used to support erythropoiesis in 
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anemic neonates with HDN. However, the vast majority of neonates usually do not lack iron, 
due to multiple intrauterine and/or postnatal transfusions. With each top-up transfusion, iron 
is transfused as well. Iron overload can cause damage to the liver, heart and other organs.70 
Therefore iron supplementation should be withheld, especially in transfused infants. More 
studies are needed to define indications for chelation therapy, which is sporadically used to 
treat iron overload in HDN.71   
Thrombocytopenia
Limited studies have shown that fetuses with red cell alloimmunization are at increased 
risk of thrombocytopenia.72-74 We investigated this topic in our study population and found 
that 26% of neonates with red cell alloimmunization had thrombocytopenia (<150 x 109 / 
L) at birth.75 Thrombocytopenia at birth was independently associated with IUT treatment, 
small for date and lower gestational age at birth. Etiologic factors contributing to thrombo-
cytopenia in red cell alloimmunization include decreased production, increased destruc-
tion and dilution.20 Moreover, thrombocytopenia is a well known complication of ET due to 
platelet-poor blood and/or catheter-related thrombosis.76-78
Leucopenia
Only scarce data are available on leucopenia in neonatal red cell alloimmunization. It appears 
that the incidence of neutropenia increases if HDN is more severe, but little is known about 
incidence and morbidity this complication deserves further scrunity.79,80 
Liver disease
Cholestatic liver disease may occur in HDN due to red cell alloimmunization and has been 
associated with iron overload due to multiple IUTs.81-84 However, data on incidence and 
severity is limited and little is known about pathogenesis, risk factors, neonatal manage-
ment and outcome. In our study on this topic we found that cholestasis occurs in 13% of 
neonates with red cell alloimmunization and is independently associated with IUT treat-
ment and Rh D type of alloimmunization. Extensive investigations were performed to rule 
out other causes of cholestasis, but all tests were normal. Cholestasis resolved spontane-
ously within 1 week to 3 months after birth in almost half of the patients. One patient was 
treated with iron chelation therapy due to a prolonged and severe course of hyperferritine-
mia.  We suggest that a full work-up to exclude other causes of cholestasis in a child with 
red cell alloimmunization treated with at least one IUT, is not necessary, provided that no 
other factors are involved and monitoring of ferritin, liver enzymes and conjugated bilirubin 
levels is guaranteed during the first 3 months of life.
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Long-term outcome
Before the LOTUS study, only a few small studies have reported on the long-term neurode-
velopmental outcome after IUT with incidences of adverse outcome ranging from 4.5 to 
12%.85-92 In the LOTUS study, a large national cohort study designed to evaluate long-term 
neurodevelopmental outcome in children treated with IUT for red cell alloimmunization at 
our center, we examined 291 children at a median age of 8.2 years. The overall incidence 
of neurodevelopmental impairment (NDI) was low, 4.8% (including cerebral palsy, severe 
developmental delay and bilateral deafness). Several factors were associated with increased 
risk for NDI, including fetal hydrops, number of IUTs and severe neonatal morbidity. The 
high rate of intact survival proves the success of antenatal IUT-treatment. Whether reducing 
the incidence of risk factors (in particular severe hydrops) will also reduce the incidence of 
long-term neurodevelopmental outcome needs to be investigated in future studies.
Future perspectives
During the last decades, a significant evolution in prenatal and postnatal care strategies for 
patients with red cell alloimmunization has occurred. New management options have led 
to a remarkable decrease in perinatal mortality and morbidity. However, several questions 
are still unanswered. This paragraph focuses on future research perspectives.
Neonatal management
• Prospective, multicenter trials are warranted to investigate the long-term adverse events 
of (intensive) phototherapy, including bronze baby syndrome, asthma, type 1 diabetes 
and melanocytic nevus development.
• Prospective, double-blinded RCTs are necessary to evaluate benefits, adverse effects and 
neurodevelopmental outcome of administration of albumin, phenobarbital, metallopor-
phyrines and clofibrate in neonatal red cell alloimmunization.
• A new meta-analysis of all recently published RCTs on IVIg is needed to definitively estab-
lish the efficacy and safety of IVIg in neonatal red cell alloimmunization.
• Larger well-designed trials are needed to recommend on the use of EPO in neonates with 
HDFN to reduce the number of top-up transfusions.
• Studies on the use of folic acid are needed to determine if and in which dosage this 





• More studies are needed to determine the incidence and risk factors of iron overload in 
infants with HDN treated with and without IUT and to define indications for chelation 
therapy in infants with red cell alloimmune hemolytic disease.
• Large prospective follow-up studies are required to determine the exact course of 
cholestasis in neonates with red cell alloimmune hemolytic disease.
• Further research is required to study the prevalence and clinical significance of neutrope-
nia and thrombocytopenia in relation to red cell alloimmunization and ET. 
Long-term outcome
•	Further studies are warranted to reduce the incidence of risk factors, including fetal 
hydrops, associated with adverse long-term outcome in children treated with IUT. 
•	More research is required to determine the effect of factors such as phototherapy, ET, IVIg 
and iron overload on the immune system and the risk of diabetes, allergy and asthma.
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Rhesus hemolytic disease of the neonate (RHDN) results from alloimmunization to red 
cell antigens, for which mother and fetus are incompatible. In RHDN, maternal immuno-
globulin (IgG) antibodies cross the placenta and cause destruction of fetal red blood cells. 
RHDN may lead to excessive hyperbilirubinemia and prolonged fetal and neonatal anemia. 
Unconjugated bilirubin may pass through the blood-brain-barrier and lead to permanent 
brain damage due to kernicterus. Traditional neonatal treatment of RHDN consists of inten-
sive phototherapy and exchange transfusion (ET). 
In this thesis, several studies on neonatal red cell alloimmune hemolytic disease are pre-
sented, including various management options, associated complications and co-morbidi-
ties and the short-term and long-term outcome of children with RHDN.
   
In Chapter 2 an overview of the literature is presented. This review focuses on the manage-
ment of neonatal and pediatric complications associated with Rhesus hemolytic disease, 
discusses postnatal treatment options and summarizes the results of studies on short-term 
and long-term outcome. 
In Chapter 3 we present the results of a randomized double-blind, placebo-controlled 
trial, to test whether the prophylactic use of IVIg reduces the need for ETs in neonates with 
Rhesus hemolytic disease (HDN): the LIVIN study. ET is an invasive, high-risk procedure asso-
ciated with a significant rate of adverse effects. To avoid ET, international guidelines recom-
mend the use of intravenous immunoglobulin (IVIg) in neonates with Rhesus hemolytic 
disease in case of failure of phototherapy. However, recommendations for the routine use 
of IVIg are controversial because of the small number of RCTs reported on this topic and the 
methodological limitations of these studies. In the LIVIN study we found no difference in 
the rate of ETs between the IVIg and placebo groups (17% versus 15%), nor in duration of 
phototherapy (4.7 versus 5.1 days), maximum bilirubin levels (14.8 versus 14.1 mg/dL) and 
proportion of neonates requiring top-up red cell transfusions in the first three months of 
life (83% versus 87%). Our findings do not support the use of IVIg in neonates with Rhesus 
hemolytic disease. In view of the absence of beneficial effects, the use of IVIg for this indica-
tion should be discouraged.
In Chapter 4 we report a term neonate with RHDN treated with an ET through an umbilical 
venous catheter who developed brain abscesses due to a Bacillus cereus sepsis. This severe 
complication has not previously been reported. We discuss possible causes for this severe 




In Chapter 5 we present the results of a study on complications related to ET. As previ-
ously stated, ET is a high-risk invasive procedure requiring the use of central lines. Reported 
ET-related adverse events include mainly catheter-related complications, metabolic 
derangements, hematologic complications and cardio-respiratory reactions. To investigate 
morbidity and mortality rates associated with ET in our unit, we studied a large series of 
neonates with RHDN admitted to our center. We recorded the number and rate of com-
plications during admission in the group of neonates treated with and without ET. A total 
of 347 infants with red cell alloimmune hemolytic disease were included, 39% was treated 
with at least one ET during admission (ET-group) and 61% did not require ET (no-ET-group). 
Comparison between the ET-group and no-ET-group showed that ET treatment was inde-
pendently associated with: proven sepsis (8% versus 1% respectively), leukocytopenia 
(88% versus 23%), severe thrombocytopenia (platelet count < 50 x 109/L) (63% versus 8%), 
hypocalcemia (22% versus 1%) and hypernatremia (8% versus 0%). Neonatal death did not 
occur in the group treated with ET. We conclude that in experienced hands severe perma-
nent morbidity and mortality rates due to ET-procedures can be reduced to a minimum.
Chapter 6 focuses on cholestasis, a frequently observed neonatal disorder associated with 
red cell alloimmunization. Etiology of cholestatic liver disease in neonates with RHDN has 
been associated with iron overload due to (multiple) IUT(s). Data on the incidence and sever-
ity of cholestasis in neonates with HDN due to red cell alloimmunization is scarce, and little 
is known about pathogenesis, risk factors, neonatal management and outcome. We retro-
spectively studied a large group of 313 infants with red cell alloimmune hemolytic disease 
treated with or without IUT, admitted to our center. We found that cholestasis occurred 
in 13% of these infants and was indepently associated with IUT treatment and Rhesus D 
type of alloimmunization. Although cholestasis is mild and transient in most cases, a few 
neonates have severe cholestatic liver disease with protracted course and require intensive 
treatment and in one case chelation therapy was needed. We therefore conclude that larger 
follow-up studies are required to determine the exact course and etiology of cholestasis in 
infants with red cell alloimmune hemolytic disease. 
In Chapter 7 we describe the occurrence of thrombocytopenia at birth, another frequently 
noticed disorder associated with RHDN. Limited studies have shown that fetuses with red 
cell alloimmunization are at increased risk of thrombocytopenia. However, incidence and 
severity of and risk factors for thrombocytopenia at birth in neonates with red cell alloim-
munization is unclear. Therefore we retrospectively investigated the platelet count at birth 
in 362 neonates with red cell alloimmunization admitted to our center. We  determined the 
incidence of thrombocytopenia (platelet count < 150x109/L) and severe thrombocytopenia 
(platelet count < 50x109/L) and evaluated risk factors for thrombocytopenia. We found that 
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thrombocytopenia was present in 26% of included neonates at birth. Severe thrombocy-
topenia was found in 6% of neonates. Only one neonate with thrombocytopenia had clini-
cal sings of bleeding at birth (intraventricular hemorrhage grade 2).  Although this neonate 
was thrombocytopenic at birth, other factors such as prematurity and hydrops could have 
contributed to this bleeding complication. We found that three risk factors were indepen-
dently associated with thrombocytopenia at birth: treatment with IUT, small for gestational 
age (SGA) and lower gestational age at birth.
In Chapter 8 we studied the effect of a restrictive guideline for ET on the number of top-up 
transfusions (red blood cell transfusions) in neonates with RHDN in the first three months 
of life. In December 2005 we changed our ET policy (according to the recommendations 
of the American Academy of Pediatrics) from using liberal ET criteria to more restrictive 
ET criteria. In this study we included 183 (near)-term neonates with RHDN admitted to our 
center. We recorded the number of ETs and the number of top-up transfusions in the group 
of neonates before (group I, n = 156) and after (group II, n = 27) the guideline change. The 
percentage of neonates requiring an ET decreased significantly from 66% in group I to 26% 
in group II. The percentage of neonates receiving a top-up transfusion increased from 68% 
in group I to 81% in group II. We conclude that restrictive ET criteria in neonates with RHDN 
lead to a reduction of the rate of ET but an increase in the number of top-up transfusions 
for neonatal anemia.
The aim of the study described in Chapter 9 was to evaluate neonatal and hematological 
outcome in a large series of neonates with Kell HDN compared to neonates with Rhesus D 
HDN. Kell type of red cell alloimmunization is second only to Rhesus D in causing antibody-
mediated fetal anemia and accounts for 10% of all antibody-mediated fetal anemias. In con-
trast to Rhesus D HDN, fetal anemia in Kell HDN is primarily due to concomitant suppression 
of erythropoiesis rather than hemolysis of erythrocytes and is thus associated with milder 
hyperbilirubinemia. Consequently, the immediate neonatal management in Kell HDN is dif-
ferent from Rhesus D HDN and is mainly based on top-up transfusions rather than photo-
therapy or ET. In this study, we included 191 neonates and found that fetuses with severe 
Kell HDN were more often treated with IUT than fetuses with Rhesus D HDN (82% versus 66% 
respectively). Infants with HDN due to Kell-antibodies needed less phototherapy (2.4 versus 
4.1 days) and ETs (6% versus 62%) in the neonatal period than neonates with Rh D hemolytic 
disease. However, the need for top-up transfusions was similar in both groups (62% versus 
72%), justifying similar follow-up management as in Rhesus D hemolytic disease. 
The long-term neurodevelopmental outcome in children with alloimmune hemolytic 
disease of the fetus/newborn treated with IUT is presented in Chapter 10. Nowadays, treat-
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ment with IUT is the most successful procedure in fetal therapy, with perinatal survival 
rates exceeding 95% in experienced centers. However, one of the concerns of the more 
widespread and successful use of fetal therapy is that a decrease in perinatal mortality may 
lead to an increase of children with long-term handicaps. Only a few studies with small 
patient numbers have reported on long-term neurodevelopmental outcome after IUT. 
Therefore the LOTUS study was designed. The aim of this study was to determine the inci-
dence and risk factors for adverse neurodevelopmental outcome after IUT treatment in the 
largest cohort of children worldwide. Neurodevelopmental outcome in children at least 2 
years of age was assessed using standardized tests, including the Bayley Scales of Infant 
Development, the Wechsler Preschool and Primary Scale of Intelligence and the Wechsler 
Intelligence Scale for Children, according to the children’s age. Primary outcome was the 
incidence of neurodevelopmental impairment (NDI) defined as at least one of the follow-
ing: cerebral palsy, severe developmental delay, bilateral deafness and/or blindness. A total 
of 291 children were evaluated at a median age of 8.2 years (range 2 to 17 years). Cerebral 
palsy was detected in 2.1% of children, severe developmental delay in 3.1% of children and 
bilateral deafness in 1.0% of children. The overall incidence of NDI was 4.8%. We also found 
that severe hydrops was independently associated with NDI. We concluded that prevention 
of fetal hydrops by timely detection, referral and treatment may further improve long-term 
outcome.      
In conclusion, perinatal morbidity and mortality rates in red cell alloimmunization decreased 
remarkably during the last 50 years due to the significant evolution in prenatal and postna-
tal care strategies. However, several questions still remain unanswered and provide a basis 






Tijdens de zwangerschap kan zogenaamde zwangerschapsimmunisatie ontstaan. Hierbij 
maakt de moeder antistoffen tegen een stof (bloedgroepantigeen) die niet op haar eigen 
rode bloedcellen (erytrocyten) aanwezig is, maar wel op die van de foetus. Als deze anti-
stoffen van de moeder (zogenaamde immunoglobulinen type IgG) de placenta kunnen 
passeren en in de bloedsomloop van de foetus komen, kunnen ze het bloed van de foetus 
afbreken waardoor deze bloedarmoede (anemie) krijgt. De afbraak van erytrocyten wordt 
hemolyse genoemd en het ziektebeeld heet derhalve hemolytische ziekte van de foetus en 
pasgeborene (HZFP). Het sterkste bloedgroepantigeen is het Rhesus D-antigeen en om die 
reden wordt HZFP ook wel Rhesus (hemolytische) ziekte genoemd. 
HZFP kan bij de foetus en de pasgeborene (neonaat) leiden tot ernstige bloedarmoede 
door sterk verhoogde bloedafbraak. Bij de afbraak van rode bloedcellen komt bilirubine vrij 
in de bloedbaan, een stof die een gele verkleuring van de huid geeft. Ongebonden (onge-
conjugeerd) bilirubine kan bij pasgeborenen de bloed-hersen-barrière passeren,zich afzet-
ten in het hersenweefsel en tot ernstige hersenschade leiden. Dit beeld wordt kernicterus 
genoemd. Het kind kan blijvende neurologische verschijnselen en gehoorverlies hieraan 
overhouden of zelfs hierdoor overlijden. Als HZFP adequaat behandeld wordt, kan hersen-
schade voorkomen worden. Na de geboorte bestaat de traditionele behandeling van HZFP 
uit intensieve fototherapie (lichttherapie) en wisseltransfusie. Bij fototherapie wordt het 
ongeconjugeerde bilirubine onder invloed van licht omgezet in een wateroplosbare stof 
die het lichaam kan verlaten. Fototherapie bij HZFP dient direct na de geboorte gestart te 
worden, omdat het bilirubinegehalte snel kan stijgen. Dit houdt in dat een zo groot moge-
lijk huidoppervlak door fototherapielampen beschenen moet worden: het kind ligt zonder 
kleding en luier op een biliblanket (lichtmatje) en wordt beschenen door maximaal 4 spots. 
Als ondanks intensieve fototherapie het bilirubinegehalte verder doorstijgt, wordt een wis-
seltransfusie verricht. Met een wisseltransfusie wordt het bloed van het kind in kleine porties 
gewisseld voor bloed van een donor. Meestal wordt gewisseld met een volume bloed dat 
tweemaal zo groot is als het circulerend bloedvolume van de baby. Dit gebeurt via een 
katheter die aangelegd wordt in de navelstrengader. Met behulp van een wisseltransfusie 
worden het bilirubine en de hemolytische antistoffen verwijderd en kan tevens een eventu-
ele bloedarmoede gecorrigeerd worden.  
In dit proefschrift worden verschillende studies over HZFP gepresenteerd, waaronder 
studies over verschillende (andere) behandelingsmogelijkheden, bijkomende complicaties 
en comorbiditeit en korte en lange termijn uitkomsten van kinderen met HZFP.
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Hoofdstuk 2 bevat een samenvatting van de literatuur en een overzicht van de behan-
deling van neonatale en pediatrische complicaties die geassocieerd zijn met HZFP. Ook 
worden de verschillende behandelingsopties besproken en de resultaten van studies over 
korte en lange termijn uitkomst.
In Hoofdstuk 3 presenteren we de resultaten van een gerandomiseerde, dubbel-blinde, 
placebo-gecontroleerde studie die we uitgevoerd hebben op de afdeling neonatologie van 
het LUMC naar het effect van het preventief geven van intraveneus immunoglobuline (IVIg) 
direct na de geboorte. Het doel van deze studie (LIVIN studie) was om te onderzoeken of 
het gebruik van IVIg de behoefte aan wisseltransfusies zou doen afnemen bij pasgebore-
nen met HZFP. Een wisseltransfusie is een invasieve, risicovolle procedure met een aanzien-
lijke kans op complicaties. Complicaties die kunnen optreden zijn met name gerelateerd 
aan problemen die kunnen ontstaan met een katheter in de navelstrengader, zoals infec-
ties, stolsels en bloedingen. Om wisseltransfusies te voorkomen, wordt in internationale 
richtlijnen geadviseerd om IVIg te gebruiken bij pasgeborenen met HZFP als fototherapie 
faalt. Aanbevelingen voor het routinematig gebruik van IVIg zijn echter controversieel 
vanwege het kleine aantal studies dat bekend is over dit onderwerp en de methodolo-
gische beperkingen van deze studies. In de LIVIN studie vonden we geen verschil in het 
percentage wisseltransfusies tussen de IVIg- en de placebogroep (17% versus 15%), noch 
in de duur van de fototherapie (4,7 versus 5,1 dagen), maximum bilirubine (14,8 versus 
14,1 mg/dL) en het percentage pasgeborenen dat een zogenaamde  top-up transfusie 
met rode bloedcellen in de eerste drie maanden na de geboorte nodig had (83% versus 
87%). Bovenstaande resultaten bieden daarom geen ondersteuning voor het gebruik van 
IVIg bij neonaten met Rhesus hemolytische ziekte. Met het oog op het ontbreken van posi-
tieve effecten, moet het gebruik van IVIg voor deze indicatie dan ook worden ontmoedigd. 
In Hoofdstuk 4 rapporteren we een à terme pasgeborene met Rhesus hemolytische ziekte 
die werd behandeld met een wisseltransfusie via een katheter in de navelstrengader. Dit 
kind  ontwikkelde hersenabcessen als gevolg van een Bacillus cereus sepsis. Deze ernstige 
complicatie is niet eerder beschreven. We bespreken mogelijke oorzaken voor deze infectie, 
het mogelijke verband met de wisseltransfusie en suggesties voor preventie.
In Hoofdstuk 5 bespreken we de resultaten van een studie over complicaties gerelateerd 
aan wisseltransfusies. Zoals eerder vermeld, is een wisseltransfusie een risicovolle, inva-
sieve procedure waarbij gebruik gemaakt wordt van centrale lijnen in de bloedbaan (bij-
voorbeeld in een navelstrengader). Eerder gerapporteerde bijwerkingen van wisseltrans-
fusies omvatten hoofdzakelijk katheter-gerelateerde complicaties, metabole stoornissen 
(van elektrolieten), hematologische complicaties en cardio-respiratoire problemen. Om te 
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onderzoeken wat het ziekte- en sterftepercentage ten gevolge van wisseltransfusies was 
op onze afdeling, hebben we een grote serie pasgeborenen met Rhesus hemolytische 
ziekte bestudeerd, die opgenomen waren geweest op onze afdeling. We registreerden 
het aantal complicaties tijdens opname in de groep van pasgeborenen behandeld met 
en zonder wisseltransfusie. Van totaal 347 kinderen met HZFP die geanalyseerd werden, 
werd 39% behandeld met ten minste één wisseltransfusie tijdens opname (ET-groep) en in 
61% werd geen wisseltransfusie gegeven (niet-ET-groep). Vergelijking tussen de ET-groep 
en niet-ET-groep toonde aan dat behandeling met wisseltransfusie onafhankelijk geas-
socieerd was met: bewezen sepsis (respectievelijk 8% versus 1%), leukopenie (te kort aan 
witte bloedcellen) (88% versus 23%), ernstige trombocytopenie (te kort aan bloedplaat-
jes) (trombocytenaantal < 50 x 109/L) (63% versus 8%), hypocalciëmie (te laag calcium-
gehalte in het bloed) (22% versus 1%) en hypernatriëmie (te hoog natriumgehalte in het 
bloed) (8% versus 0%). Dit waren allemaal voorbijgaande problemen. Neonatale sterfte 
kwam niet voor in de groep die behandeld werd met wisseltransfusie. Concluderend 
kunnen we stellen dat in ervaren handen ernstige blijvende morbiditeit en mortali-
teit ten gevolge van wisseltransfusie-procedures tot een minimum kan worden beperkt. 
Hoofdstuk 6 bespreekt het probleem van cholestase, een regelmatig waargenomen com-
plicatie van Rhesus hemolytische ziekte. Cholestase is een leverziekte waarbij er een te hoge 
concentratie geconjugeerd (gebonden) bilirubine in de bloedbaan is. Etiologie van cho-
lestatische leverziekte bij neonaten met HZFP wordt in verband gebracht met ijzerstape-
ling als gevolg van rode bloedceltransfusies aan de foetus in de baarmoeder (intra-uteriene 
transfusies, IUT). Gegevens over de incidentie en de ernst van cholestase bij pasgeborenen 
met HZFP zijn schaars en er is weinig bekend over pathogenese, risicofactoren, neonatale 
behandeling en uitkomst. We bestudeerden retrospectief een grote groep van 313 kin-
deren met Rhesus hemolytische ziekte die behandeld waren met of zonder IUT en na de 
geboorte opgenomen op onze afdeling. We zagen dat cholestase voorkwam bij 13% van de 
pasgeborenen en dat het onafhankelijk geassocieerd was met behandeling met IUT en met 
het hebben van Rhesus D-type alloimmunisatie. Hoewel de cholestase meestal mild en van 
voorbijgaande aard was, waren er enkele pasgeborenen met een ernstige cholestatische 
leverziekte met langdurig beloop, waarbij intensieve behandeling en in één geval ontijze-
ringstherapie nodig was. We concluderen daarom dat grotere follow-up studies zijn nodig 
om het exacte beloop en de etiologie van cholestase vast te stellen bij kinderen met HZFP. 
In Hoofdstuk 7 beschrijven we een andere veel voorkomende complicatie van HZFP, 
namelijk trombocytopenie bij de geboorte. Beperkte studies hebben aangetoond dat 
foetussen met Rhesus hemolytische ziekte een verhoogd risico hebben op trombocy to-
penie. Echter, de incidentie, ernst en risicofactoren van trombocytopenie bij de geboorte 
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zijn onduidelijk. Daarom hebben we retrospectief 362 neonaten met HZFP onderzocht, 
die opgenomen waren geweest op onze afdeling. We hebben bloedplaatjes gemeten bij 
de geboorte en de incidentie van trombocytopenie (< 150x109/L), ernstige trombocyto-
penie (< 50x109/L) en risicofactoren voor trombocytopenie geëvalueerd. Wij zagen dat 
trombocytopenie voorkwam in 26% van de pasgeborenen met HZFP bij de geboorte. 
Ernstige trombocytopenie werd gevonden in 6% van de pasgeborenen. Slechts één pas-
geborene met trombocytopenie had klinische symptomen van een hersenbloeding 
bij de geboorte (intraventriculaire bloeding graad 2). Hoewel deze neonaat trombocy-
topenie had bij de geboorte, hebben zeer waarschijnlijk ook andere factoren, zoals pre-
maturiteit en hydrops bijgedragen aan het krijgen van een bloedingscomplicatie. We 
vonden dat drie risicofactoren onafhankelijk van elkaar geassocieerd waren met trom-
bocytopenie bij de geboorte, namelijk behandeling met IUT, dysmaturiteit (te klein voor 
de zwangerschapsduur) en prematuriteit (lagere zwangerschapsduur bij de geboorte). 
In Hoofdstuk 8 bestudeerden we het effect van een restrictieve richtlijn voor het geven 
van wisseltransfusies op het aantal top-up transfusies (rode bloedceltransfusies) bij neo-
naten met HZFP in de eerste drie maanden na de geboorte. In december 2005 veran-
derden we ons wisseltransfusie-beleid (volgens de aanbevelingen van de American 
Academy of Pediatrics) van het gebruik van liberale wisseltransfusie-criteria naar meer 
restrictieve wisseltransfusie-criteria. In deze studie hebben we 183 (bijna) à terme neo-
naten met HZFP geïncludeerd, allen opgenomen op onze afdeling. We registreerden het 
aantal wisseltransfusies en het aantal top-up transfusies in de groep van pasgeborenen 
vóór (groep I, n = 156) en na (groep II, n = 27) de wijziging van de richtlijn. Het percen-
tage van pasgeborenen bij wie een wisseltransfusie werd gegeven, daalde aanzienlijk 
van 66% in groep I naar 26% in groep II. Het percentage dat een top-up transfusie kreeg, 
was gestegen van 68% in groep I tot 81% in groep II. We concludeerden dat meer res-
trictieve wisseltransfusie-criteria bij neonaten met HZFP leiden tot een vermindering 
van het aantal wisseltransfusies, maar een toename van het aantal top-up transfusies. 
Het doel van de studie beschreven in Hoofdstuk 9 was om neonatale uitkomsten en hema-
tologische complicaties te evalueren in een grote serie van neonaten met Kell hemolytische 
ziekte vergeleken met neonaten met Rhesus D hemolytische ziekte. Kell alloimmunisatie 
speelt na Rhesus D de belangrijkste rol in het ontstaan  van door antistof veroorzaakte foetale 
bloedarmoede. Het mechanisme van het ontstaan van foetale bloedarmoede bij Kell hemo-
lytische ziekte is anders dan bij Rhesus D hemolytische ziekte. Bij Kell hemolytische ziekte ligt 
de nadruk niet zozeer op de afbraak (hemolyse) van de rode bloed cellen maar op de aanmaak 
van nieuwe rode bloed cellen. De aanmaak is namelijk sterk onderdrukt en kan leiden tot ern-
stige foetale bloedarmoede. Daardoor is de neonatale behandeling van pasgeborenen met 
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Kell hemolytische ziekte anders dan bij Rhesus D hemolytische ziekte. Doordat de hemolyse 
minder ernstig verloopt, hebben neonaten met Kell hemolytische ziekte ook minder last 
van hyperbilirubinemie. Wel hebben ze, net als bij Rhesus D hemolytische ziekte, last van 
bloedarmoede en moeten regelmatig met een top-up transfusie behandeld worden. In deze 
studie hebben we 191 pasgeborenen geïncludeerd en we zagen dat neonaten met Kell-
antistoffen minder fototherapie nodig hadden (2,4 versus 4,1 dagen) en minder wisseltrans-
fusies (6% versus 62%) vergeleken met neonaten met Rhesus D hemolytische ziekte. Echter, 
de behoefte aan top-up transfusies was vergelijkbaar in beide groepen (62% versus 72%). 
De lange termijn neurologische uitkomsten bij kinderen met HZFP, die behandeld zijn met 
IUT, worden gepresenteerd in Hoofdstuk 10. De behandeling met IUT is tegenwoordig één 
van de meest succesvolle procedures in de foetale therapie, met een perinatale overleving 
van meer dan 95% in ervaren centra. Echter, één van de zorgen omtrent het succesvolle 
gebruik van foetale therapie is dat een daling van de perinatale sterfte kan leiden tot een 
toename van kinderen met lange termijn handicaps en/of ontwikkelingsachterstand. Slechts 
een paar studies met kleine aantallen patiënten hebben in het verleden gekeken naar lange 
termijn neurologische uitkomsten na IUT. Daarom is de LOTUS studie opgezet. Het doel 
van deze studie was om de incidentie en risicofactoren van afwijkende psychomotorische 
ontwikkeling na behandeling met IUT te bepalen. Psychomotorische uitkomst bij kinderen 
van tenminste 2 jaar oud werd beoordeeld met behulp van gestandaardiseerde tests, waar-
onder de ‘Bayley Scales of Infant Development’, de ‘Wechsler Preschool and Primary Scale of 
Intelligence’ en de ‘Wechsler Intelligence Scale for Children’, afhankelijk van de leeftijd van het 
kind. Primaire uitkomstmaat was de incidentie van afwijkende psychomotorische ontwikke-
ling, gedefinieerd als tenminste één van de volgende: spasticiteit, ernstige vertraging in de 
ontwikkeling en bilaterale doofheid en/of blindheid. In totaal werden 291 kinderen onder-
zocht met een mediane leeftijd van 8,2 jaar, variërend van 2 tot 17 jaar. Spasticiteit kwam in 
2,1% van de kinderen voor, ernstige ontwikkelingsachterstand in 3,1% en bilaterale doofheid 
in 1,0%. De totale incidentie van ernstige afwijkende neurologische ontwikkeling was 4,8%. 
We vonden ook dat ernstige hydrops onafhankelijk geassocieerd was met afwijkende psycho-
motorische ontwikkeling. We concludeerden dat preventie van foetale hydrops door tijdige 
detectie, verwijzing en behandeling, de lange termijn uitkomst nog verder kan verbeteren. 
   
Concluderend kunnen we stellen dat perinatale morbiditeit en mortaliteit van rode bloed-
cel alloimmunisatie sterk is afgenomen de laatste 50 jaren als gevolg van een significante 
vooruitgang in pre- en postnatale zorg en behandeling. Echter, een aantal vragen omtrent 
de behandeling en complicaties van HZFP blijft nog onbeantwoord en dit vormt de basis 
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